Research activity information

• 2024 日本消化器外科学会 AGSurg Forum 2024 受賞


• 2013 日本消化器病学会学術研究助成 受賞

• Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

  Emi Tanaka, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Tomomitsu Matono, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  Aim The lymphocyte-to-monocyte ratio (LMR) has emerged as a potential immune-related biomarker; however, its prognostic significance in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) remains unclear. To investigate the prognostic significance of the LMR in patients with unresectable HCC treated with Atezo/Bev. Methods This multicentre study included 941 patients with unresectable HCC treated with Atezo/Bev therapy at 30 institutions in Japan. The optimal LMR cutoff value was determined using time-dependent receiver operating characteristic (ROC) analysis. Multivariate survival analyses were performed for progression-free survival (PFS) and overall survival (OS). The prognostic utility of the LMR was compared with that of the neutrophil-to-lymphocyte ratio (NLR) using integrated discrimination improvement and net reclassification improvement. Results Time-dependent ROC analysis identified an optimal LMR cutoff value of 3.6 based on median OS. The median PFS was 5.6 months in patients with an LMR < 3.6 and 8.9 months in those with an LMR ≥ 3.6 (P<0.01). The disease control rate was significantly higher in the high LMR group (P<0.01). Multivariate analysis identified the LMR as an independent factor associated with prolonged PFS (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.90-0.98; P<0.01) and OS (HR, 0.90; 95% CI, 0.85-0.96; P<0.01). Compared with NLR, LMR demonstrated a significantly greater improvement in prognostic predictive performance for both PFS and OS (P<0.01). Conclusions The LMR is a simple and clinically useful prognostic biomarker for predicting both PFS and OS in patients with unresectable HCC treated with Atezo/Bev therapy.

  Aug. 2026, Oncology, 1 - 26, English, International magazine

  Scientific journal


• 99mTc GSA scintigraphy predicts post-hepatectomy liver failure in biliary tract cancer.

  Masayuki Akita, Hiroaki Yanagimoto, Keitaro Sofue, Jun Ishida, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Shohei Komatsu, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Technetium-99m-diethylenetriamine-penta-acetic acid-galactosyl human serum albumin (99mTc-GSA) scintigraphy is a useful method for assessing liver function and its heterogeneity. We evaluated its predictive usefulness for post-hepatectomy liver failure (PHLF) in liver resection for biliary tract cancer. METHODS: Between 2013 and 2024, 95 patients underwent major hepatectomy with bile duct resection for biliary tract cancer and had preoperative 99mTc-GSA scintigraphy. The GSA-K value was defined using established reduction formulas of indocyanine green plasma clearance rate (ICG-K) values based on LHL15 value (99mTc-GSA uptake ratio of the liver to the liver plus heart at 15 min) from 99mTc-GSA scintigraphy. Functional remnant liver volume (f-RLV) ratio was estimated by dividing scintillation counts of the future remnant liver by total counts of the whole liver. We compared volumetric (ICG-Krem: ICG-K x RLV ratio) and functional (GSA-Krem: GSA-K x f-RLV ratio) assessment methods of the future remnant liver for predicting PHLF. RESULTS: PHLF was observed in 34 patients (35.8%) and a receiver operating characteristic curve revealed cut-off values for predicting PHLF of 0.088 for ICG-Krem and 0.086 for GSA-Krem. Positive predictive values for PHLF were 53.2% (ICG-Krem) and 87.6% (GSA-Krem). In patients with portal vein embolization (PVE), GSA-Krem showed 89.1% of positive predictive value for PHLF, and ICG-Krem was very low (53.3%). The multivariate analysis identified GSA-Krem as one of independent predictors of PHLF. CONCLUSIONS: GSA-Krem derived from 99mTc-GSA scintigraphy is a valuable predictor of PHLF.

  Aug. 2026, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 52(8) (8), 111914 - 111914, English, International magazine

  Scientific journal


• Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

  Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Fujimasa Tada, Hideko Ohama, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takumi Fukumoto, Takanori Matsuura, Soo Ki Kim, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIMS: For unresectable hepatocellular carcinoma (HCC), atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) are widely used first-line immunotherapies; however, biomarkers to guide regimen selection before treatment initiation remain undefined. We investigated whether baseline des-γ-carboxy prothrombin (DCP) modifies objective response rate (ORR) according to treatment regimen. METHODS: We analysed 1464 patients with unresectable HCC treated with first-line systemic therapy between 2020 and 2025 across multiple centers. Patients were divided into training and validation cohorts. Restricted cubic spline-based interaction models were used to evaluate the association between baseline DCP and ORR according to treatment regimen. The predicted absolute difference in ORR (ΔORR) between regimens was examined across continuous DCP values, with a prespecified 10% threshold considered clinically meaningful. Robustness was assessed using leave-one-center-out and repeated random-split sensitivity analyses. RESULTS: Overall ORR did not differ significantly between Atez/Bev and Dur/Tre. However, a significant interaction between baseline DCP and treatment regimen was observed in both cohorts. Atez/Bev showed a relatively stable ORR across DCP concentrations, whereas Dur/Tre showed a DCP-dependent increase in ORR. At low DCP levels, Atez/Bev was favoured; with increasing DCP levels, the relative benefit shifted toward Dur/Tre. Sensitivity analyses confirmed a consistent DCP-dependent transition pattern, although the DCP level at which ΔORR exceeded 10% varied across analyses, supporting a transition zone rather than a fixed cutoff. CONCLUSIONS: Baseline DCP may modify the relative treatment benefit between Atez/Bev and Dur/Tre in unresectable HCC. Rather than defining a rigid cutoff, DCP appears to delineate a continuum in which higher levels increasingly favour Dur/Tre, providing a practical framework for individualized immunotherapy selection.

  Aug. 2026, Liver international : official journal of the International Association for the Study of the Liver, 46(8) (8), e70803, English, International magazine

  Scientific journal


• Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

  Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Hironori Tanaka, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Yoshihide Ueda, Soo Ki Kim, Shintaro Takaki, Fujimasa Tada, Hideko Ohama, Shinichiro Nakamura, Takanori Matsuura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Jumpei Okamura, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Tamami Abe, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIM: Atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) are widely used first-line immune checkpoint inhibitor (ICI)-based regimens for unresectable hepatocellular carcinoma (uHCC). However, reliable biomarkers to inform treatment choice remain limited. This study evaluated whether the simplified BALAD-based score (BALAD-S) is associated with differential treatment outcomes. MATERIALS AND METHODS: This multicenter retrospective study included 752 Japanese patients with uHCC who received first-line Atez/Bev (n = 645) or Dur/Tre (n = 107) between October 2020 and March 2026. BALAD-S was calculated using bilirubin, albumin, AFP, AFP-L3, and des-γ-carboxy prothrombin, and patients were stratified into BALAD-S low (≤ 2) and high (≥ 3) groups. Treatment response, progression-free survival (PFS), and overall survival (OS) were evaluated. RESULTS: In the BALAD-S low group, Atez/Bev showed longer PFS than Dur/Tre (10.5 vs. 4.3 months; p < 0.001), with longer OS also observed (28.3 vs. 19.4 months; p = 0.049). In the BALAD-S high group, PFS did not differ significantly (7.0 vs. 5.3 months with Dur/Tre and Atez/Bev, respectively, p = 0.210), whereas OS was longer with Dur/Tre than with Atez/Bev (27.3 vs. 16.4 months; p = 0.022). Treatment effects differed by BALAD-S category (HR for Dur/Tre vs. Atez/Bev: 1.50 in BALAD-S low and 0.55 in BALAD-S high; p for interaction = 0.005). In patients treated from 2023 onward, similar treatment-effect heterogeneity was observed (HR 1.61 in BALAD-S low and 0.59 in BALAD-S high; p for interaction = 0.007). CONCLUSION: Outcomes with Atez/Bev and Dur/Tre differed according to BALAD-S score. BALAD-S may help identify patients with differential outcomes between first-line ICI-based regimens and represents a candidate stratification marker requiring validation.

  Jul. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, English, International magazine

  Scientific journal


• A novel bile leak test using contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a prospective single-arm trial.

  Takeshi Urade, Yuhi Shimura, Masahiro Kido, Kenji Fukushima, Shinichi So, Hidetoshi Gon, Daisuke Tsugawa, Motofumi Tanaka, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto, Shohei Komatsu

  BACKGROUND: Bile leak (BL) remains a major complication after liver resection and is associated with substantial postoperative morbidity. Conventional dye-based tests can identify visible leakage from the transection surface, but whether the injected reagent has adequately reached peripheral intrahepatic ducts adjacent to the cut surface is often uncertain. We evaluated the feasibility and safety of a novel BL test using contrast-enhanced intraoperative ultrasonic cholangiography (CE-IOUSC) for real-time confirmation of intrabiliary reagent filling. METHODS: This prospective single-arm trial included 29 patients undergoing open liver resection under the finalized protocol between March 2021 and February 2024. A reagent consisting of diluted Sonazoid, indigo carmine, and saline was injected through a cystic-duct catheter while the distal common bile duct was clamped. Ductal filling near the transection plane was assessed using contrast harmonic ultrasonography during and immediately after manual divided injection. Outcomes included technical success, postoperative BL, injection-related adverse events, and exploratory comparison of postoperative liver enzymes with a historical conventional-test cohort. RESULTS: CE-IOUSC testing was technically successful in 25 of 29 patients (86.2%). The median total injected volume was 5 mL (range 2-22 mL), and the median number of divided injections was 2 (range 1-6). Intraoperative BL was detected and sutured in 3 patients. Postoperative BL occurred in 5 patients (17.2%): 4 after technical success and 1 after technical failure. No adverse events related to intrabiliary reagent injection were observed. Postoperative AST and ALT elevations were significantly lower than in the historical cohort, although this comparison was exploratory. CONCLUSIONS: CE-IOUSC-based BL testing was feasible and safe in open liver resection and enabled real-time confirmation of intrabiliary reagent filling near the transection surface. Its clinical efficacy in reducing postoperative BL or liver injury remains unproven and should be evaluated in future comparative studies.

  Jul. 2026, Surgical endoscopy, English, International magazine

  Scientific journal


• Clinical impact of indocyanine green fluorescence imaging on perioperative outcomes in laparoscopic anatomical liver segmentectomy.

  Motochika Hamanaka, Takeshi Urade, Shohei Komatsu, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Kosuke Iguchi, Masayuki Akita, Takuya Mizumoto, Jun Ishida, Yoshihide Nanno, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Laparoscopic anatomical segmentectomy is technically demanding due to the lack of visible surface landmarks identifying segmental borders. While indocyanine green (ICG) fluorescence imaging offers real-time navigation, its specific impact on anatomical orientation remains understudied. We evaluated the clinical impact of ICG fluorescence guidance on perioperative efficiency and outcomes in laparoscopic anatomical segmentectomy. METHODS: We analyzed 78 consecutive patients (2017-2025) undergoing laparoscopic anatomical segmentectomy, stratified into ICG-guided (n = 51, negative staining) and conventional (n = 27) groups. Endpoints included perioperative outcomes (operative time, complications, and hospital stay), anatomical precision (RMSE between simulated volume and specimen weight), and long-term prognosis (RFS/OS) in a hepatocellular carcinoma (HCC) subgroup operated before 2023. RESULTS: While the non-ICG group included a higher proportion of high-difficulty cases according to the IWATE criteria (85.2 vs. 58.8%; p = 0.022), the ICG group demonstrated a substantially shorter median operative time (369 vs. 478 min; p < 0.001). Notably, the ICG group achieved zero major morbidity (Clavien-Dindo ≥ IIIa), whereas the conventional group had a rate of 22.2% (p < 0.001). The ICG group also showed superior anatomical precision with a lower RMSE (46.97 vs. 59.36). Intraoperative blood loss and R0 resection rates were comparable. Subgroup analysis confirmed that the ICG group maintained superior efficiency even in the later study period. In the HCC subset, RFS and OS were comparable between the groups (p = 0.352 and p = 0.080, respectively), indicating the oncological safety of the ICG-guided approach. CONCLUSIONS: ICG fluorescence guidance with negative staining improves operative efficiency and safety in laparoscopic anatomical segmentectomy. By visualizing the otherwise invisible demarcation, this technique streamlines parenchymal transection and is associated with reduced major morbidity. While the baseline difficulty imbalance warrants cautious interpretation, our findings suggest that ICG navigation provides a feasible and promising approach for improving surgical precision and outcomes.

  Jul. 2026, Surgical endoscopy, 40(7) (7), 5751 - 5759, English, International magazine

  Scientific journal


• Postoperative liver function trajectories and risk factors after hepatectomy for hepatocellular carcinoma.

  Masaki Omori, Shohei Komatsu, Motochika Hamanaka, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Dongha Lee, Masayuki Akita, Takuya Mizumoto, Jun Ishida, Yoshihide Nanno, Hiroaki Yanagimoto, Takumi Fukumoto

  PURPOSE: Hepatectomy is a curative treatment for hepatocellular carcinoma (HCC) but deteriorating postoperative liver function can limit its benefits, especially for patients with borderline resectable (BR) HCC. We evaluated postoperative liver function trajectories and their impact on long-term survival. METHODS: The subjects of this retrospective analysis were 790 patients who underwent initial curative hepatectomy, stratified by resectability (R, BR1, BR2) and modified albumin-bilirubin (mALBI) grade. Liver function was assessed via ALBI scores pre- and postoperatively. Deterioration was defined as an ALBI score ratio < 0.9. RESULTS: Median overall survival (OS) differed significantly, being 109.9, 54.4, and 40.4 months for the R, BR1, and BR2 groups, respectively (p < 0.001). While functional status at POD 90 influenced recurrence-free survival, deterioration at POD 180 was identified as a robust independent predictor of OS (HR 1.53, p = 0.005). Notably, no single preoperative or perioperative factor was a significant predictor of this long-term functional decline at POD 180. Postoperative recovery was heterogeneous, with 47.5% of patients with mALBI grade 2a improving to grade 1 by POD 180. CONCLUSIONS: Post-hepatectomy liver function at POD 180 is a key determinant of long-term survival. As this late deterioration is difficult to predict perioperatively, continuous monitoring of hepatic reserve is essential to maintain eligibility for subsequent multidisciplinary therapies.

  Jun. 2026, Surgery today, English, Domestic magazine

  Scientific journal


• Prognostic impact of malnutrition based on the global leadership initiative on malnutrition criteria in older patients undergoing liver resection for hepatocellular carcinoma.

  Satoshi Omiya, Takeshi Urade, Shohei Komatsu, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Masayuki Akita, Takuya Mizumoto, Jun Ishida, Yoshihide Nanno, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  PURPOSE: This study aimed to evaluate preoperative malnutrition using the Global Leadership Initiative on Malnutrition (GLIM) criteria and determine whether its prognostic impact after initial liver resection (LR) differs between older (≥70 years) and younger (<70 years) patients with hepatocellular carcinoma (HCC). METHODS: This retrospective analysis included 330 patients with HCC who underwent LR between January 2011 and December 2019 at our institution. Overall survival (OS), recurrence-free survival (RFS), postoperative recurrence patterns, and treatment strategies for recurrence were compared between the two groups. RESULTS: Among the 330 patients with HCC, 150 and 180 were classified into younger and older groups, respectively. Preoperative severe malnutrition was independently associated with OS (p=0.001) and RFS (p=0.044) in older patients and with RFS (p=0.039), but not OS, in younger patients. Moreover, in older patients, preoperative malnutrition was associated with a lower rate of aggressive treatments for intrahepatic recurrence (p=0.018) and a higher rate of extrahepatic recurrence (p=0.023) after LR, which was not observed in younger patients. CONCLUSIONS: Severe malnutrition, as per the GLIM criteria, is a significant independent predictor of OS and RFS in older patients with HCC who underwent LR. Preoperative malnutrition was associated with the treatment strategies for intrahepatic recurrence and the rate of extrahepatic recurrence in this population.

  Jun. 2026, Surgery today, English, Domestic magazine

  Scientific journal


• Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic cancer.

  Jun Ishida, Hirochika Toyama, Yoshihide Nanno, Takuya Mizumoto, Dongha Lee, Masayuki Akita, Keisuke Arai, Toshihiko Yoshida, Shinichi So, Takeshi Urade, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Portomesenteric vein (PMV) resection is performed for pancreatic ductal adenocarcinoma with venous invasion. However, positive transection margins may lead to local recurrence. This study aimed to evaluate whether routine intraoperative frozen section analysis (FSA) reduces positive PMV transection margins. METHODS: This retrospective study reviewed patients who underwent pancreatectomy with PMV resection at Kobe University Hospital from 2010 to 2020. Routine FSA of the PMV transection margin was introduced in 2017. Clinicopathological factors and the incidence of positive PMV transection margins were compared between patients who underwent FSA (PMV frozen [+]) and those who did not (PMV frozen [-]). Cox regression was used to assess the prognostic effect of margin status. RESULTS: A total of 115 patients were included (57 in the PMV frozen [+] group and 58 in the PMV frozen [-] group). The rate of positive PMV transection margins was significantly lower in the PMV frozen (+) group than in the PMV frozen (-) group (1.8% vs 17.2%, respectively; P =.003). Multivariate logistic regression analysis demonstrated that intraoperative FSA of the PMV transection margin was an independent factor associated with a reduced risk of positive PMV transection margins on final pathological diagnosis (odds ratio, 13.7 [95% CI, 1.61-116.7]; P =.017). However, the positive PMV transection margin was not associated with overall survival (hazard ratio, 0.96 [95% CI, 0.31-2.50; P =.937). CONCLUSION: Routine FSA of the PMV transection margin markedly reduces positive PMV transection margins after pancreatectomy. However, the prognostic effect of a positive PMV transection margin remains unclear. Larger prospective studies are needed to determine its prognostic relevance.

  Jun. 2026, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 30(6) (6), 102410 - 102410, English, International magazine

  Scientific journal


• Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

  Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Yoshiko Nakamura, Osamu Yoshida, Kazuya Kariyama, Kazuhiro Nouso, Joji Tani, Asahiro Morishita, Masanori Atsukawa, Norio Itokawa, Tomomi Okubo, Taeang Arai, Koichi Takaguchi, Akemi Tsutsui, Takuya Nagano, Ei Itobayashi, Takashi Nishimura, Shinya Fukunishi, Hirayuki Enomoto, Kunihiko Tsuji, Kazunari Tanaka, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Takeshi Hatanaka, Yuki Kanayama, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Atsushi Naganuma, Hisashi Kosaka, Kosuke Matsui, Masaki Kaibori, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Jumpei Okamura, Shohei Komatsu, Takanori Matsuura, Shinichiro Nakamura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIM: This study evaluated clinical outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre) in routine practice, stratified by whether they fulfilled the eligibility criteria of the phase 3 HIMALAYA trial. METHODS: A total of 412 patients with unresectable HCC receiving Dur/Tre at 30 Japanese institutions were enrolled. Of these, 92 fulfilled the HIMALAYA trial eligibility criteria (HIMALAYA group) and 320 did not (non-HIMALAYA group). RESULTS: Median progression-free survival (PFS) was 5.4 months in the HIMALAYA group and 3.0 months in the non-HIMALAYA group (p = 0.012). Multivariable analysis identified body mass index ≥ 25 kg/m2 (hazard ratio [HR], 0.780; 95% confidence interval [CI], 0.612-0.993; p = 0.044) and portal vein invasion (HR, 1.509; 95% CI, 1.049-2.170; p = 0.027) as independent predictors of PFS. Median overall survival (OS) was 19.4 months in the HIMALAYA group versus 15.4 months in the non-HIMALAYA group (p = 0.014). Multivariable analysis showed Eastern Cooperative Oncology Group performance status ≥ 1 (HR, 1.878; 95% CI, 1.253-2.814; p = 0.002) and albumin-bilirubin grade ≥ 2 (HR, 2.032; 95% CI, 1.319-3.318; p = 0.001) as independent determinants of OS. Any-grade endocrine dysfunction occurred in 13 (14.1%) and 21 (6.6%) patients (p = 0.030), with grade ≥ 3 events in 5 (5.4%) and 2 (0.6%), respectively (p = 0.007). Subgroup analysis suggested that non-HIMALAYA patients with ALBI grade 1 may have OS comparable to the HIMALAYA group. CONCLUSIONS: Patients fulfilling the HIMALAYA trial eligibility criteria and those who did not but had preserved hepatic function demonstrated favorable survival outcomes with Dur/Tre.

  May 2026, Journal of gastroenterology and hepatology, 41(7) (7), 2138 - 2149, English, International magazine

  Scientific journal


• ASO Author Reflections: Avoiding Mobilization in Laparoscopic Surgery for Huge Hepatocellular Carcinoma in the Right Posterior Section.

  Takeshi Urade, Masahiro Kido, Shohei Komatsu, Takumi Fukumoto

  May 2026, Annals of surgical oncology, 33(8) (8), 7080 - 7081, English, International magazine

  Scientific journal


• Laparoscopic Anterior-Approach Right Posterior Sectionectomy for Huge Hepatocellular Carcinoma: Technique and Short-Term Outcomes.

  Takeshi Urade, Masahiro Kido, Shohei Komatsu, Kenji Fukushima, Toshihiko Yoshida, Keisuke Arai, Kosuke Iguchi, Masayuki Akita, Takuya Mizumoto, Jun Ishida, Yoshihide Nanno, Hiroaki Yanagimoto, Takumi Fukumoto

  BACKGROUND: Laparoscopic liver resection is technically demanding for hepatocellular carcinoma (HCC) ≥10 cm in the right liver. In open liver resection, the anterior approach is established for large right-lobe tumors because it avoids parenchymal compression during mobilization.1, 2 However, its laparoscopic use remains limited,3 particularly in right posterior sectionectomy (RPS). This study describes the technique and perioperative outcomes of laparoscopic RPS using the anterior approach for huge HCCs. METHODS: Among 799 minimally invasive liver resections performed between 2011 and 2025, four men (median age 72.5 years, range 60-84) with huge tumors (median diameter 11.5 cm, range 10-12) underwent laparoscopic (extended) RPS with an anterior approach. As the tumor bulk caused firm adhesion to the diaphragm and retroperitoneum, the right lobe was left in situ. Parenchymal transection was initiated caudally and progressed cranially along the right inferior vena cava. The specimen was detached only after the transection. Patients were placed in the left hemilateral decubitus position with French lithotomy, and clamp-crushing was used for transection. RESULTS: Two standard and two extended RPSs were completed. The median operative time was 524 minutes (range 418-603), and blood loss was 80 mL (range 10-550); no transfusions were required. The median weight was 753.5 g (range 450-934). No Clavien-Dindo ≥IIIa complications occurred. The median postoperative stay was 11 days (range 9-16). All margins were negative. CONCLUSIONS: Laparoscopic anterior-approach RPS is feasible and safe for huge right posterior HCCs, enabling secure transection without mobilization and yielding favorable short-term outcomes.

  May 2026, Annals of surgical oncology, 33(8) (8), 7061 - 7062, English, International magazine

  Scientific journal


• The convenience of contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a study protocol for a randomized, prospective, off-label trial.

  Takeshi Urade, Kentaro Oji, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Hayata Sano, Sae Murakami, Takumi Fukumoto

  BACKGROUND: Intraoperative cholangiography (IOC) is widely used to delineate biliary anatomy and confirm ductal integrity during liver resection. However, conventional radiographic IOC requires a C-arm set-up, may interrupt the operative workflow, and exposes patients and operating-room personnel to ionizing radiation. Contrast-enhanced intraoperative ultrasonic cholangiography (CE-IOUSC) combines intrabiliary injection of highly diluted perfluorobutane microbubbles (Sonazoid®) with contrast harmonic ultrasonography, enabling real-time visualization that can be repeated on demand without radiation. We hypothesize that CE-IOUSC provides superior procedural convenience while maintaining biliary visualization and safety. METHODS: This is a single-center, open-label, randomized, parallel-group, phase III comparative trial. Adults (≥ 20 years) scheduled for liver resection, including living donors, are eligible when cholecystectomy and transcystic catheterization via the cystic duct are feasible. After informed consent, participants are randomized 1:1 (stratified by liver condition: normal vs. impaired) to CE-IOUSC or conventional radiographic IOC using a computer-generated sequence. In both arms, cholangiography is performed twice-before and after bile duct division-with additional imaging permitted as clinically required. Conventional IOC uses diluted iothalamate contrast (Urografin®) under C-arm fluoroscopy. CE-IOUSC uses 1,000-fold diluted Sonazoid® administered through the cystic duct and evaluated using intraoperative ultrasonography in contrast mode. Cross-over "rescue" cholangiography with the alternative modality is allowed when the assigned method is unsuccessful or inadequate. The primary endpoint is the cumulative time required to complete intraoperative cholangiography, including any additional imaging and repeated attempts. Secondary endpoints include surgeon-rated usability (5-point Likert questionnaire completed by the primary operator immediately after surgery), detectability of biliary structures (segmental visualization rates assessed by predefined criteria), postoperative biliary complications (bile leak or stricture graded by Clavien-Dindo), cross-over rescue efficacy, and safety outcomes (procedure-related adverse events and perioperative laboratory changes). Outcomes will be analyzed primarily on an intention-to-treat basis. DISCUSSION: This trial will quantify whether CE-IOUSC improves the efficiency and usability of intraoperative biliary imaging without compromising visualization or patient safety. The results will inform evidence-based adoption of ultrasound-based cholangiography as a practical alternative to conventional radiographic IOC in liver resection. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT), jRCTs051230202.

  May 2026, BMC surgery, 26(1) (1), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Optimizing bevacizumab exposure in atezolizumab-based therapy for unresectable hepatocellular carcinoma: A nationwide real-world study.

  Kaho Aoe, Toshifumi Tada, Atsushi Hiraoka, Tomomitsu Matono, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Naganuma Atsushi, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIMS: Atezolizumab plus bevacizumab is administered for unresectable HCC, with bevacizumab dosed by body weight, which may not adequately reflect body composition. This study evaluated the association between body surface area (BSA)-adjusted bevacizumab dosing, expressed as the bevacizumab-BSA index (BBI), and outcomes. APPROACH AND RESULTS: This retrospective study included 1507 patients with unresectable HCC treated with atezolizumab plus bevacizumab at 30 Japanese institutions. BBI was the ratio of actual to standard dose per BSA. Restricted cubic spline analyses identified the optimal BBI range. Outcomes were compared among BBI groups. Spline analysis revealed a nonlinear association between BBI and overall survival (OS), with an optimal BBI range of 106%-121%. Accordingly, the patients were classified into under (n=924), target (n=522), and over (n=61) groups. The median progression-free survival was significantly longer in the target group than in the nontarget group (10.3 vs. 6.5 mo, p <0.001), and the median OS was prolonged (24.9 vs. 19.2 mo, p =0.008). Multivariable analysis demonstrated that the target BBI group was independently associated with improved progression-free survival (HR, 0.807; 95% CI: 0.715-0.910; p <0.001) and OS (HR, 0.850; 95% CI: 0.733-0.985; p =0.031). The objective response rate was significantly higher in the Target group ( p =0.023), while treatment-related adverse event rates were comparable across the BBI groups, with no significant differences in proteinuria, hypertension, or other toxicities. CONCLUSIONS: BSA-adjusted bevacizumab dosing was associated with improved efficacy without increased toxicity in patients with unresectable HCC treated with atezolizumab plus bevacizumab.

  May 2026, Hepatology (Baltimore, Md.), English, International magazine

  Scientific journal


• 高齢者におけるSTRIDEレジメンの有効性と安全性

  多田 俊史, 熊田 卓, 平岡 淳, 谷 丈二, 厚川 正則, 高口 浩一, 糸林 詠, 辻 邦彦, 石川 達, 玉井 秀幸, 豊田 秀徳, 畑中 健, 柿崎 暁, 能祖 一裕, 松浦 敬憲, 小松 昇平, 黒田 英克, 海堀 昌樹, 日浅 陽一, 工藤 正俊

  (株)アークメディア, May 2026, 肝胆膵, 92(5) (5), 634 - 636, Japanese


• Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child-Pugh Class B: A Real-World Study.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Hironori Tanaka, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Yoshihide Ueda, Soo Ki Kim, Fujimasa Tada, Shinichiro Nakamura, Takanori Matsuura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Jumpei Okamura, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIM: Evidence regarding the optimal first-line immune checkpoint inhibitor (ICI) regimen for treating unresectable hepatocellular carcinoma (uHCC) with Child-Pugh class B (CP-B) liver function remains limited. This study compared atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre group) in real-world settings. METHODS: In this multicenter retrospective study, 211 consecutive patients with uHCC and CP-B liver function who underwent ICI-based therapy as a first-line therapy were analyzed. Treatment responses, survival outcomes, albumin-bilirubin (ALBI) score changes, and adverse events were evaluated. Survival analyses were adjusted using inverse probability weighting (IPW). RESULTS: The median progression-free survival associated with the Atez/Bev and Dur/Tre regimens was 5.0 and 3.5 months, respectively; the median corresponding overall survival was 10.5 and 12.4 months. After IPW adjustment, no significant differences were observed in progression-free or overall survival. The Atez/Bev regimen-associated disease control rate was significantly higher (75.2% vs. 55.0%, p = 0.02). The Dur/Tre regimen, meanwhile, was associated with a significantly higher immune-related adverse event incidence (10.5% vs. 32.7%, p < 0.01) and a greater need for high-dose corticosteroid treatment. In contrast, the Atez/Bev regimen resulted in a progressive decrease in ALBI scores, whereas the Dur/Tre regimen maintained the hepatic functional reserve. CONCLUSIONS: The Atez/Bev and Dur/Tre regimens afforded comparable survival outcomes but differed substantially in safety and effects on the hepatic functional reserve. Given the trade-off between immunotoxicity and liver function preservation, treatment selection for CP-B liver function should be individualized, considering baseline hepatic reserve, tolerability, and anticipated treatment trajectory.

  May 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(5) (5), 716 - 724, English, International magazine

  Scientific journal


• Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.

  Fujimasa Tada, Atsushi Hiraoka, Hideko Ohama, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takumi Fukumoto, Takanori Matsuura, Soo Ki Kim, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIM: Atezolizumab plus bevacizumab (Atez/Bev) in unresectable hepatocellular carcinoma (uHCC) is a standard first-line therapy, but bleeding-related adverse events (BL-AEs) remain clinically concerning, particularly in real-world patients with advanced tumors, portal hypertension, or undergoing antithrombotic therapy (ATT). We aimed to evaluate whether ATT increases bleeding risk, identify pretreatment factors associated with BL-AEs, and assess the impact of bleeding on progression-free survival (PFS) and overall survival (OS) in patients with uHCC treated with Atez/Bev. METHODS: This multicenter retrospective study included 981 patients with uHCC treated with Atez/Bev. BL-AEs were identified by clinical assessment, imaging, or endoscopy. Predictors of BL-AEs were analyzed using logistic regression. Survival outcomes were compared by Kaplan-Meier method, with inverse probability weighting (IPW) applied to adjust for baseline imbalances. RESULTS: BL-AEs occurred in 102 patients (10.4%) and led to treatment discontinuation in 2.7% patients. Independent predictors of BL-AEs included advanced tumor burden components, such as Vp ≥ 3 portal vein invasion and extrahepatic metastasis. Neither ATT nor portal hypertension-related factors were associated with bleeding risk. PFS did not differ between groups, whereas OS was significantly shorter in the BL group before IPW adjustment than after IPW adjustment. CONCLUSIONS: During Atez/Bev therapy, BL-AEs were primarily associated with advanced tumor burden rather than with ATT or baseline portal hypertension-related factors. Although BL-AEs were associated with poorer OS, this should be interpreted cautiously, as bleeding may reflect aggressive tumor biology rather than a direct mortality cause. Careful monitoring for bleeding complications may be required in patients with advanced tumor burden receiving Atez/Bev.

  Apr. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(8) (8), 1274 - 1285, English, International magazine

  Scientific journal


• Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab.

  Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Yoshihide Ueda, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Jumpei Okamura, Hideyuki Tamai, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Fujimasa Tada, Hideko Ohama, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Shohei Komatsu, Takumi Fukumoto, Takanori Matsuura, Soo Ki Kim, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND & AIMS: Systemic therapy is the standard care for patients with hepatocellular carcinoma (HCC) and extrahepatic metastases. However, the relative prognostic importance of the intrahepatic tumor burden versus the extent of extrahepatic disease in the era of immune checkpoint inhibitor-based therapy remains unclear. This study aimed to clarify the prognostic impact of intrahepatic tumor burden in patients with metastatic HCC treated with atezolizumab plus bevacizumab (Atez/Bev). METHODS: We conducted a multicenter retrospective study of patients with HCC and extrahepatic metastases who received first-line Atez/Bev therapy. The intrahepatic tumor burden was assessed using established radiologic parameters, including tumor size, number, and vascular invasion, and the patients were stratified according to the intrahepatic disease severity. Overall survival (OS) was defined as the primary endpoint. Survival analyses were carried out using the Kaplan-Meier method and Cox proportional hazards models. RESULTS: Overall, 306 patients were included in the study. During a median follow-up of 13.5 months, the OS differed markedly according to the intrahepatic tumor burden and macrovascular invasion. The median OS was 17.8 months in the mild MVI group, 12.2 months in the severe MVI group, 29.8 months in the UT7 in group, and 15.2 months in the UT7 out group (p < 0.001). In multivariate analysis, the intrahepatic tumor burden remained an independent predictor of OS, whereas the extent and number of extrahepatic metastatic sites were not significantly associated with prognosis. CONCLUSIONS: In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.

  Apr. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(8) (8), 1246 - 1253, English, International magazine

  Scientific journal


• Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma.

  Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  INTRODUCTION: Atezolizumab plus bevacizumab (Atez/Bev) was the first immune checkpoint inhibitor regimen approved in 2020 for unresectable hepatocellular carcinoma (uHCC), followed by durvalumab plus tremelimumab (Dur/Tre) in 2023. There is very little data available comparing the efficacy and safety of Atez/Bev with those of Dur/Tre. This study aimed to clarify the therapeutic outcomes and safety of Atez/Bev and Dur/Tre. METHODS: We retrospectively analyzed patients with uHCC (BCLC-B/C and Child-Pugh class A) treated with Atez/Bev (n = 302) or Dur/Tre (n = 129) as first-line systemic therapy across multiple institutions between 2023 and 2025. A retrospective comparison of the treatment outcomes and safety of Atez/Bev and Dur/Tre was conducted. RESULTS: The objective response rate and disease control rate were comparable between the Atez/Bev and Dur/Tre groups (31.8%/71.9% vs. 28.7%/63.6%, p = 0.570/p = 0.110, respectively). Median progression-free survival (PFS) was longer with Atez/Bev (9.1 vs. 5.0 months, p = 0.002), while OS was comparable (25.6 vs. 22.1 months, p = 0.172). Similar results were shown after adjusting with inverse probability weighting (IPW). Grade 5 immune-related adverse events occurred in 0.3% (n = 1, interstitial pneumonia) of the patients receiving Atez/Bev and 0.8% (n = 1, colitis) of those receiving Dur/Tre. In the Cox hazard analysis adjusted with IPW, Dur/Tre demonstrated a favorable trend in OS (hazard ratio [HR] <0.75) in patients with elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 0.72, interaction p = 0.006) or double positive elevation of tumor marker (AFP and des-gamma-carboxy prothrombin [≥100 mAU/mL]) (HR 0.66, interaction p = 0.005). CONCLUSION: Although Atez/Bev was associated with a longer PFS, OS did not differ significantly between Atez/Bev and Dur/Tre. This dissociation between PFS and OS may reflect differences in disease biology, treatment sequencing, and post-progression management rather than intrinsic superiority of either regimen. These findings highlight the importance of individualized treatment selection and careful consideration of tumor characteristics and hepatic reserve when choosing first-line immunotherapy for uHCC.

  Apr. 2026, Liver cancer, English, International magazine

  Scientific journal


• Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

  Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Takanori Matsuura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Shinya Fukunishi, Kazunari Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Jumpei Okamura, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND AND AIMS: This multicenter retrospective study in Japan aimed to investigate the prognostic significance of lymphocyte-to-monocyte ratio (LMR) in patients with unresectable hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 377 patients with HCC and treated with Dur/Tre across 30 institutions in Japan were included in this multicenter study. Time-dependent receiver operating characteristic (ROC) analysis was performed to determine the optimal LMR cut-off value. Hazard ratio (HR) spline curve analysis was used to identify the optimal LMR range for predicting progression-free survival (PFS) and overall survival (OS). RESULTS: Time-dependent ROC analysis identified an optimal LMR cut-off value of 2.52 for predicting median OS. Multivariate analysis demonstrated that an LMR of ≥ 2.52 was independently associated with superior PFS (HR: 0.777) and OS (HR: 0.657). The median PFS was 2.6 months in patients with an LMR of < 2.52, compared with 3.5 months in those with an LMR of ≥ 2.52 (p = 0.022). The median OS was 12.8 months in patients with an LMR of < 2.52, compared with 23.4 months in those with an LMR of ≥ 2.52 (p < 0.001). The disease control rate was significantly higher in the high LMR group (p = 0.032). The HR spline curve analysis revealed that an LMR range of approximately 1.8-2.6 represents an optimal cut-off for predicting both PFS and OS. CONCLUSIONS: LMR is a readily accessible prognostic biomarker for both PFS and OS in patients with unresectable HCC treated with Dur/Tre, and may serve as a practical tool for risk stratification in clinical practice.

  Apr. 2026, Liver international : official journal of the International Association for the Study of the Liver, 46(4) (4), e70570, English, International magazine

  Scientific journal


• Impact of Borderline Resectable Criteria on Hepatocellular Carcinoma Treatment From the Perspective of Tumor Burden.

  Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Masaki Omori, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Hiroaki Yanagimoto, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: The classification of oncological resectability for hepatocellular carcinoma (HCC) has been established, requiring validation of treatment outcomes for hepatectomy and systemic chemotherapy. METHODS: The study evaluated treatment outcomes in 978 patients who underwent hepatectomy and 222 patients with HCC who received first-line systemic chemotherapy (atezolizumab plus bevacizumab, lenvatinib, or durvalumab plus tremelimumab). RESULTS: Among three factors defining patients with borderline resectable 1 (BR1) and 2 (BR2), macrovascular invasion factor was associated with significantly worse prognosis in a hepatectomy group (BR1: 34.2 vs. 63.4 months, p = 0.04; BR2: 14.4 vs. 20.9 months, p = 0.004). In contrast, in the systemic chemotherapy group, none of the three factors affected prognosis in either BR1 or BR2 patients. In BR2 patients undergoing hepatectomy, those with a single risk factor had significantly better outcomes than those with 2-3 factors (20.1 vs. 12.6 months, p < 0.001). Similarly, in the entire systemic chemotherapy cohort, patients with a single risk factor had better outcomes than those with 2-3 (22.6 vs. 11.9 months, p = 0.001). However, among chemotherapy responders (per modified Response Evaluation Criteria in Solid Tumors), prognosis did not significantly differ between those with one factor and those with 2-3 factors (25.4 vs. 24.5 months, p = 0.502). CONCLUSION: Macrovascular invasion significantly impacted prognosis in patients undergoing hepatectomy, for both BR1 and BR2, whereas any of the tumor factors did not affect the prognosis of patients receiving systemic chemotherapy. Tumor burden correlated with prognosis in the entire cohort but not in chemotherapy responders, suggesting effective treatment may overcome poor prognostic indicators.

  Apr. 2026, World journal of surgery, 50(4) (4), 1049 - 1058, English, International magazine

  Scientific journal


• Preoperative albumin-bilirubin grade predicts the prognosis in patients with perihilar cholangiocarcinoma.

  Michihiko Yoshida, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Yuki Okazoe, Ryunosuke Konaka, Toru Takahashi, Jun Ishida, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Takumi Fukumoto

  PURPOSE: Perihilar cholangiocarcinoma (PHCC) accounts for 50–60% of cholangiocarcinoma and it has a poor prognosis, with low survival rates after surgery. The albumin–bilirubin (ALBI) score, based on serum albumin and bilirubin levels, has been reported to predict survival more accurately than the Child–Pugh score. This study aimed to evaluate the prognostic value of the modified ALBI score (mALBI) in patients with PHCC following radical resection. METHODS: We retrospectively analyzed the medical records of patients with PHCC who underwent major hepatectomy with extrahepatic bile duct resection between January 2001 and December 2023 at Kobe University. RESULTS: We included 100 patients with PHCC in the analysis. Patients in the low mALBI group (grades 1 and 2a; n = 44) had a significantly better overall and recurrence-free survival than those in the high mALBI group (grades 2b and 3; n = 56). The high mALBI group was associated with higher preoperative CA19-9 levels, a higher incidence of preoperative cholangitis, and recurrent venous and perineural invasion. Postoperatively, the patients in the high mALBI group showed a delayed recovery of serum albumin levels and persistently elevated bilirubin levels. Furthermore, liver regeneration after right hepatectomy was significantly greater in the low mALBI group, whereas no significant difference was observed after left hepatectomy. CONCLUSIONS: The mALBI grade is a promising prognostic biomarker for both overall and recurrence-free survival in patients with PHCC following curative resection.

  Apr. 2026, Surgery today, English, Domestic magazine

  Scientific journal


• Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy.

  Nobuaki Ishihara, Shohei Komatsu, Toshifumi Tada, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Masaki Omori, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Kentaro Tai, Toshihiko Yoshida, Keisuke Arai, Hiroaki Yanagimoto, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  INTRODUCTION: Recurrent hepatocellular carcinoma (HCC) after hepatectomy remains a major clinical challenge, necessitating effective prognostic stratification. The oncological resectability criteria recently proposed by the Japan Liver Cancer Association and the Japanese Society of Hepato-Biliary-Pancreatic Surgery have not yet been validated in recurrent settings. This study aimed to evaluate the prognostic utility of these criteria in patients with recurrent HCC after hepatectomy. METHODS: This retrospective study included 505 patients with recurrent HCC following initial hepatectomy. Patients were classified into three groups-resectable (R), borderline resectable 1 (BR1), and borderline resectable 2 (BR2)-based on the oncological resectability criteria. Post-recurrence survival was evaluated using the Kaplan-Meier method, and multivariate analysis was performed to identify clinical factors associated with post-recurrence survival. RESULTS: Among the 505 patients, 248 patients were classified as R, 80 as BR1, and 177 as BR2. The median post-recurrence survival was 73.4 months for the R group, 33.6 months for the BR1 group, and 12.4 months for the BR2 group (p < 0.001). Multivariate analysis identified BR1/BR2 classification (p < 0.001), modified albumin-bilirubin grade 2b or 3 (p < 0.001), and recurrence within 1 year (p = 0.004) as independent predictors of poor post-recurrence survival. CONCLUSIONS: The oncological resectability criteria effectively stratified post-recurrence survival in patients with recurrent HCC. These findings suggest that a multidisciplinary approach may benefit patients with BR1 or BR2 recurrence. Further studies are warranted to explore optimal treatment strategies for recurrent HCC.

  Mar. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(3) (3), 368 - 376, English, International magazine

  Scientific journal


• Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study.

  Jun Ishida, Hirochika Toyama, Takayuki Kodama, Yoshihide Nanno, Takuya Mizumoto, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Tomoo Ito, Takumi Fukumoto

  BACKGROUND: Pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) with arterial abutment is a complex, high-risk surgery. We aimed to investigate the clinicopathological features, risk factors, and learning curve for local recurrence after pancreatectomy for PDAC with arterial abutment. METHODS: Sixty consecutive patients who underwent pancreatectomy for borderline resectable and locally advanced PDAC with arterial abutment at Kobe University Hospital between 2010 and 2020 were enrolled in this retrospective study. Logistic regression analysis was performed to investigate the risk factors for local recurrence. The local recurrence rate was examined for every 10 cases over time. RESULTS: Eighteen (30.0%) patients developed local recurrence; 12 (20.0%) developed local-only recurrence, and six (10.0%) developed local and other recurrences. The median survival time after surgery was similar between patients with local-only (n = 12) and other recurrences (n = 31) (18.9 vs. 17.3 months, p = 0.650). The local recurrence rate was significantly lower during the late period than during the early period (13.3% vs. 46.7%, respectively). In the multivariate analyses, the operative period (odds ratio, 7.01; 95% CI: 1.09-45.2; p = 0.041) was the independent factor associated with local recurrence. The local recurrence rate in the first 10 patients was 70%, but it gradually decreased to 10% in the last 10 patients. CONCLUSIONS: Local recurrence has a significant impact on survival, as do other recurrences after pancreatectomy for PDAC with arterial abutment. A learning curve may exist for the local recurrence rate, suggesting that it should be performed by experienced surgical teams at high-volume centers.

  Mar. 2026, Annals of gastroenterological surgery, 10(2) (2), 559 - 569, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Association Between Postoperative Complications Assessed by the Comprehensive Complication Index (CCI) and Early Recurrence after Pancreaticoduodenectomy for Biliary Tract Cancer.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Michihiko Yoshida, Ryunosuke Konaka, Toru Takahashi, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Takumi Fukumoto

  BackgroundThis study aimed to evaluate the impact of postoperative complications on early recurrence (ER) after pancreaticoduodenectomy (PD) for biliary tract cancer (BTC).MethodsPatients who underwent PD for BTC between 2009 and 2022 were enrolled in this study. Postoperative complications were assessed using the comprehensive complication index (CCI), calculated by summing all the complications. The optimal CCI cutoff value for predicting ER was selected based on the minimum P value from the chi-square test. ER was defined as recurrence within 12 months of resection. Risk factors for ER were identified using multivariate analysis.ResultsA total of 118 patients were analyzed. ER was observed in 34 (28.8 %) patients, indicating a significantly poorer prognosis than those without ER (log-rank, P < .001). No significant differences were observed in the primary tumor site or pathological features between the low CCI (<42.6) and high CCI (≥42.6) groups. The incidence of ER was significantly higher in the high CCI group than in the low CCI group (50.0% vs 24.0%, P = .015). Multivariate analysis revealed that high CCI (odds ratio [OR] 4.43, 95% confidence interval [CI] 1.41-13.97, P = .011) and R1 resection (OR 4.88, 95% CI 1.43-16.70, P = .012) were independent risk factors for ER.DiscussionPostoperative complications after PD for BTC were found to be independent risk factors for ER.

  Feb. 2026, The American surgeon, 92(2) (2), 386 - 392, English, International magazine

  Scientific journal


• Impact of intrahepatic lesions on lesion-specific response rates in patients with hepatocellular carcinoma treated with lenvatinib or immune checkpoint inhibitors.

  Masaki Omori, Shohei Komatsu, Toshifumi Tada, Nobuaki Ishihara, Takanori Matsuura, Eisuke Ueshima, Yoshimi Fujishima, Jun Ishihda, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: This study evaluated how lesion location affects treatment response and prognosis in hepatocellular carcinoma (HCC) patients treated with lenvatinib (LEN) or immune checkpoint inhibitors (ICIs; atezolizumab/bevacizumab or durvalumab/tremelimumab). Considering tumor microenvironment and heterogeneity, we analyzed lesion-specific responses to optimize therapy. METHODS: In this retrospective study, lesion-specific responses were assessed for intrahepatic lesions (IHLs), lung, lymph node, intra-abdominal, and other lesions; bone metastases were excluded due to evaluation limitations. Responses were measured using a modified size-based RECIST 1.1 method. Lesion-specific objective response rate (ORR) and disease control rate (DCR) were compared between LEN and ICI groups. RESULTS: ORR for IHLs was higher with ICIs than LEN (16.3 % vs. 3.5 %, P = 0.002). No significant differences were observed for lung, lymph node, or intra-abdominal lesions; adrenal metastases showed no response in either group. Subgroup analysis indicated better ORR and DCR for lung lesions treated with ICIs and lymph node lesions treated with LEN in patients without IHLs versus those with IHLs. CONCLUSIONS: ICIs achieved higher ORR in IHLs than LEN, with no significant differences for metastatic lesions. The presence of IHLs may influence distant lesion response, and therapeutic efficacy varies with treatment regimen.

  Feb. 2026, HPB : the official journal of the International Hepato Pancreato Biliary Association, 28(2) (2), 209 - 217, English, International magazine

  Scientific journal


• Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer.

  Dongha Lee, Hirochika Toyama, Yoshihide Nanno, Hiroyuki Nakamura, Taisuke Okawa, Takuya Mizumoto, Jun Ishida, Masayuki Akita, Keisuke Arai, Toshihiko Yoshida, Shinichi So, Tsuyoshi Urade, Kenji Fukushima, Shohei Komatsu, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND/AIM: The prognostic impact of the timing of adjuvant chemotherapy initiation in patients with resected pancreatic cancer is unclear. Therefore, this study aimed to investigate whether delayed initiation of S-1 adjuvant chemotherapy affects the survival of patients with resectable pancreatic cancer. PATIENTS AND METHODS: Patients who received S-1 adjuvant chemotherapy after undergoing R0/R1 resection were grouped according to whether adjuvant chemotherapy was initiated <60 (n=36) or ≥60 days (n=27) after surgery. Correlations between the time to chemotherapy initiation, clinicopathological factors, and survival were analyzed. RESULTS: The median and mean times to chemotherapy initiation were 58 and 61 days, respectively. The delayed group had worse 2-year overall (57% vs. 80%, p=0.032) and recurrence-free survival (35% vs. 54%, p=0.044) rates than the early group. These results were similar in patients who completed S-1 adjuvant chemotherapy. In multivariate analysis, delayed initiation of chemotherapy, R1 resection, and tumor size (≥40 mm) were independent prognostic factors for poor overall survival. The delayed group had more patients with severe postoperative complications (Clavien-Dindo grade ≥III) (30% vs. 8%, p=0.028) and delayed recovery of serum albumin levels (postoperative days 7, 14, and 30: p=0.040, 0.004, and 0.003, respectively) than the early group. CONCLUSION: Delayed initiation of S-1 adjuvant chemotherapy had an adverse impact on survival and was correlated with severe postoperative complications and delayed recovery of postoperative nutritional status.

  Feb. 2026, Anticancer research, 46(2) (2), 987 - 999, English, International magazine

  Scientific journal


• Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND: Findings regarding long-term outcomes of unresectable hepatocellular carcinoma (uHCC) patients treated with atezolizumab and bevacizumab (Atez/Bev) have yet to be reported. This study was performed to evaluate results regarding 3 year survival of such patients treated in real-world clinical settings. METHODS: This multicenter retrospective study included 555 patients with Child-Pugh A and BCLC stage B or C, for whom Atez/Bev treatment was initiated in the period from 2020 to 2021. Best treatment response, progression-free survival (PFS), overall survival (OS), post-progression survival (PPS), and immune-related adverse events (irAEs) were analyzed. RESULTS: Median age was 73 years and 80.2% were male. Atez/Bev was given as first-line therapy in 55.3%. Objective response rate (ORR) was 41.3% and disease control rate (DCR) was 79.4%. Median PFS was 6.2 months, while median OS was 21.6 months with a 3 year survival rate of 29.7%. Patients treated with Atez/Bev as first-line therapy showed a higher 3 year survival rate of 35.9%. Post-progression treatment was administered to 54.1% of the patients and median PPS in those was 10.9 months. Conversion therapy was performed in 5.9%. IrAEs occurred in 13.3% (grade 5: 0.7%). CONCLUSIONS: uHCC patients treated with Atez/Bev in clinical practice settings showed good ORR and DCR, as well as favorable long-term survival with a 3 year survival rate of approximately 30%, including 35.9% for first-line users.

  Feb. 2026, Cancer medicine, 15(2) (2), e71640, English, International magazine

  Scientific journal


• 肝細胞癌腫瘍学的切除可能性分類に基づいた肝切除および薬物療法治療成績の検証

  小松 昇平, 多田 俊史, 上嶋 英介, 松浦 敬憲, 祖父江 慶太郎, 木戸 正浩, 福島 健司, 浦出 剛史, 吉田 俊彦, 荒井 啓輔, 南野 佳英, 柳本 泰明, 児玉 裕三, 村上 卓道, 福本 巧

  (株)アークメディア, Jan. 2026, 肝胆膵, 92(1) (1), 112 - 114, Japanese


• Prognosis Using Modified Albumin-Bilirubin Grade in Resected Biliary Tract Cancer: A Multicenter Propensity Score-matched Analysis.

  Toru Takahashi, Hiroaki Yanagimoto, Masayuki Akita, Daisuke Tsugawa, Michihiko Yoshida, Yasuhiro Ueda, Taro Okazaki, Kimihiko Ueno, Hayato Miyazaki, Izuru Otsubo, Shohei Komatsu, Takumi Fukumoto

  BACKGROUND/AIM: Currently, the modified albumin-bilirubin (mALBI) grade, a novel liver function assessment, is used as a prognostic factor in many areas of gastrointestinal cancer. We evaluated whether mALBI grade predicted survival in a large multicenter cohort of patients who underwent curative-intent resection for biliary tract cancer (BTC). PATIENTS AND METHODS: We retrospectively analyzed data for 634 patients who underwent curative resection for BTC at four centers during 2001-2023. The mALBI grade was calculated from preoperative albumin and total bilirubin levels. Cox proportional hazards regression was used to assess the association of mALBI grade with overall survival (OS) and recurrence-free survival (RFS) in a propensity score-matched cohort. The mALBI grade was defined by subdividing ALBI grade 2 at a cutoff of -2.27; patients with mALBI grades 1-2a were classified as the low mALBI group, and those with grades 2b-3 as the high mALBI group. RESULTS: After propensity score-matching, the high mALBI group remained associated with poorer OS (44 vs. 70 months; p=0.015) than the low mALBI group. Multivariate analysis revealed that high mALBI grade was independently associated with poor OS (hazard ratio=1.584, 95% confidence interval=1.077-2.331; p=0.020) and RFS (hazard ratio =1.447, 95% confidence interval=1.023-2.046, p=0.037). CONCLUSION: A high mALBI grade was associated with shorter OS and RFS in patients with resected BTC. Preoperative mALBI grade is an important prognostic indicator for risk stratification and prognostic evaluation.

  2026, Cancer diagnosis & prognosis, 6(4) (4), 703 - 714, English, International magazine

  Scientific journal


• Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.

  Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Satoru Kakizaki, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Hiroki Nishikawa, Takashi Nishimura, Kazuhito Kawata, Hisashi Kosaka, Kosuke Matsui, Atsushi Naganuma, Hironori Tanaka, Hideko Ohama, Hidekatsu Kuroda, Tomomitsu Matono, Tomoko Aoki, Hironori Ochi, Michitaka Imai, Shinichiro Nakamura, Shohei Komatsu, Hideyuki Tamai, Jumpei Okamura, Yuki Kanayama, Kazunari Tanaka, Fujimasa Tada, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takanori Matsuura, Hidenao Noritake, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  AIMS: This study aimed to evaluate the therapeutic efficacy of durvalumab and tremelimumab (Dur/Tre) in patients with hepatocellular carcinoma (HCC) who had a tumor thrombus in the main portal vein trunk (Vp4) or high tumor burden (HTB). METHODS: A total of 309 patients with BCLC stage B or C HCC who received Dur/Tre between March 2023 and October 2024 were included. HTB was defined as the presence of at least one of the following radiological findings: ≥ 50% liver involvement by HCC, bile duct invasion, or the presence of Vp4. RESULTS: Both the patients with Vp4 and HTB-positive group had significantly higher proportions of BCLC stage C disease (p = 0.01 and 0.007, respectively) and serum DCP levels ≥ 100 mAU/mL (p = 0.03 and < 0.001, respectively), and significantly higher neutrophil-to-lymphocyte ratio (p = 0.04 and p = 0.004, respectively) compared to their respective counterparts. While the objective response rate did not significantly differ between the HTB-positive and HTB-negative groups (21.6% vs. 16.2%, p = 0.5), it was significantly higher in patients with Vp4 than in those without (42.9% vs. 15.6%, p = 0.02). There were no significant differences in progression-free survival or overall survival (OS) between patients with and without Vp4 (p = 0.1 and 0.3, respectively) and nor between the HTB-positive and HTB-negative groups (both p = 0.3). Among patients with both Vp4 and HTB, responders had longer OS than non-responders. CONCLUSIONS: Dur/Tre may be a viable treatment option for patients with Vp4 and HTB.

  Jan. 2026, Hepatology research : the official journal of the Japan Society of Hepatology, 56(1) (1), 89 - 99, English, International magazine

  Scientific journal


• Impact of Child-Pugh score on surgical outcomes after distal gastrectomy and right hemicolectomy: a retrospective study from the Japanese National Clinical Database.

  Ayako Shimada, Hideki Endo, Osamu Itano, Hiroyuki Yamamoto, Shohei Komatsu, Hiroshi Hasegawa, Yoshihiro Kakeji, Ken Shirabe

  BACKGROUND: The association between preoperative liver function and short-term outcomes after gastrointestinal cancer surgery is unknown. This study investigated the impact of Child-Pugh score-based preoperative liver dysfunction on short-term outcomes after distal gastrectomy and right hemicolectomy. MATERIALS AND METHODS: We included patients who underwent distal gastrectomy for gastric cancer or right hemicolectomy for colon cancer between 2018 and 2022 from the Japanese National Clinical Database. Patients were classified based on their Child-Pugh scores, and the association between Child-Pugh scores and short-term outcomes was assessed using multivariable logistic regression. Overall postoperative mortality and incidence of postoperative complications within 30 days (Clavien-Dindo Grade >III) were evaluated. RESULTS: A total of 104 905 distal gastrectomy and 62 775 right hemicolectomy cases were included. Overall surgery-related mortality increased to 31.8% and 20.7% and overall complication rate increased to 18.2% and 31% in patients with a Child-Pugh score of 9 who underwent distal gastrectomy and right hemicolectomy, respectively. Even after risk adjustment, those with a score of 9 had a significantly higher risk of surgical mortality than patients with a Child-Pugh score of 5 following distal gastrectomy [odds ratio (OR) 64.80, 95% confidence interval (CI) 23.64-177.65] and right hemicolectomy (OR 39.56, 95% CI 14.77-106.01). CONCLUSIONS: Surgical mortality and incidence of surgical complications were associated with the Child-Pugh score in a score-dependent manner. The Child-Pugh score effectively estimates postoperative risk in gastrointestinal cancer surgery. Special caution is needed for patients with poor liver function, especially those with higher Child-Pugh scores.

  Jan. 2026, International journal of surgery (London, England), 112(1) (1), 1081 - 1089, English, International magazine

  Scientific journal


• Assessment of surgical difficulty in multiple laparoscopic liver resection using the aggregate value of scores based on the IWATE criteria.

  Daisuke Takimoto, Hidetoshi Gon, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: No studies exist regarding the methods for evaluating the surgical difficulty of multiple laparoscopic liver resection (MLLR). Hence, this study aimed to evaluate the usefulness of total scores calculated using the IWATE criteria for each resection site to assess the surgical difficulty of MLLR. METHODS: Medical records of patients who underwent MLLR at Kobe University Hospital between 2010 and 2023 were retrospectively reviewed. First, the total difficulty score was calculated for each patient by summing the IWATE criteria scores for all resection sites. Subsequently, we analyzed the correlation between this total difficulty score and surgical outcomes of MLLR. Finally, receiver operating characteristic analysis was employed to determine the optimal cutoff value of the total difficulty score. This cutoff value was used to categorize patients into the high- and low-total difficulty score groups, allowing for a comparison of their surgical outcomes. RESULTS: This study included 63 patients. The total difficulty score correlated with operation time [r = 0.54, 95% confidential interval (CI): 0.34-0.70, P < 0.001] and blood loss (r = 0.27, 95% CI: 0.03-0.90, P = 0.029), and was associated with postoperative complications (odds ratio: 1.33, 95% CI: 1.14-1.60, P < 0.001). Patients with total difficulty scores ≤ 11 and ≥ 12 were included in the low- and high-score groups, respectively. The high-score group exhibited longer operation times (481 min vs. 372 min, P = 0.001), greater blood loss (110 ml vs. 50 ml, P = 0.005), and higher overall complication rates (71% vs. 29%, P = 0.001) than the low-score group. CONCLUSIONS: The total difficulty score based on the IWATE criteria may be a useful tool for assessing surgical difficulty in MLLR.

  Jan. 2026, Surgical endoscopy, 40(1) (1), 182 - 191, English, International magazine

  Scientific journal


• 切除不能胆嚢癌に対して術前GCD療法を行い根治切除にて組織学的奏効が得られた1例

  高橋 徹, 柳本 泰明, 津川 大介, 秋田 真之, 小中 龍之介, 南野 佳英, 浦出 剛史, 福島 健司, 小松 昇平, 浅利 貞毅, 児玉 貴之, 木戸 正浩, 伊藤 智雄, 福本 巧

  (株)癌と化学療法社, Dec. 2025, 癌と化学療法, 52(13) (13), 968 - 970, Japanese


• Exploring the potential utility of modified difficulty scores based on the IWATE criteria for assessing the surgical difficulty of laparoscopic repeat liver resection.

  Hidetoshi Gon, Shohei Komatsu, Tatsuki Kusuhara, Daisuke Takimoto, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Laparoscopic repeat liver resection (LRLR) is more challenging than initial laparoscopic liver resection in some cases because of intra-abdominal adhesions and liver deformation caused by previous operations. However, there are insufficient reports on difficulty scoring systems for LRLR. In this study, we aimed to explore whether the IWATE criteria and its modified scoring system could effectively predict surgical outcomes in patients undergoing LRLR. METHODS: Patients who underwent LRLR at the Kobe University Hospital between 2014 and 2024 were enrolled. We assessed the correlation between difficulty scores based on the IWATE criteria and LRLR surgical outcomes. The correlation between the modified difficulty scores and LRLR surgical outcomes were also evaluated. The modified difficulty scores were calculated by adding 2 points for ipsilateral recurrence and 1 point for a previous history of open liver resection to the original difficulty scores of the IWATE criteria. RESULTS: Eighty-four patients who underwent LRLR were enrolled. The median value of the IWATE criteria and modified difficulty score was 4 and 6, respectively. The median operation time and blood loss were 287 min and 10 mL, respectively. Nineteen (23%) patients experienced postoperative complications, wherein four (5%) had Clavien-Dindo grade ≥ IIIa complications. The IWATE criteria difficulty score correlated with operation time (r = 0.52, 95% confidential interval CI 0.35-0.66, P < 0.001) and blood loss (r = 0.26, 95% CI 0.05-0.45, P = 0.018), while the modified difficulty score correlated with operation time (r = 0.53, 95% CI 0.36-0.67, P < 0.001), blood loss (r = 0.31, 95% CI 0.11-0.49, P = 0.004), and overall postoperative complications (odds ratio 1.34 [interquartile range 1.23, 1.47], P = 0.019). CONCLUSIONS: The IWATE criteria and modified difficulty score may be useful for assessing LRLR surgical difficulty. Additionally, the modified difficulty score may more precisely predict the risk of postoperative complications.

  Dec. 2025, Surgical endoscopy, 39(12) (12), 8228 - 8236, English, International magazine

  Scientific journal


• 【肝内胆管癌の再考-small ductとlarge duct型分類のインパクト-】病理学的特徴と分類 肝内胆管癌の分類は臨床的に重要か

  秋田 真之, 柳本 泰明, 石田 潤, 南野 佳英, 浦出 剛史, 福島 健司, 小松 昇平, 浅利 貞毅, 水戸 正浩, 福本 巧

  (株)アークメディア, Nov. 2025, 肝胆膵, 91(5) (5), 553 - 558, Japanese


• Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  AIM: To evaluate the safety and efficacy of durvalumab plus tremelimumab (Dur/Tre) in older adults with unresectable hepatocellular carcinoma (HCC). METHODS: A total of 345 patients with HCC who received Dur/Tre were included in this study. Using propensity score matching, we compared outcomes between older (aged ≥ 75 years; n = 120) and younger individuals (n = 120). RESULTS: The median progression-free survival (PFS) was 3.3 months in the older group and 4.5 months in the younger group (p = 0.271). The median overall survival (OS) was 17.0 months in older individuals and 19.2 months in younger individuals (p = 0.598). No statistically significant differences were observed in the therapeutic response between the two groups (p = 0.264). Additionally, the incidence of immune-mediated adverse events (AEs) did not differ significantly between older and younger individuals. Multivariate analyses revealed that age group (older vs. younger) was not an independent prognostic factor for PFS (p = 0.250) or OS (p = 0.489). In a subgroup analysis stratifying older individuals into three age categories (75-79, 80-84, and ≥ 85 years), no significant differences were observed in the cumulative OS or PFS across the subgroups (p = 0.308 and 0.783). Similarly, the incidence of immune-mediated AEs did not differ significantly among the age categories. CONCLUSIONS: Dur/Tre appears to be a safe and effective treatment option for patients with HCC, regardless of age. Dur/Tre appears to be a safe and effective treatment option for patients with unresectable HCC, regardless of age.

  Nov. 2025, Hepatology research : the official journal of the Japan Society of Hepatology, 55(11) (11), 1507 - 1517, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.

  Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Teruki Miyake, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

  BACKGROUND: Immune-mediated adverse events (imAEs) are a significant concern in patients with unresectable hepatocellular carcinoma (uHCC) undergoing combination immunotherapy with durvalumab and tremelimumab (Dur/Tre). This study aimed to investigate the potential association of risk factors, particularly nutrition and immune markers, associated with the development of imAEs. METHODS: Between November 2022 and December 2024, 312 patients with uHCC treated with Dur/Tre were enrolled and retrospectively analyzed. Clinical characteristics, inflammatory markers, and nutritional indices (Geriatric Nutritional Risk Index [GNRI], body mass index, Prognostic Nutritional Index-Onodera, C-reactive protein-to-albumin ratio, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio) were evaluated to identify predictors for imAE development. RESULTS: The imAEs occurred in 122 patients (39.1%), most commonly affecting dermatological, gastrointestinal, and endocrine systems. On multivariate analysis, only normal GNRI (≥ 98) was independently associated with a higher incidence of imAE (odds ratio: 1.99, 95% confidence interval: 1.05-3.79, P = 0.036). Patients with GNRI ≥ 98 also showed better overall survival (OS) than those with GNRI < 98 (not reached vs. 12.5 months, P < 0.001). Among patients who developed imAEs, no significant differences were observed in the imAE types or high-dose steroid use between the GNRI ≥ 98 group (n = 66) and the GNRI < 98 group (n = 56) (40.9% vs. 58.9%, P = 0.069). CONCLUSIONS: Normal GNRI status (≥ 98) was associated with an increased risk of imAE development and improved OS in patients with uHCC receiving Dur/Tre therapy. GNRI may be a useful clinical factor for identifying patients at higher risk of developing imAEs.

  Nov. 2025, Journal of gastroenterology, 60(11) (11), 1427 - 1436, English, Domestic magazine

  Scientific journal


• Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery.

  Takuya Mizumoto, Yoshihide Nanno, Jun Ishida, Dongha Lee, Kenji Fukushima, Shohei Komatsu, Hiroaki Yanagimoto, Sadaki Asari, Masahiro Kido, Takumi Fukumoto

  AIM: Regarding the resectability of pancreatic adenocarcinoma (PDAC), not only anatomical factors but also biological and conditional factors have come to be considered. This study examined the impact of the Global Leadership Initiative on Malnutrition (GLIM) criteria on prognosis after resection of anatomically resectable PDAC. METHODS: The medical records of consecutive patients who underwent resection for resectable PDAC between January 1, 2014, and December 31, 2022, were retrospectively reviewed. Patients were classified as normal, moderately, or severely malnourished according to the GLIM criteria. RESULTS: In total, 194 patients were included in the analysis. According to the GLIM criteria, 61 (31.4%), 49 (25.2%), and 84 (42.3%) patients were normal, moderately, and severely malnourished, respectively. Patients with malnutrition had shorter overall, recurrence-free, and disease-specific survival (OS, RFS, and DSS) than normal patients (OS, normal vs. moderate, p = 0.015; normal vs. severe, p < 0.001; RFS, normal vs. moderate p = 0.012, normal vs. severe, p < 0.001; DSS, normal vs. moderate, p = 0.023; normal vs. severe, p < 0.001). In multivariate analysis regarding OS using all factors, moderate or severe malnutrition according to the GLIM criteria (p = 0.007), performance status (p = 0.086), preoperative diabetes (p = 0.017), tumor diameter ≥ 3 cm (p = 0.002), lymph node metastasis (p < 0.001), and postoperative adjuvant therapy (p = 0.027) were independent prognostic factors. In multivariate analysis using preoperative factors, malnutrition according to the GLIM criteria remained a significant prognostic factor (p = 0.003). CONCLUSION: The GLIM criteria are effective prognostic predictors in patients with resectable PDAC undergoing upfront surgery. Preoperative nutritional assessment using these criteria may contribute to determining treatment plans for resectable PDAC.

  Nov. 2025, Annals of gastroenterological surgery, 9(6) (6), 1351 - 1361, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 術前ICU入室症例に対する生体肝移植の術後成績の検討

  滝本 大輔, 福島 健司, 荒井 啓輔, 小松 昇平, 木戸 正浩, 浦出 剛史, 宗 慎一, 吉田 俊彦, 田井 謙太郎, 井口 浩輔, 南野 佳英, 柳本 泰明, 福本 巧

  (一社)日本移植学会, Oct. 2025, 移植, 60, 342 - 342, Japanese


• 当院におけるICU管理後の肝移植の治療成績

  荒井 啓輔, 小松 昇平, 福島 健司, 滝本 大輔, 木戸 正浩, 浦出 剛史, 宗 慎一, 吉田 俊彦, 田井 謙太郎, 井口 浩輔, 南野 佳英, 柳本 泰明, 松浦 敬憲, 福本 巧

  (一社)日本移植学会, Oct. 2025, 移植, 60, 342 - 342, Japanese


• 一過性門脈ガスを生じた高齢ドナーからの脳死肝移植の一例

  吉田 俊彦, 福島 健司, 木戸 正浩, 小松 昇平, 浦出 剛史, 宗 慎一, 荒井 啓輔, 井口 浩輔, 秋田 真之, 水本 拓也, 石田 潤, 南野 佳英, 浅利 貞毅, 柳本 泰明, 福本 巧

  (一社)日本移植学会, Oct. 2025, 移植, 60, 344 - 344, Japanese


• 膵腎同時移植後3ヵ月で発症した外腸骨動脈吻合部仮性動脈瘤に対し血管内治療を施行し移植膵グラフトを温存し得た一例

  横田 雅治, 南野 佳英, 石田 潤, 水本 拓也, 李 東河, 大川 太資, 中村 浩之, 荒井 啓輔, 吉田 俊彦, 浦出 剛史, 福島 健司, 小松 昇平, 浅利 貞毅, 木戸 正浩, 福本 巧

  (一社)日本移植学会, Oct. 2025, 移植, 60, 363 - 363, Japanese


• Multidisciplinary strategies including local treatment to achieve drug-free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto

  Atezolizumab plus bevacizumab (AteBev) is used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Combining AteBev with sequential local treatment holds potential; however, optimal timing, modality and continuation of systemic chemotherapy remain undetermined. In the present study, a retrospective analysis of 123 patients with HCC treated with AteBev at two institutions was performed. Patients with no apparent residual lesions after sequential local treatment or AteBev treatment alone were followed up without any systemic chemotherapy ('drug-free' cohort). Outcomes focused on the impact of achieving 'drug-free' status, with timing assessed based on tumor size and α-fetoprotein levels. The results revealed that serum α-fetoprotein levels and tumor shrinkage plateaued at ~3 and 6 months post-AteBev treatment, respectively. Patients achieving 'drug-free' status demonstrated prolonged median survival (P<0.001) and progression-free survival (P<0.001), comparable with patients with 'clinical complete response' or 'drug-off' statuses. Moreover, particle radiotherapy was the most common local treatment modality. In conclusion, achieving a 'drug-free' status was associated with favorable prognoses. Optimal timing for sequential local treatment is suggested as 3-6 months after AteBev initiation, with multidisciplinary strategies to achieve 'drug-free' status offering a promising option for the treatment of advanced HCC.

  Oct. 2025, Oncology letters, 30(4) (4), 466 - 466, English, International magazine

  Scientific journal


• Utilizing the Conversion Concept Based on Disease Status Following Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

  Shohei Komatsu, Toshifumi Tada, Kazuki Terashima, Nobuaki Ishihara, Masaki Omori, Takanori Matsuura, Eisuke Ueshima, Keitaro Sofue, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND: The introduction of atezolizumab plus bevacizumab (Ate/Bev) has improved hepatocellular carcinoma (HCC) treatment, enabling the concept of "ABC conversion," where curative treatments follow Ate/Bev. However, the optimal post-Ate/Bev treatment strategy remains unclear. METHODS: This study evaluated 149 patients with unresectable HCC treated with Ate/Bev and categorized them into six groups: drug-free, surgery, radiotherapy, transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy (TACE/HAIC), chemotherapy, and best supportive care (BSC). The surgery, radiotherapy, and TACE/HAIC groups were classified as "local conversion" and further subdivided into two subtypes based on the therapeutic intent: "curative local conversion" and "palliative local conversion." RESULTS: The 3-year overall survival (OS) rates for patients in the drug-free, surgery, radiotherapy, TACE/HAIC, chemotherapy, and BSC groups were 100.0%, 66.7%, 52.6%, 41.0%, 13.6%, and 10.1%, respectively (p < 0.001). No significant differences were observed between the surgery and TACE/HAIC groups (3-year OS: 66.7% vs. 41.0% and p = 0.441) or between the radiotherapy and TACE/HAIC groups (3-year OS: 52.6% vs. 41.0% and p = 0.838). Patients who underwent local conversion had a significantly better median survival time (28.0 vs. 16.3 months and p < 0.001). The 3-year OS rates for patients who underwent curative and palliative local conversion were 68.6% and 37.0%, respectively. Although curative local conversion demonstrated better prognosis than that noted with palliative local conversion, the difference was not statistically significant (p = 0.155). CONCLUSION: Local conversion after Ate/Bev treatment may potentially improve survival rates. Even when curative local conversion is not feasible, palliative local conversion may still offer clinical benefits.

  Oct. 2025, World journal of surgery, 49(10) (10), 2854 - 2862, English, International magazine

  Scientific journal


• Space-making Particle Therapy Using Bioabsorbable Spacer for Bone and Soft Tissue Sarcomas: Two-institution Experience.

  Akifumi Kajihara, Yusuke Demizu, Kazuma Iwashita, Sungchul Park, Nobuyoshi Fukumitsu, Sunao Tokumaru, Daiki Takahashi, Yoshiro Matsuo, Kazuki Terashima, Tomoaki Okimoto, Satoshi Seno, Takeaki Ishihara, Daisuke Miyawaki, Shohei Komatsu, Yi-Wei Chen, Takumi Fukumoto, Ryohei Sasaki

  BACKGROUND/AIM: Particle therapy for bone and soft tissue sarcomas (BSTSs) is limited if the tumor is close to the intestine. Space-making particle therapy (SMPT) using a bioabsorbable spacer (BAS) may treat this condition. We aimed to evaluate SMPT outcomes using a BAS for BSTSs. PATIENTS AND METHODS: We retrospectively identified 28 patients who underwent SMPT with BAS between November 2019 and August 2023. Outcomes and associations with each factor were analyzed using the Kaplan-Meier method and log-rank test. Adverse events were determined using CTCAE v5.0. RESULTS: The median age was 48.5 years (1-78), and the most common histological type was chordoma (25%). Among all patients, 71% were treated with proton therapy and 29% with carbon ion therapy. The most frequent dose fractionations were 70.4 Gy (relative biological effectiveness) in 16 fractions (36%) and 32 fractions (36%). The median follow-up period was 29.5 months (7-48). The 3-year overall survival, progression-free survival, and local control rates were 83%, 63%, and 80%, respectively. Tumor location (pelvis) and low aggressive sarcoma (chordoma and Ewing sarcoma) were significantly associated with better progression-free survival. Adverse events related to the BAS included grade 2 constipation in 7% of patients. Radiation toxicities included acute grade 2 and 3 dermatitis in 36% and 4% of patients, respectively. Late grade 2 toxicities included fractures (7%), peripheral motor neuropathy (4%), dermatitis (4%), superficial soft tissue fibrosis (4%), and skin pain (4%). Late grade 3 toxicities involved fractures (4%). CONCLUSION: SMPT using a BAS appears effective and safe for treating BSTSs near critical organs, enabling curative dosing with minimal toxicity. Longer follow-up is needed to assess long-term outcomes.

  Sep. 2025, Anticancer research, 45(9) (9), 3785 - 3794, English, International magazine

  Scientific journal


• Vascular Invasion Within the Resectability Criteria Is a Prognostic Factor in Patients Treated With Atezolizumab and Bevacizumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  BACKGROUND AND AIMS: To assess the outcomes of patients with hepatocellular carcinoma (HCC) who were treated with atezolizumab plus bevacizumab (Atezo/Bev), categorised by oncological resectability criteria, which reflect tumour burden and extent of disease. METHODS: A cohort of 467 HCC patients who received Atezo/Bev was enrolled. Patients were classified into two groups based on oncological resectability criteria: BR (borderline resectable) 1 (n = 153) and BR2 (n = 314). RESULTS: The median progression-free survival (PFS) was 9.0 months in the BR1 group and 6.8 months in the BR2 group (p = 0.014). Multivariable analysis identified the following independent prognostic factors for PFS: age ≥ 75 years (hazard ratio [HR], 1.309), albumin-bilirubin (ALBI) grade ≥ 2 (HR, 1.494), neutrophil-to-lymphocyte ratio (NLR) ≥ 3 (HR, 1.289), α-fetoprotein ≥ 100 ng/mL (HR, 1.523) and BR2 classification (HR, 1.360). The median overall survival (OS) was 25.3 months in the BR1 group and 22.3 months in the BR2 group (p = 0.048). Multivariable analysis identified the following independent prognostic factors for OS: age ≥ 75 years (HR, 1.522), ALBI grade ≥ 2 (HR, 2.411), NLR ≥ 3 (HR, 1.635), α-fetoprotein ≥ 100 ng/mL (HR, 1.530) and BR2 classification (HR, 1.421). When oncological resectability factors (tumour number and size, vascular invasion and extrahepatic spread) were incorporated into the multivariable analysis, major vascular invasion emerged as a significant predictor of both PFS (HR, 3.188) and OS (HR, 2.650). CONCLUSIONS: In patients with HCC characterised by limited resectability undergoing Atezo/Bev, vascular invasion, in addition to liver function, is a critical prognostic determinant of tumour progression.

  Aug. 2025, Liver international : official journal of the International Association for the Study of the Liver, 45(8) (8), e70217, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Single-chain variable fragment antibodies targeting the antileukemia agent harringtonine for enzyme-linked immunosorbent assay development.

  Seiichi Sakamoto, Shohei Komatsu, Ai Moriyasu, Gorawit Yusakul, Waraporn Putalun, Poomraphie Nuntawong, Hiroyuki Tanaka, Satoshi Morimoto

  In this study, we generated a single-chain variable fragment (scFv) specific to a potent antileukemic substance, harringtonine (HT) (HT-scFv) that can be used in enzyme-linked immunosorbent assay (ELISA) for the quantitative analysis of HT in the plant genus Cephalotaxus. The variable heavy (VH) and light chain (VL) genes were directly cloned from the cDNA of the hybridoma cell line 1D2, which secretes monoclonal antibody against HT (MAb 1D2). These genes were then assembled with a flexible peptide linker, specifically (Gly4Ser)3, through splicing by overlap extension PCR. The resulting HT-scFv gene was expressed in Escherichia coli. The denatured HT-scFv, produced as inclusion bodies, was solubilized and refolded using a dilution method to restore its functionality as an antibody. Characterization of the HT-scFv demonstrated its high specificity for HT. Additionally, its remarkable properties facilitated the development of an ELISA for HT detection, achieving a limit of detection (LOD) of 12.2 ng/mL. Furthermore, validation analyses showed that the ELISA using HT-scFv exhibited good accuracy and reliability for the quantitative assessment of HT in C. harringtonia "Fastigiata." This study highlights the potential of HT-scFv as a valuable tool for ELISA in the quantitative analysis of HT.

  Jul. 2025, Journal of immunoassay & immunochemistry, 46(5) (5), 1 - 16, English, International magazine

  Scientific journal


• Robotic pancreaticoduodenectomy for portal annular pancreas: how to do it.

  Jun Ishida, Hirochika Toyama, Yoshihide Nanno, Takuya Mizumoto, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  Portal annular pancreas (PAP) is an uncommon anomaly in which the pancreatic parenchyma surrounds the portal or superior mesenteric vein. An adequate operative approach is necessary to prevent clinically relevant postoperative pancreatic fistula after pancreaticoduodenectomy for PAP. We herein report a case of robotic pancreaticoduodenectomy for PAP. In PAP, dissection of the retroportal parenchyma is the most important aspect of surgery. Adequate retraction of the portal system using vessel loops allows for a safe dissection and transection of the retroportal parenchyma. The robotic approach has some advantages for dissecting the retroportal parenchyma. The magnified three-dimensional view helps the surgeon distinguish the nerve plexus from the pancreatic parenchyma. The caudal view allows for direct dissection of the retroportal parenchyma from the superior mesenteric artery. Dissection can easily be performed using articulated forceps. Owing to these advantages, robotic pancreaticoduodenectomy can be safely performed for PAP.

  Jul. 2025, Surgery today, 55(7) (7), 1004 - 1007, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The potential efficacy of atezolizumab plus bevacizumab treatment for hepatocellular carcinoma patients with macroscopic portal vein tumor thrombus.

  Shohei Komatsu, Yoshihiko Yano, Kazuki Terashima, Yoshimi Fujishima, Jun Ishida, Nobuaki Ishihara, Takanori Matsuura, Tomoaki Okimoto, Yuzo Kodama, Takumi Fukumoto

  PURPOSE: The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the first-order or main trunk/contralateral branches (Vp3/4) is poor. The present study aimed to clarify the real-world data of atezolizumab plus bevacizumab treatment (Ate/bev) for HCC patients with Vp3/4 PVTT. METHODS: The subjects of this study were 22 consecutive HCC patients with Vp3/4 PVTT, who were treated with Ate/bev. Survival rates and radiological responses were evaluated based on the modified albumin-bilirubin (mALBI) grade [mALBI 1 + 2a (1/2a) versus 2b + 3 (2b/3)] using the modified Response Evaluation Criteria in Solid Tumors. RESULTS: The median survival time of the 22 patients was 15.0 months, with 1- and 2-year survival rates of 62.7% and 49.3%, respectively. The objective response (OR) rates of patients with mALBI 1/2a and 2b/3 were 91.7% (11/12) and 10.0% (1/10), respectively, with a significant difference (p < 0.001). The 2-year survival rates of patients with mALBI 1/2a and 2b/3 were 78.6% and 20.0%, respectively, with a significant difference (p = 0.0041). CONCLUSION: Ate/bev was effective for treating HCC patients with Vp3/4 PVTT. OR rate and MST were favorable, particularly for patients with preserved liver function (mALBI 1/2a), suggesting its great potential for the treatment of HCC in patients with Vp3/4 PVTT.

  Jul. 2025, Surgery today, 55(7) (7), 900 - 908, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab.

  Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

  AIM: To investigate the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) on outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre). METHODS: A total of 182 patients with HCC who received Dur/Tre were included in the analysis. Univariate and multivariate survival analyses were conducted. Additionally, hazard ratio (HR) spline curve analysis was used to determine the optimal NLR cut-off values for predicting overall survival (OS). RESULTS: The median progression-free survival (PFS) was 3.5 months (95% confidence interval [CI]: 2.7-4.4), whereas the median OS was not reached (95% CI: 12.1 months-not reached). Multivariate analysis demonstrated that treatment with Dur/Tre as a second-line therapy or beyond was independently associated with worse PFS (HR: 1.819; 95% CI: 1.230-2.688; p = 0.003). Furthermore, an NLR of ≥ 2.56 was identified as an independent predictor of reduced OS (HR: 1.919; 95% CI: 1.033-3.566; p = 0.039). The median OS was not reached (95% CI: 12.3 months-not reached) in patients with an NLR of < 2.56, compared with 12.1 months (95% CI: 9.0 months-not reached) in those with an NLR of ≥ 2.56 (p = 0.016). A Sankey diagram illustrating post-treatment outcomes revealed that a significantly larger proportion of patients with high NLRs did not proceed to subsequent therapies but instead received best supportive care (p = 0.046). Spline curve analysis showed that an NLR range of approximately 2.3-3.0 represents an appropriate cut-off for predicting OS. CONCLUSIONS: The NLR is a significant prognostic biomarker for OS in patients with HCC treated with Dur/Tre.

  Jun. 2025, Hepatology research : the official journal of the Japan Society of Hepatology, 55(9) (9), 1285 - 1295, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.

  Shohei Komatsu, Toshifumi Tada, Takashi Nishimura, Motofumi Tanaka, Atsushi Takebe, Saeko Kushida, Yoshimi Fujishima, Nobuaki Ishihara, Takanori Matsuura, Ikuo Nakamura, Taro Okazaki, Masahiro Tsuda, Jun Ishida, Ippei Matsumoto, Seiko Hirono, Hirayuki Enomoto, Yuzo Kodama, Takumi Fukumoto

  INTRODUCTION: Oncological resectability criteria for hepatocellular carcinoma have been defined (resectable [R]/borderline resectable 1 [BR1]/borderline resectable 2 [BR2]); however, their validation is necessary. METHODS: A total of 1,469 patients who underwent hepatectomy and 525 patients who received systemic chemotherapy, including lenvatinib, atezolizumab plus bevacizumab, and durvalumab plus tremelimumab, as first-line treatment were analyzed. RESULTS: In the BR1 group, the median survival times (MSTs) of patients who underwent hepatectomy and systemic chemotherapy were 52.7 and 34.6 months, respectively, without a significant difference (p = 0.075). In the propensity score matching (PSM) analysis of the BR1 group, the MSTs of hepatectomy and systemic chemotherapy were 42.4 and 35.1 months, respectively, without a significant difference (p = 0.772). Hepatitis virus infection, modified albumin-bilirubin (mALBI) grade 2b + 3, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas mALBI grade 2b + 3 was the only poor prognostic factor for systemic chemotherapy. In the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 19.5 months, respectively, with significantly better survival for hepatectomy than for systemic chemotherapy (p = 0.017). In the PSM analysis of the BR2 group, the MSTs of hepatectomy and systemic chemotherapy were 20.1 and 21.0 months, respectively, without a significant difference (p = 0.375). Serum alpha-fetoprotein levels≥100, intrahepatic tumor number ≥6, and the presence of extrahepatic metastasis were identified as poor prognostic factors for hepatectomy, whereas female, serum alpha-fetoprotein levels ≥100, mALBI grade 2b + 3, intrahepatic maximal tumor size >5 cm, and the presence of extrahepatic metastasis were identified as poor prognostic factors for systemic chemotherapy. CONCLUSION: In the PSM analysis, no significant differences were observed between the BR1 and BR2 groups for hepatectomy and systemic chemotherapy. The intrahepatic tumor number for hepatectomy and the intrahepatic maximal tumor size for systemic chemotherapy are significant risk factors for BR2 patients, highlighting the characteristics of each treatment and the potential for selecting the optimal modality.

  Jun. 2025, Liver cancer, 15(1) (1), 38 - 49, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Combination Treatment with Spacer Placement Surgery Followed by Particle Radiotherapy for Lymph Node Metastasis from Uterine Cancer.

  Shohei Komatsu, Satoshi Nagamata, Kazuki Terashima, Yusuke Demizu, Masaki Suga, Masahiro Kido, Hiroaki Yanagimoto, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Yoshito Terai, Takumi Fukumoto

  BACKGROUND: The effectiveness of local treatment in lymph node metastasis from uterine cancer has been proven; the standard treatment is surgical intervention. Although radiotherapy, including particle radiotherapy (PRT), is an alternative local treatment, its application is often contraindicated owing to its proximity to the gastrointestinal tract. Combination treatment with spacer placement surgery followed by PRT is a potential solution to this problem. This study aimed to evaluate the outcomes of this combination treatment of lymph node metastases from uterine cancer. PATIENTS AND METHODS: Between December 2007 and March 2023, ten consecutive patients who underwent combination treatment comprising spacer placement surgery and subsequent PRT were assessed for treatment outcomes. RESULTS: The median survival time was 53.5 months; the 3- and 5-year overall survival rates were 76.2% and 38.1%, respectively. The 3- and 5-year local control rates in all patients were both 88.9%. The median volume irradiated at 95% of the treatment planning dose (V95%) of the gross tumor volume, clinical target volume, and planning target volume were 100.0%, 99.8%, and 92.2%, respectively. The median dose intensity covering 95% of the target volume (D95%) of the gross tumor volume/planned dose, clinical target volume/planned dose, and planning target volume/planned dose were 98.9%, 99.0%, and 87.2%, respectively. CONCLUSIONS: Spacer placement surgery contributed to the optimized PRT dose distribution and might have contributed to favorable local control and survival rates. This innovative combination treatment might have a significant effect on the treatment of lymph node metastases from uterine cancers.

  Jun. 2025, Annals of surgical oncology, 32(6) (6), 4313 - 4321, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Features Can Predict Immune-Excluded Phenotype of Hepatocellular Carcinoma.

  Eisuke Ueshima, Keitaro Sofue, Takahiro Kodama, Shuhei Yamamoto, Masato Komatsu, Shohei Komatsu, Nobuaki Ishihara, Akihiro Umeno, Takeru Yamaguchi, Masatoshi Hori, Takumi Fukumoto, Tetsuo Takehara, Takamichi Murakami

  INTRODUCTION: Immunotherapy is the first-line treatment for intermediate-advanced stage hepatocellular carcinoma (HCC), although its outcomes vary. This study aimed to identify imaging biomarkers of immunotherapy susceptibility linked to gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and immune phenotypes, particularly immune-excluded phenotypes, with a tumor immune barrier. METHODS: We performed immunohistochemical staining with a CD8+ antibody, and samples were classified into immune-inflamed, -intermediate, -excluded, and -ignored phenotypes. We assessed EOB-MRI findings obtained from 104 patients who underwent hepatectomy for HCC and evaluated the relationship between MRI findings and immune phenotype. Spatial transcriptome analysis of tumor tissues in each immune phenotype was performed to characterize the MRI findings. For validation, we analyzed the treatment effect on 60 nodules in another cohort of 27 patients who received combined immunotherapy using anti-programmed death-ligand 1 and anti-vascular endothelial growth factor (VEGF) antibodies. RESULTS: HCCs with rim arterial phase hyperenhancement (APHE) (odds ratio [OR] 17.3, p = 0.009), peritumoral enhancement in the arterial phase (OR: 8.6, p < 0.004), and intermediate intensity on the hepatobiliary phase (HBP) measured with a visual 3-point scale (OR: 28.2, p = 0.002) were associated with immune-excluded phenotype, where tumors tended to be larger and of the single nodular type with extranodular growth and confluent multinodular rather than the simple nodular type. Spatial transcriptome analysis revealed a spatial relationship among cytotoxic T lymphocytes, VEGF signals, and cancer-associated fibroblasts at the tumor-invasive margins in this phenotype. From the validation study, nodules with any one of these three imaging findings had a significantly prolonged time to-nodular progression (p = 0.007, median not reached vs. 226 days). CONCLUSION: HCCs with rim APHE, peritumoral enhancement in arterial phase, and intermediate intensity on HBP with visual 3-point scale could be non-invasive biomarkers to predict the immune-excluded phenotype with the tumor immune barrier. These HCCs were most likely to respond to combined immunotherapy.

  Jun. 2025, Liver cancer, 14(3) (3), 271 - 285, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Using the comprehensive complication index to assess the impact of Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition on postoperative complications after resection for biliary tract cancer.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takuya Mizumoto, Toshihiko Yoshida, Shinichi So, Jun Ishida, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: The Global Leadership Initiative on Malnutrition (GLIM) criteria, proposed in 2018, provide universal diagnostic standards for malnutrition, a known risk factor for postoperative complications in patients with various cancers. However, its impact on surgery for biliary tract cancer (BTC) remains unclear. This study evaluates the relationship between GLIM-defined malnutrition and postoperative complications after resection for BTC. METHODS: The subjects of this retrospective study were patients who underwent pancreaticoduodenectomy or major hepatectomy with extrahepatic bile duct resection for BTC between January, 2013 and December, 2021. The comprehensive complication index (CCI), an indicator of postoperative complications, was calculated based on the total number and severity of postoperative complications. RESULTS: GLIM-defined malnutrition was diagnosed in143 (71.1%) of the total 201 patients. The median CCI was significantly higher in the GLIM-defined malnutrition group than in the non-malnutrition group (37.2 vs. 28.3; P < 0.001). Multivariate logistic regression analysis revealed that GLIM-defined malnutrition (odds ratio 2.87 [95% confidence interval 1.38-5.96], P = 0.005) and intraoperative blood loss > 1,000 mL (odds ratio 3.77 [95% confidence interval 1.06-13.47], P = 0.041) were independent predictors of high morbidity (CCI ≥ 37.1). CONCLUSION: Preoperative GLIM-defined malnutrition was closely associated with increased postoperative complications in patients who underwent resection for BTC.

  May 2025, Surgery today, 55(11) (11), 1598 - 1608, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ー

  大森 將貴, 小松 昇平, 石原 伸朗, 寺嶋 千貴, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 沖本 智昭, 福本 巧

  May 2025, 日本消化器外科学会雑誌, 58(5) (5), 286 - 294, Japanese

  Scientific journal


• Prognostic factors and clinical significance of preoperative systemic therapy in patients with borderline resectable hepatocellular carcinoma: A JSHBPS project study 2023, Part 2.

  Junichi Shindoh, Masaru Matsumura, Shohei Komatsu, Takumi Fukumoto, Akihiko Ichida, Kiyoshi Hasegawa, Takamichi Ishii, Etsuro Hatano, Masafumi Nakamura, Masayuki Ohtsuka

  PURPOSE: To explore factors influencing the prognosis in patients with borderline-resectable hepatocellular carcinoma (BR-HCC) undergoing surgery. METHODS: The clinical data of patients with BR-HCC according to the definition in the Expert Consensus Statement 2023 were collected from board-certified HPB training centers and analyzed in detail. RESULTS: Data of a total of 1509 patients with BR-HCC (BR1, n = 718 and BR2, n = 791) who underwent surgery were collected. The 5-year disease-specific survival rate (DSS) and 3-year recurrence-free survival rate (RFS) were determined as 40.8% and 19.7%, respectively. Multivariate analysis identified the oncological resectability category (i.e., BR2 vs. BR1) as a significant prognostic factor, and also the number of criteria fulfilled for classification into BR2 disease as being predictive of the DSS (hazard ratio (HR) [95% CI]: one factor: 1.32 [1.13-1.54]; two to three factors: 1.51 [1.15-1.96]). Preceding systemic therapy was significantly correlated with a longer DSS (HR, 0.41: 95% CI, 0.18-0.91) and RFS (HR, 0.80: 95% CI, 0.66-0.97) in the patients with BR1 disease, while its clinical significance was unclear in the patients with BR2 disease. CONCLUSION: Multicenter data confirm the clinical relevance of the oncological resectability category and the potential advantage of preceding systemic therapy in a specific group of BR-HCC.

  May 2025, Journal of hepato-biliary-pancreatic sciences, 32(5) (5), 374 - 384, English, Domestic magazine

  Scientific journal


• Impact of a dilated main pancreatic duct in the expected remnant pancreas on the incidence of clinically significant remnant pancreatic lesion after resection of noninvasive and microinvasive intraductal papillary mucinous neoplasms.

  Takuya Mizumoto, Hirochika Toyama, Yoshihide Nanno, Jun Ishida, Yuichiro Uchida, Hideaki Iwama, Masayuki Kojima, Takeshi Takahara, Koichi Suda, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Partial pancreatectomies for intraductal papillary mucinous neoplasms (IPMN) often leave a dilated main pancreatic duct (MPD). However, its impact on the development of remnant pancreatic lesions is unknown. METHODS: Medical records of consecutive patients who underwent partial pancreatectomy for noninvasive or microinvasive IPMN with dilated MPD on preoperative imaging between April 2007 and March 2023 at two tertiary referral centers in Japan were retrospectively reviewed. A dilated remnant MPD (DRM) was defined as an MPD diameter of the expected remnant pancreas of ≥5 mm. The clinically significant remnant pancreatic lesion (CSRPL) was defined as a remnant pancreatic lesion which requires intervention. RESULTS: A total of 172 patients (106 males and 66 females) were analyzed. Preoperatively, 132 patients (76.7 %) had mixed-type IPMN and 40 (23.1 %) had main duct IPMN. Among them, 16 patients (9.3 %) had CSRPL at 1569 days (median; range, 120-5503 days) after the initial surgery. In the preoperative imaging analysis, 104 patients (60.5 %) had DRM. The univariate analysis revealed that high-grade or micro-invasive pathology (p = 0.013) was significantly associated with CSRPL, whereas DRM was inversely associated with CSRPL (p = 0.021). The multivariate analysis revealed that the trends of DRM (p = 0.002) and high-grade/micro-invasive pathology (p = 0.003) remained significant. CONCLUSIONS: Leaving a dilated MPD did not increase but instead inversely associated with the incidence of CSRPL after IPMN resection. It was suggested that preserving the pancreas, including the dilated MPD, is oncologically safe if the lesion of interest can be resected.

  May 2025, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 25(3) (3), 440 - 449, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Biomarker-guided strategy for Denver peritoneovenous shunts in refractory ascites: a retrospective single-center study.

  Yuhi Shimura, Shohei Komatsu, Yoshimasa Hashimoto, Miho Nishio, Yu Hashimoto, Michihiko Yoshida, Toshihiko Yoshida, Kenji Fukushima, Itsuo Fujita, Takumi Fukumoto

  PURPOSE: This study aimed to evaluate the utility of peritoneovenous shunt (PVS) placement for refractory ascites (RA) based on preoperative biomarkers. METHODS: This retrospective cohort study included patients with malignant and cirrhotic RA undergoing PVS placement treated at Sumoto Itsuki Hospital between January 2001 and March 2024. The efficacy of PVSs was defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). The usefulness of the prognostic nutritional index, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and C-reactive protein-to-albumin ratio as prognostic indicators for the efficiency of PVS was evaluated. RESULTS: In total, 149 consecutive patients (malignant RA, n = 100; cirrhotic RA, n = 49) were included in this study. PVS placement satisfied the efficacy criteria for ascites in 102 (68%) patients in the entire cohort. The estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2 was an independent predictor for the inefficacy of PVSs (odds ratio: 2.82, 95% CI: 1.04-7.73, P = 0.042). Based on receiver operating characteristic curve and multivariate analysis of the entire cohort, NLR ≥ 5.8 was an independent risk factor for death within 1 week after PVS placement (odds ratio: 18.2, 95% CI: 2.07-29.7, P = 0.016). CONCLUSION: PVS placement for RA may be a treatment option when preoperative eGFR is > 30 mL/min/1.73 m2 and NLR is < 5.8.

  Apr. 2025, Langenbeck's archives of surgery, 410(1) (1), 140 - 140, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Achieving textbook outcome in liver resection for hepatocellular carcinoma: malnutrition's pivotal role.

  Kentaro Oji, Takeshi Urade, Satoshi Omiya, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: To investigate the impact of textbook outcome (TO) achievement on survival post-liver resection for hepatocellular carcinoma (HCC) and explore the associated factors. METHODS: We retrospectively reviewed 330 patients diagnosed with HCC who underwent initial liver resection at our hospital between January 2011 and December 2019. We also investigated the achievement rates of five TOs and sub-analyzed the relationship between them and malnutrition. The patient's nutritional status was classified following the Global Leadership Initiative on Malnutrition (GLIM) criteria. RESULTS: The TO achievement rate was 72.7%. In the prognostic analysis, the TO-achieving group showed significantly longer overall survival (OS) and recurrence-free survival (RFS). Significant differences in age, body mass index, weight loss, muscle mass, serum aspartate aminotransferase level, serum protein induced by vitamin K absence or antagonist-II, tumor characteristics, intraoperative blood loss, perioperative transfusion, and nutritional status were found between the groups. CONCLUSIONS: TO achievement is associated with OS and RFS post-liver resection for HCC. The TO is valuable for evaluating treatment quality in liver resection. Additionally, malnutrition graded following the GLIM criteria, age, tumor stage, and intraoperative blood loss are independent factors for achieving a TO post-liver resection for HCC.

  Apr. 2025, Langenbeck's archives of surgery, 410(1) (1), 139 - 139, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Comparison of the surgical difficulty between segment 7 and 8 partial liver resection untilizing the laparoscopic and open approaches.

  Hidetoshi Gon, Akihiro Fujisawa, Shohei Komatsu, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: We aimed to investigate the differences in surgical difficulty between laparoscopic partial liver resections of segments 7 and 8. METHODS: We analyzed 173 patients who underwent partial liver resections of segments 7 or 8 between 2010 and 2022 at two institutions. We investigated differences in the surgical outcomes of each procedure using propensity score matching. We compared these outcomes with those of open partial liver resections for segments 7 and 8 to determine whether the differences were unique to the laparoscopic approach. RESULTS: Thirty and 54 patients underwent laparoscopic partial liver resections of segments 7 and 8. In the matched cohort (22 in each group), the operation time was significantly longer (377 vs. 278 min, P = 0.020) and the proportion of postoperative complications significantly higher in segment 7 (27% vs. 0%, P = 0.008). Forty-one and 48 patients underwent open partial liver resections of segments 7 and 8, respectively. There were no significant differences in the surgical outcomes between the segments in the matched cohort (20 in each group). CONCLUSIONS: Laparoscopic partial liver resections of segment 7 may be more challenging than that of segment 8. This difference in difficulty was not observed in open partial liver resections.

  Apr. 2025, Surgery today, 55(10) (10), 1383 - 1392, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Immunoscore Predicted by Dynamic Contrast-Enhanced Computed Tomography Can Be a Non-Invasive Biomarker for Immunotherapy Susceptibility of Hepatocellular Carcinoma.

  Eisuke Ueshima, Keitaro Sofue, Shohei Komatsu, Nobuaki Ishihara, Masato Komatsu, Akihiro Umeno, Kentaro Nishiuchi, Ryohei Kozuki, Takeru Yamaguchi, Takanori Matsuura, Toshifumi Tada, Takamichi Murakami

  Background/Objectives: Although immunotherapy is the primary treatment option for intermediate-stage hepatocellular carcinoma (HCC), its efficacy varies. This study aimed to identify non-invasive imaging biomarkers predictive of the immunoscore linked to dynamic contrast-enhanced computed tomography (CECT). Methods: We performed immunohistochemical staining with CD3+ and CD8+ antibodies and counted the positive cells in the invasive margin (IM) and central tumor (CT), converting them to an immunoscore of 0 to 4 points. We assessed the dynamic CECT findings obtained from 96 patients who underwent hepatectomy for HCC and evaluated the relationship between dynamic CECT findings and immunoscores. For validation, we assessed the treatment effects on 81 nodules using the Response Evaluation Criteria in Solid Tumors in another cohort of 41 patients who received combined immunotherapy with atezolizumab and bevacizumab (n = 27) and durvalumab and tremelizumab (n = 14). Results: HCCs with peritumoral enhancement in the arterial phase (p < 0.001) and rim APHE (p = 0.009) were associated with the immunoscore in univariate linear regression analysis and peritumoral enhancement in the arterial phase (p = 0.004) in multivariate linear regression analysis. The time to nodular progression in HCCs with peritumoral enhancement in the arterial phase was significantly longer than that in HCCs without this feature (p < 0.001). Conclusions: We identified HCCs with peritumoral enhancement in the arterial phase as a noninvasive imaging biomarker to predict immune-inflamed HCC with a high immunoscore tendency. These HCCs were most likely to respond to combined immunotherapy.

  Mar. 2025, Cancers, 17(6) (6), English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Novel orthotopic patient-derived xenograft model using human pancreatic cancer tissue fragments to recapitulate distant metastasis and cancer-related hypercoagulability.

  Takuma Miura, Arisa Watanabe, Mutsumi Miyake, Sayaka Suga, Makoto Miyoshi, Kumiko Miyashita, Shohei Komatsu, Noriyuki Nishimura, Kazuya Shimizu, Yuichi Hori

  Pancreatic cancer is a malignant tumor that metastasizes to distant organs, such as the liver and lungs from an early stage. Few animal models can reproduce early metastasis. In addition, no model has been reported that reproduces cancer-related hypercoagulability, which is characteristic of pancreatic ductal adenocarcinoma and other adenocarcinomas. We hypothesized that the reason why the commonly used orthotopic cell xenograft model cannot reproduce the disease is inadequate construction of the cancer microenvironment. We developed an orthotopic tissue fragment xenograft model in which tumor tissue was transplanted into the pancreas of mice while preserving the microenvironment. Briefly, we injected single cancer cells subcutaneously to form a tumor, which was then cut with a scalpel into tumor fragments. A fragment was then sutured and fixed to the surface of the pancreatic tail. In this study, we evaluated the superiority of this model over a conventional orthotopic cell xenograft model. As a result, the novel orthotopic tissue xenograft model reproduced early distant metastasis to the liver and lung, nerve invasion, and cancer-related hypercoagulability of human pancreatic cancer, and showed greater similarity to clinical cases than the control orthotopic cell xenograft model.

  Mar. 2025, Medical molecular morphology, 58(3) (3), 183 - 192, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ー

  小松 昇平, 出水 祐介, 福本 巧

  金原出版(株), Mar. 2025, 手術, 79(3) (3), 339 - 344, Japanese

  Research society


• Chemokine (C-C Motif) Ligand 2/CCR2/Extracellular Signal-Regulated Kinase Signal Induced through Cancer Cell-Macrophage Interaction Contributes to Hepatocellular Carcinoma Progression.

  Nobuaki Ishihara, Yu-Ichiro Koma, Masaki Omori, Shohei Komatsu, Rikuya Torigoe, Hiroki Yokoo, Takashi Nakanishi, Keitaro Yamanaka, Yuki Azumi, Shuichi Tsukamoto, Takayuki Kodama, Mari Nishio, Manabu Shigeoka, Hiroshi Yokozaki, Takumi Fukumoto

  Tumor-infiltrating macrophages, known as tumor-associated macrophages, play a crucial role in the tumor microenvironment. Herein, immunohistochemistry revealed that intratumoral CD68-positive macrophages are associated with poor prognosis and clinicopathologic factors in patients with hepatocellular carcinoma (HCC). Subsequently, an indirect co-culture system involving HCC cells and peripheral blood-derived macrophages was developed. cDNA microarray analysis revealed that chemokine (C-C motif) ligand 2 (CCL2) was highly expressed in HCC cells co-cultured with macrophages. CCL2 neutralization suppressed proliferation, migration, and phosphorylation of extracellular signal-regulated kinase (Erk) in HCC cells and macrophages enhanced through co-culture. In contrast, recombinant human CCL2 (rhCCL2) addition facilitated these malignant phenotypes and increased Erk phosphorylation levels in HCC cells and macrophages. The primary CCL2 receptor, CCR2, was expressed in HCC cells and macrophages and was up-regulated in co-cultured HCC cells. CCR2 inhibition suppressed malignant phenotypes and reduced phosphorylated levels of Erk enhanced by rhCCL2. Additionally, the inhibition of Erk signal suppressed rhCCL2-enhanced malignant phenotypes. Moreover, serum CCL2 levels were higher in patients with HCC than those in healthy donors. On the basis of immunohistochemistry, CCL2-positive cases with high CCR2 expression and phosphorylated Erk-positive cases exhibited poor survival outcomes. Therefore, CCL2 up-regulation through interactions between HCC cells and macrophages contributed to HCC progression, making the CCL2/CCR2/Erk signal a potential target for HCC treatment.

  Mar. 2025, The American journal of pathology, 195(3) (3), 589 - 608, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Treatment outcomes of hepatectomy and systemic chemotherapy based on oncological resectability criteria for hepatocellular carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Nobuaki Ishihara, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  AIM: The oncological resectability criteria for hepatocellular carcinoma (HCC) have recently been established (R/BR1/BR2), and validating the outcomes is an urgent issue. This study aimed to analyze the outcomes of hepatectomy and systemic chemotherapy based on the oncological resectability criteria. METHODS: A total of 931 patients in the hepatectomy group and 273 in the systemic chemotherapy group who received atezolizumab/bevacizumab, lenvatinib, or durvalumab plus tremelimumab were recruited. RESULTS: The median survival times (MST) in the hepatectomy group were R, 107.2 mo; BR1, 44.4 mo; and BR2, 18.4 mo (p < 0.0001). The MSTs in the systemic chemotherapy group were R, 16.3 mo; BR1, 24.5 mo; and BR2, 16.1 mo (p = 0.3598). A comparison of survival of patients in the BR2 category revealed no significant difference between the two groups for those with modified albumin-bilirubin grade 1 + 2a (p = 0.7343) and grade 2b + 3 (p = 0.6589). The BR2 definition comprised three tumor factors, and the MST of patients with only one BR2-defining factor tended to be better in the hepatectomy group than in the systemic chemotherapy group (22.9 vs 20.2 mo, p = 0.0977). Meanwhile, the MST tended to be better in the systemic chemotherapy group than in the hepatectomy group (16.5 vs 12.6 mo) for those with two to three BR2-defining factors, although the difference was insignificant (p = 0.4252). CONCLUSION: The oncological resectability criteria for HCC effectively stratified the prognosis after hepatectomy. Treatment outcomes of hepatectomy in patients with two to three BR2-defining factors are limited, suggesting the need for multidisciplinary treatment.

  Mar. 2025, Annals of gastroenterological surgery, 9(2) (2), 235 - 243, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma.

  Yuta Inoue, Yoshihiko Yano, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Eiichiro Yasutomi, Hirotaka Hirano, Soo Ki Kim, Ryutaro Yoshida, Yoshihide Ueda, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Tomomitsu Matono, Atsushi Yamamoto, Hiroshi Tei, Chiharu Nishioka, Yosuke Yagi, Shoji Tamura, Tatsuya Sakane, Mayumi Ehara, Miki Kawano, Jun Kitadai, Takanori Matsuura, Yuuki Shiomi, Shohei Komatsu, Takumi Fukumoto, Toshifumi Tada, Yuzo Kodama

  BACKGROUND AND AIMS: Tremelimumab plus durvalumab (Dur/Tre) combination therapy is now a first-line systemic therapy for advanced hepatocellular carcinoma (HCC). Because systemic therapy is not effective in some patients, it is clinically important to identify factors that could predict the response to treatment at an early stage. We investigated the factors associated with the response to Dur/Tre for advanced HCC in a clinical setting. METHODS: Seventy patients (median age 74 years; 61 men) who received Dur/Tre between March 2023 and September 2024 were analyzed. We examined the factors associated with the treatment response, including pretreatment factors and factors early in treatment. RESULTS: The median treatment duration was 77.5 (interquartile range [IQR] 28-187) days. The overall response and disease control rates were 25.8% and 58.1%, respectively. The median (IQR) progression-free survival (PFS) and overall survival (OS) were 82 (61-133) and 415 (337-NA) days, respectively. Multivariable analysis revealed that higher absolute lymphocyte count (ALC) and lower des-γ-carboxyprothrombin (DCP) levels were significantly associated with PFS. Receiver operating characteristic curve analysis showed that the cutoff value for ALC after 4 weeks of treatment in relation to clinical efficacy was 1125/mm3. A log-rank test using the Kaplan-Meier method showed that OS was significantly longer in patients with ALC above the cutoff and in patients whose DCP levels decreased after starting treatment. CONCLUSION: Higher ALC and lower DCP levels after treatment initiation were associated with the clinical efficacy of Dur/Tre for advanced HCC.

  Feb. 2025, JGH open : an open access journal of gastroenterology and hepatology, 9(2) (2), e70123, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of depth of body cavity at the upper-right portion of the abdomen on open and laparoscopic liver resection of segment 7.

  Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: The impact of body-cavity depth on open (OLR) and laparoscopic liver resection (LLR) of segment 7 remains unclear. Therefore, we investigated the influence of body-cavity depth at the upper-right portion of the abdomen on LLR and OLR of segment 7. METHODS: In total, 101 patients who underwent segment-7 liver resection over 2010-2023 were included. Body-cavity depth was measured from the abdominal-wall surface to the deepest site on the right side of the liver. Patients were categorized into shallow (< 18.4 cm) and deep (≥ 18.4 cm) populations based on median body-cavity depth. We compared surgical outcomes between OLR and LLR in shallow and deep populations after propensity-score adjustments. RESULTS: In OLR and LLR groups, 27 and 22 patients in the shallow population, respectively, and 26 and 26 patients were included in the deep population, respectively, were included. The OLR group in the deep population had significantly greater blood loss than the corresponding LLR group (difference: 144 mL, 95% confidence interval (CI): [50, 238], P = 0.004). Other surgical outcomes, including operative time, were similar between groups. In the shallow population, the OLR group had significantly shorter operative time (difference: - 54 mL, 95% CI: [-101, - 6], P = 0.028) and similar blood loss than the LLR group. CONCLUSIONS: For segment-7 liver resection, LLR is likely favorable for patients with a deep body cavity, with similar operative time and lower blood loss compared to OLR. Body-cavity depth could be a useful indicator for determining the suitable surgical approach for segment-7 liver resection.

  Jan. 2025, Langenbeck's archives of surgery, 410(1) (1), 37 - 37, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy and safety of indocyanine green-fluorescence imaging guided liver resection: a single-arm prospective cohort study.

  Hidetoshi Gon, Satoshi Omiya, Shohei Komatsu, Nobuaki Yamasaki, Sae Murakami, Kenji Fukushima, Takeshi Urade, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: This study aimed to evaluate the efficacy of indocyanine green (ICG)-fluorescence imaging for the identification of hepatic boundaries during liver resection and its advantages in surgical outcomes over conventional methods. METHODS: This prospective, exploratory, single-arm clinical trial included 47 patients with liver tumors who underwent liver resection using ICG-fluorescence imaging (ICG-LR) between 2019 and 2020. The primary outcome measure was the successful identification of hepatic boundaries during liver resection, from the perspective of both the hepatic surface and intrahepatic boundary, using ICG-fluorescence imaging. The secondary outcomes comprised surgical outcomes. Using propensity score matching (PSM), the surgical outcomes were subsequently compared between the ICG-LR group and patients who underwent conventional liver resection (C-LR, n = 100) between 2017 and 2018. RESULTS: Hepatic boundaries were successfully identified in 28 patients (60%; 95% confidence interval, 45-72%), including 21 and 7 who underwent anatomical and non-anatomical liver resection, respectively. After PSM, 40 patients were included in each of the ICG-LR and C-LR groups. The surgical outcomes were similar between the groups. Subsequently, surgical outcomes were compared between the groups focusing on anatomical liver resection. After PSM, 21 patients were included in each group. The ICG-LR group had a lower rate of Clavien-Dindo grade ≥ IIIa complications (0% vs. 24%; P = 0.017), including ascites and bile leak, and a shorter hospital stay (12 vs. 14 days, P = 0.041) than the C-LR group did. CONCLUSION: ICG-fluorescence imaging could be used to recognize hepatic boundaries during liver transection. Additionally, ICG-LR may be useful in preventing severe liver-associated complications. TRIAL REGISTRATION NUMBER: This study is registered at the UMIN Clinical Trials Registry: UMIN0000180139 and Japan Registry of Clinical Trials: jRCT1051180070. The Registration Data Set is available at https://jrct.niph.go.jp/ .

  Jan. 2025, Langenbeck's archives of surgery, 410(1) (1), 34 - 34, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Usefulness of A Portal Vein Stent for Sinistral Portal Hypertension: A Case Report.

  Daisuke Takimoto, Jun Ishida, Hirochika Toyama, Yoshihide Nanno, Takuya Mizumoto, Toshihiko Yoshida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  INTRODUCTION: Portal vein (PV) and splenic vein (SV) stenosis are known complications of pancreatoduodenectomy (PD) and often lead to portal hypertension. PV stenosis extending to the SV confluence can result in sinistral portal hypertension (SPH), characterized by gastrointestinal varices and splenomegaly in the presence of normal liver function. There is no standardized treatment strategy for SPH following PD. CASE PRESENTATION: A 42-year-old female underwent robot-assisted PD for a pancreatic neuroendocrine tumor without immediate PV complications. Postoperatively, the patient experienced fluid retention; however, this did not pose a problem, and no therapeutic intervention was necessary. Two months later, imaging revealed PV stenosis and SV obstruction. Eleven months after surgery, the patient presented with melena, and imaging confirmed the presence of gastroesophageal varices with severe PV stenosis and complete SV obstruction. Endoscopic variceal ligation was performed, and the hemodynamic status of the portal system was assessed using computed tomography during arterial portography (CTAP). CTAP showed communication between the superior mesenteric vein and the SV via the middle colic vein. Therefore, we decided to perform PV stenting. The stent was successfully placed, resulting in a significant improvement in the esophageal varices. The patient was discharged on postoperative day 4, receiving anticoagulant therapy, with no further complications. CONCLUSIONS: This case demonstrates the efficacy of PV stenting after careful hemodynamic assessment in a patient who developed SPH due to PV stenosis and SV obstruction following PD.

  2025, Surgical case reports, 11(1) (1), English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• GLIM Criteria as Prognostic Factor in Patients Undergoing Adjuvant S-1 Chemotherapy for Biliary Tract Cancer.

  Ryunosuke Konaka, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takuya Mizumoto, Toshihiko Yoshida, Shinichi Sou, Jun Ishida, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND/AIM: Biliary tract cancers (BTCs) have poor prognoses, with limited curative options beyond surgical resection. Adjuvant S-1 chemotherapy has shown survival benefits in Japanese patients undergoing resection for BTC. However, prognostic factors influencing survival in these patients remain uncertain. In this study, we aimed to investigate the efficacy of preoperative nutritional status using the Global Leadership Initiative on Malnutrition (GLIM) criteria as a prognostic factor in patients receiving adjuvant S-1 chemotherapy for BTC. PATIENTS AND METHODS: In this retrospective study, excluding intrahepatic cholangiocarcinoma, we evaluated 58 patients who underwent curative surgery for BTC at Kobe University from 2013 to 2022, followed by adjuvant S-1 chemotherapy. Nutritional status was classified by GLIM criteria into normal/moderate and severe malnutrition groups. Overall (OS) and recurrence-free (RFS) survival were analyzed using Kaplan-Meier and Cox proportional hazards models. RESULTS: Of the 58 patients, 3.4% had no malnutrition, 72.5% had moderate malnutrition, and 24.1% had severe malnutrition. Patients with severe malnutrition had significantly worse 5-year OS (24.7% vs. 52.5%, p=0.0014) and RFS (34.3% vs. 52.0%, p=0.0066). Severe malnutrition was an independent prognostic factor for poorer OS (hazard ratio=3.40, 95% confidence interval=1.46-7.94; p=0.0047) and RFS (hazard ratio=2.48, 95% confidence interval=1.07-5.76; p=0.035). No significant difference in S-1 completion rates was observed. CONCLUSION: Severe malnutrition, as defined by GLIM criteria, is a poor prognostic factor in patients with BTCs undergoing adjuvant S-1 chemotherapy.

  2025, Cancer diagnosis & prognosis, 5(5) (5), 557 - 565, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ASO Author Refections: The potential role of particle therapy as a therapeutic option for patients with recurrent hepatocellular carcinoma after liver resection.

  Tatsuki Kusuhara, Hidetoshi Gon, Kazuki Terashima, Shohei Komatsu, Yoshiro Matsuo, Sunao Tokumaru, Hirochika Toyama, Masahiro Kido, Tomoaki Okimoto, Takumi Fukumoto

  Jan. 2025, Annals of surgical oncology, 32(1) (1), 448 - 449, English, International magazine

  Scientific journal


• Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takanori Matsuura, Toshifumi Tada, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab (AteBev) is widely used as a first-line treatment for advanced hepatocellular carcinoma (HCC). However, evidence regarding the optimal drug sequence following AteBev treatment is limited. This study aimed to compare the treatment outcomes between tyrosine kinase inhibitors (TKIs) and durvalumab plus tremelimumab (DurTre) following AteBev treatment. PATIENTS AND METHODS: Overall, 134 consecutive patients who received AteBev for advanced HCC were enrolled in this study. Treatment outcomes were retrospectively compared between TKIs (AteBev→TKI group) and DurTre (AteBev→DurTre group). RESULTS: The AteBev→TKI and Ate→DurTre groups included 46 and 7 patients, respectively. The AteBev→TKI group had significantly longer median progression-free survival after second-line treatment (3.6 vs. 0.94 months, p<0.001). The disease control rate was significantly higher in the AteBev→TKI group (p=0.020). The serum alpha-fetoprotein levels significantly decreased at one month in the AteBev→TKI group (0.909 vs. 1.435, p=0.035), whereas the albumin-bilirubin score significantly decreased at one month in the AteBev→TKI group (0.875 vs. 0.952, p=0.017). Each group reported no new unmanageable adverse events. CONCLUSION: TKIs may be a more optimal drug sequence than DurTre after AteBev treatment from an oncological perspective. TKIs following AteBev treatment require careful monitoring for deteriorating liver function.

  Jan. 2025, Anticancer research, 45(1) (1), 251 - 260, English, International magazine

  Scientific journal


• A Case of Unresectable Hepatocellular Carcinoma Treated with Spacer Placement Surgery with Bioabsorbable Spacer and Subsequent Proton Beam Therapy.

  Toru Takahashi, Shohei Komatsu, Yusuke Demizu, Keisuke Arai, Nobuaki Ishihara, Akihiro Fujisawa, Hidetoshi Gon, Hirochika Toyama, Sunao Tokumaru, Takumi Fukumoto

  INTRODUCTION: Hepatocellular carcinoma (HCC) often requires repeated therapy and poses challenges in treatment selection, particularly in patients with impaired liver function. Although hepatic resection, radiofrequency ablation, and liver transplantation are standard local curative therapies, the position of radiotherapy, including proton beam therapy (PBT), remains relatively underexplored. Herein, we report an illustrative case of unresectable HCC treated with spacer placement surgery using a bioabsorbable spacer, followed by PBT. CASE PRESENTATION: We report the case of a 77-year-old male patient diagnosed with a 6 cm HCC in segment 8, accompanied by impaired liver function, precluding hepatic resection. PBT was planned; however, because of the proximity of the gastrointestinal tract to the tumor, spacer placement was deemed necessary, and a bioabsorbable polyglycolic acid spacer was placed, followed by PBT. Owing to the sufficient space provided by the spacer, curative doses of PBT could be delivered to the tumor, and the patient survived for 26 months after spacer placement surgery without any sign of recurrence. CONCLUSIONS: Bioabsorbable spacer placement surgery and subsequent PBT are feasible and promising treatment options for unresectable HCC with impaired liver function.

  2025, Surgical case reports, 11(1) (1), English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Laparoscopic Liver Resection for Hepatocellular Adenomas in Pediatric Glycogen Storage Disease Type Ia: A Case With Consideration for Future Transplantation.

  Kentaro Oji, Takeshi Urade, Ryosuke Bo, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Kentaro Tai, Keisuke Arai, Takumi Fukumoto

  A 13-year-old girl presented with enlarging hepatocellular adenomas and a history of glycogen storage disease type Ia. Her liver function was well controlled by nutritional therapy. The options of resection and transplantation were considered, and the patient was successfully treated with laparoscopic liver resection. However, pathology revealed fatty liver, indicating that subsequent surgical treatment may be necessary. Herein, we report the patient's clinical progress, including the strategy for determining the surgical approach. In cases where the patient is a low priority for transplantation, laparoscopic liver resection is an important therapeutic choice, even though regrowth of residual lesions has been reported.

  2025, Asian journal of endoscopic surgery, 18(1) (1), e70090, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 腹腔鏡補助下膵頭十二指腸切除術でR0切除となった胆管原発神経内分泌癌の1例

  吉田 道彦, 柳本 泰明, 津川 大介, 秋田 真之, 南野 佳英, 浦出 剛史, 福島 健司, 権 英寿, 小松 昇平, 浅利 貞毅, 児玉 貴之, 木戸 正浩, 外山 博近, 伊藤 智雄, 福本 巧

  (株)癌と化学療法社, Dec. 2024, 癌と化学療法, 51(13) (13), 1633 - 1635, Japanese

  Research society


• -

  浦出 剛史, 小松 昇平, 柳本 泰明, 外山 博近, 木戸 正浩, 福本 巧

  Dec. 2024, Precision Medicine, 7(13) (13), 78 - 80, Japanese

  Scientific journal


• Assessment of the biliary branching pattern of the caudate lobe in perihilar cholangiocarcinoma using ENBD-CT cholangiography.

  Masayuki Akita, Hiroaki Yanagimoto, Daisuke Tsugawa, Keitaro Sofue, Hidetoshi Gon, Shohei Komatsu, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Preoperative recognition of the anatomy of caudate biliary branches is important for the safe and complete resection of perihilar cholangiocarcinoma (PHC). In the present study, we identified these branches using an endoscopic nasobiliary drainage tube (ENBD). METHODS: Between January 2012 and October 2022, 89 patients with suspected PHC underwent computed tomographic (CT) cholangiography through ENBD and caudate biliary branching patterns were examined. Multidetector raw CT (MDCT) scans on 85 patients with PHC without biliary drainage were also investigated. The caudate biliary branches detected by each modality were evaluated. RESULTS: ENBD-CT cholangiography detected 206 caudate branches (2.44 branches/patient), while MDCT identified 62 branches (0.78 branches/patient). ENBD-CT cholangiography showed that 89 caudate branches drained into the left hepatic duct (LHD), 87 into the posterior hepatic duct (Bpost), and 30 into the right hepatic duct. LHD and Bpost were the common roots of the caudate branches. Some branches (20%) joined the contralateral hepatic duct across the left-right border, but not the anterior hepatic duct or infraportal-type Bpost. CONCLUSIONS: ENBD-CT cholangiography clearly showed the caudate biliary branches in patients with PHC after biliary drainage.

  Nov. 2024, Journal of hepato-biliary-pancreatic sciences, 31(11) (11), 809 - 815, English, Domestic magazine

  Scientific journal


• Comparison of Prognostic Outcomes Between Repeat Liver Resection and Particle Therapy for Patients with Recurrent Hepatocellular Carcinoma.

  Tatsuki Kusuhara, Hidetoshi Gon, Kazuki Terashima, Shohei Komatsu, Yoshiro Matsuo, Sunao Tokumaru, Hirochika Toyama, Masahiro Kido, Tomoaki Okimoto, Takumi Fukumoto

  BACKGROUND: Particle therapy (PT) as an initial hepatocellular carcinoma (HCC) treatment has been reported to be effective; however, its efficacy for the treatment of recurrent HCC remains unclear. OBJECTIVE: This study aimed to evaluate the efficacy of PT compared with repeat liver resection for treating recurrent HCC after initial LR, with a focus on prognostic outcomes. METHODS: Between 2005 and 2019, 89 and 49 patients underwent repeat LR and PT for recurrent HCC after initial LR, respectively. The 5-year overall survival (OS) and recurrence-free survival (RFS) were evaluated using propensity score matching. Treatment-related complications were scored using the National Institute Common Terminology Criteria for Adverse Events (CTCAE) and were compared between the repeat LR and PT groups. RESULTS: In the entire cohort, the 5-year OS was significantly better in the repeat LR group than in the PT group (75% vs. 48%; p = 0.0003), and the 5-year RFS was comparable in both groups (22% vs. 13%; p = 0.088). Propensity score matching created 34 pairs of patients; no significant differences in the 5-year OS (65% vs. 48%; p = 0.310) and RFS (21% vs. 8%; p = 0.271) were observed between the repeat LR and PT groups. The proportion of CTCAE grade ≥3 complications was 8.8% and 5.9% in the repeat LR and PT groups, respectively (p = 0.641). CONCLUSIONS: After initial LR, the prognosis and treatment-related complications in patients with recurrent HCC were comparable between the repeat LR and PT groups in the matched cohort; therefore, PT may remain one of the multidisciplinary treatment options for recurrent HCC.

  Oct. 2024, Annals of surgical oncology, 32(2) (2), 1073 - 1082, English, International magazine

  Scientific journal


• 【肝癌診療2024】肝細胞癌集学的治療の進歩

  小松 昇平, 木戸 正浩, 権 英寿, 福島 健司, 浦出 剛史, 宗 慎一, 吉田 俊彦, 田井 謙太郎, 荒井 啓輔, 柳本 泰明, 外山 博近, 福本 巧

  (株)へるす出版, Sep. 2024, 消化器外科, 47(9) (9), 1059 - 1070, Japanese


• Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy.

  Yoshihide Nanno, Hirochika Toyama, Takuya Mizumoto, Jun Ishida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Systemic inflammation and altered metabolism are essential hallmarks of cancer. We hypothesized that the rapid turnover protein transthyretin (TTR) (half-life: 2-3 days), compared with the conventional marker albumin (21 days), better reflects the inflammatory/metabolic dynamics of pancreatic ductal adenocarcinoma (PDAC) after neoadjuvant therapy (NAT) and is a useful prognostic marker. METHODS: Serum TTR and albumin levels were measured in 104 consecutive post-NAT PDAC patients before curative resection. The associations of preoperative TTR and albumin levels with overall survival (OS) after pancreatectomy were retrospectively analyzed. RESULTS: The mean (SD) TTR and albumin levels were 21.6 (6.4) mg/dL (normal range: ≥22.0 mg/dL) and 3.9 (0.55) g/dL. A low (<22.0 mg/dL) post-NAT TTR level was associated with an advanced tumor stage and higher CEA and CRP levels. Patients with low TTR levels showed significantly worse OS compared with normal levels (3-year OS 39 % vs. 54 %, P = 0.037), although albumin levels did not. We modified prognostic biomarkers of systemic inflammation/metabolism, such as GPS, PNI, and CONUT scores, using the serum TTR instead of albumin level and successfully showed that modified scores were better associated with OS compared with original scores using serum albumin level. CONCLUSIONS: Our data suggest that the TTR level is a promising prognostic biomarker for PDAC patients after NAT.

  Sep. 2024, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 24(6) (6), 917 - 924, English, International magazine

  Scientific journal


• Comparison of laparoscopic liver resection for the ventral versus the dorsal areas of segment 8.

  Kentaro Oji, Takeshi Urade, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Nobuaki Yamasaki, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Masayuki Akita, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  PURPOSE: The technical difficulties of laparoscopic liver resection (LLR) are greatly associated with the location of liver tumors. Since segment 8 (S8) contains a wide area, the difficulty of LLR for S8 tumors may vary depending on the location within the segment, such as the ventral (S8v) and dorsal (S8d) area, but the difference is unclear. METHODS: We retrospectively investigated 30 patients who underwent primary laparoscopic partial liver resection for liver tumors in S8 at Kobe University Hospital between January 2018 and June 2023. RESULTS: Thirteen and 17 patients underwent LLR for S8v and S8d, respectively. The operation time was significantly longer (S8v 203[135-259] vs. S8d 261[186-415] min, P = 0.002) and the amount of blood loss was significantly higher (10[10-150] vs. 10[10-200] mL, P = 0.034) in the S8d group than in the S8v group. No significant differences were observed in postoperative complications or postoperative length of hospital stay. Additionally, intraoperative findings revealed that the rate at which the case performed partial liver mobilization in the S8d group was higher (2[15.4%] vs. 8[47.1%], P = 0.060) and the median parenchymal transection time of the S8d group was longer (102[27-148] vs. 129[37-175] min, P = 0.097) than those in the S8v group, but there were no significant differences. CONCLUSION: The safety of LLR for the S8d was comparable to that of LLR for S8v, although LLR for S8d resulted in longer operative time and more blood loss. THE TRIAL REGISTRATION NUMBER: B230165 (approved at December 26, 2023).

  Aug. 2024, Langenbeck's archives of surgery, 409(1) (1), 243 - 243, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• [A Case of Radical Hepatectomy in a Patient with Recurrent Liver Metastasis of Gallbladder Cancer after Successful Chemotherapy with GC+Durvalumab].

  Taiichiro Miyake, Takeshi Urade, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Keisuke Arai, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  A 49-year-old man underwent an open cholecystectomy for advanced gallbladder cancer in 2021. Three months after surgery, the patient underwent an additional resection, which showed no malignant findings, but 12 months after surgery, contrast-enhanced CT and MRI showed a new mass lesion in segment 8 of the liver, and the patient was diagnosed with postoperative hepatic metastatic recurrence of gallbladder cancer. After referral to our institution, he received 1 course of gemcitabine+cisplatin(GC)therapy and 8 courses of gemcitabine+cisplatin+durvalumab(GCD)therapy. Contrast- enhanced CT and MRI showed that the metastases had shrunk, and PET scan showed no FDG accumulation. Two months after completion of chemotherapy, there was no evidence of metastatic enlargement and new metastasis including distant metastasis, and the patient was referred to our department. Since curative resection was expected, a laparoscopic partial hepatectomy of segment 8 of the liver was performed. Pathological diagnosis revealed no residual tumor. If the metastases could be well controlled by systemic chemotherapy, hepatectomy for hepatic metastases of biliary tract cancer could be a treatment option.

  Aug. 2024, Gan to kagaku ryoho. Cancer & chemotherapy, 51(8) (8), 843 - 845, Japanese, Domestic magazine

  Scientific journal


• GC+デュルバルマブ療法が奏効し根治的肝切除術を施行し得た胆嚢癌術後肝転移再発の1例

  三宅 泰一郎, 浦出 剛史, 小松 昇平, 権 英寿, 福島 健司, 宗 慎一, 荒井 啓輔, 浅利 貞毅, 柳本 泰明, 外山 博近, 木戸 正浩, 福本 巧

  (株)癌と化学療法社, Aug. 2024, 癌と化学療法, 51(8) (8), 843 - 845, Japanese


• 膵・胆管合流異常に合併した2型IPNBに相当する胆嚢内乳頭状腫瘍の1例

  吉田 道彦, 柳本 泰明, 津川 大介, 秋田 真之, 藤田 千佳, 吉田 俊彦, 宗 慎一, 石田 潤, 南野 佳英, 浦出 剛史, 福島 健司, 権 英寿, 小松 昇平, 浅利 貞毅, 児玉 貴之, 木戸 正浩, 外山 博近, 神保 直江, 伊藤 智雄, 福本 巧

  日本膵・胆管合流異常研究会, Aug. 2024, 日本膵・胆管合流異常研究会プロシーディングス, 47, 16 - 16, Japanese


• Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

  Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, Eisuke Ueshima, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  AIM: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy. METHODS: Ninety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes. RESULTS: Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy. CONCLUSIONS: Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions.

  Aug. 2024, Hepatology research : the official journal of the Japan Society of Hepatology, 54(8) (8), 773 - 780, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Novel concept of "sequential particle radiotherapy" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.

  Shohei Komatsu, Kazuki Terashima, Nobuaki Ishihara, Yoshiro Matsuo, Masahiro Kido, Hiroaki Yanagimoto, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Takumi Fukumoto

  Owing to the high objective response rate of atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC), the concept of sequential conversion to local treatment has recently become mainstream. The conversion concept is mainly applied to Barcelona Clinic for Liver Cancer (BCLC) stage B cases, and radiotherapy is rarely considered as a conversion local treatment. We herein report three patients who were treated with the novel concept of "sequential particle radiotherapy," consisting of Atez/Bev therapy followed by particle radiotherapy (PRT) for HCC with advanced portal vein tumor thrombus (Vp3/4 PVTT). All patients achieved partial response radiologically and were switched to PRT. All patients were recurrence free at 1 year after the introduction of Atez/Bev therapy without any additional treatment. This upcoming combination strategy includes the advocacy of sequential concepts for BCLC stage C cases and the introduction of PRT as a local treatment after Atez/Bev.

  Aug. 2024, Surgery today, 54(8) (8), 972 - 976, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Evaluation of Interaction With Bio-absorbable Polyglycolic Acid Spacer and Anti-adhesive Agents Using a Rat Experimental Model.

  Akihiro Fujisawa, Shohei Komatsu, Satoshi Omiya, Ryosuke Fujinaka, Nobuaki Yamasaki, Hiroaki Yanagimoto, Masahiro Kido, Hirochika Toyama, Ryohei Sasaki, Takumi Fukumoto

  BACKGROUND/AIM: Neskeep®, an absorbable polyglycolic acid spacer, has been developed as the optimal material for spacer placement surgery. However, preventing its severe adhesion is a crucial concern. Therefore, we aimed to identify an effective anti-adhesion agent for Neskeep® using rat models. MATERIALS AND METHODS: Animal experiments were performed using 60 rats, which underwent Neskeep® placement on the abdominal wall. Three types of anti-adhesion agents were employed, establishing four subgroups: Seprafilm®, INTERCEED®, AdSpray®, and only Neskeep® (control) groups. Rats were sacrificed on postoperative days 7, 14, and 28 to assess adhesion levels around the Neskeep® Macroscopic visual assessment with the Lauder score and histopathological evaluation were performed to assess the degree of adhesion. RESULTS: There were no significant differences in the proportion of Lauder scores on days 7 and 14 between the four groups. Histological evaluation revealed no significant differences between groups at any observation time. However, the mean Lauder scores at day 28 were 5.0, 1.6, 4.0, and 4.8 in the Neskeep®, Seprafilm®, INTERCEED®, and AdSpray® groups, respectively. The proportion of milder Lauder score was significantly higher in the Seprafilm® group on day 28. CONCLUSION: Seprafilm® may exhibit an anti-adhesive effect when used with Neskeep®.

  Aug. 2024, Anticancer research, 44(8) (8), 3349 - 3353, English, International magazine

  Scientific journal


• Impact of bile leak on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection.

  Hidetoshi Gon, Shohei Komatsu, Hirotoshi Soyama, Motofumi Tanaka, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  PURPOSE: The impact of postoperative bile leak on the prognosis of patients with hepatocellular carcinoma who underwent liver resection is controversial. This study aimed to investigate the prognostic impact of bile leak for patients with hepatocellular carcinoma who underwent liver resection. METHODS: Patients with hepatocellular carcinoma who underwent liver resection between 2009 and 2019 at Kobe University Hospital and Hyogo Cancer Center were included. After propensity score matching between the bile leak and no bile leak groups, differences in 5-year recurrence-free and overall survival rates were evaluated using the Kaplan-Meier method. RESULTS: A total of 781 patients, including 43 with postoperative bile leak, were analyzed. In the matched cohort, 40 patients were included in each group. The 5-year recurrence-free survival rates after liver resection were 35% and 32% for the bile leak and no bile leak groups, respectively (P = 0.857). The 5-year overall survival rates were 44% and 54% for the bile leak and no bile leak groups, respectively (P = 0.216). CONCLUSION: Overall, bile leak may not have a profound negative impact on the prognosis of patients with hepatocellular carcinoma who have undergone liver resection.

  Jul. 2024, Langenbeck's archives of surgery, 409(1) (1), 233 - 233, English, International magazine

  Scientific journal


• Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus: A case report.

  Nobuaki Ishihara, Shohei Komatsu, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Tremelimumab plus durvalumab (Dur/Tre) is the first-line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68-year-old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1.) 6 months after treatment administration. Subsequently, immune-related adverse events, including type 1 diabetes mellitus and diabetic ketoacidosis, emerged, leading to treatment discontinuation. The patient was undergoing outpatient follow-up in a drug-free state with no signs of recurrence 290 days after the initial administration of Dur/Tre. Although long-term and meticulous observations are required, the present findings could influence the choice of systemic chemotherapy for advanced HCC.

  Jul. 2024, Oncology letters, 28(1) (1), 332 - 332, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Takuya Mimura, Akihiro Minami, Kenji Momose, Hirotaka Hirano, Motofumi Tanaka, Yuki Ueda, Kentaro Tai, Yuki Yasuhara, Daisuke Nakagawa, Atsushi Yamamoto, Masahiro Kido, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Sorafenib and lenvatinib have long been used as a first-line treatment for advanced hepatocellular carcinoma (HCC). Along with the development of systemic chemotherapy for HCC, the concept of conversion hepatectomy has recently become widespread. The present study aimed to assess the clinical outcomes of sorafenib and lenvatinib for HCC regarding the possibility of conversion hepatectomy in clinical practice. PATIENTS AND METHODS: A total of 295 patients with advanced HCC receiving sorafenib and lenvatinib, accounting for 306 treatments (sorafenib, n=157; lenvatinib, n=149, 11 patients received lenvatinib after sorafenib treatment) at five different institutions were enrolled. Patients were assessed for their clinical characteristics and therapeutic response using both Response Evaluation Criteria in Solid Tumors criteria (RECIST) and modified RECIST (mRECIST) criteria. Additionally, an indication of surgery after tyrosine kinase inhibitor administration was determined based on the tumor status of patients. RESULTS: The median survival times of patients treated with sorafenib and lenvatinib were 12.8 and 16.4 months, respectively, without significant difference (p=0.1645). The objective response rates (ORR) of sorafenib based on mRECIST and RECIST were 10.1% and 5.9%, respectively, and those of lenvatinib were 38.1% and 19.0%, respectively. Among the 306 treatments, two cases (sorafenib and lenvatinib, one each) underwent hepatectomy after systemic chemotherapy. CONCLUSION: Few cases with unresectable HCC were amenable to conversion hepatectomy after sorafenib and lenvatinib treatments due to the limited ORR by RECIST. Cautious approach must be taken when administering neoadjuvant chemotherapy aimed at conversion hepatectomy.

  Jul. 2024, Anticancer research, 44(7) (7), 3097 - 3103, English, International magazine

  Scientific journal


• 巨大肝転移を伴う高悪性度胎児性肺腺癌が疑われた若年肺癌の1例

  島田 天美子, 山本 賢, 平野 克也, 秦 明登, 浦出 剛史, 小松 昇平, 木戸 正浩, 児玉 貴之

  (NPO)日本肺癌学会, Jun. 2024, 肺癌, 64(3) (3), 240 - 240, Japanese


• Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.

  Michihiko Yoshida, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  INTRODUCTION: Surgical resection is considered an effective cure for biliary tract cancer (BTC); however, the prognosis is unsatisfactory despite improved surgical techniques and perioperative management. The recurrence rate remains high even after curative resection. The efficacy of adjuvant chemotherapy in pancreatic and gastric cancers has been previously reported, and the feasibility of adjuvant therapy with S-1 has recently been reported in patients with resected BTC. We aimed to retrospectively investigate the effects of adjuvant chemotherapy with S-1 on resected advanced BTC. METHODS: We included data from 438 BTC patients who underwent resection between 2001 and 2020. After excluding patients with pTis-pT1 (n = 112) and other exclusion criteria, 266 patients were included in the analysis. RESULTS: After propensity score matching, 48 patients received S-1 adjuvant chemotherapy (S-1 group), and 48 patients received non-S1 adjuvant chemotherapy or underwent surgery alone (Non-S-1 group). The patients in the S-1 group had significantly better overall survival (OS) than those in the non-S-1 group (MST 51 vs 37 months, hazard ratio [HR]:.54, 95% confidence interval [CI]:.30-.98, P = .04). The S-1 group had a significantly better recurrence-free survival (RFS) than the non-S-1 group (94 vs 21 months, HR: .57, 95% CI: .33-.97, P = .03). Subgroup analyses for OS and RFS exhibited the benefits of S-1 in patients aged <75 years and in patients with primary sites of extrahepatic and perineural invasion and curability of R0. DISCUSSION: S-1 adjuvant therapy is promising for improving the postoperative survival of patients with resected advanced BTC, positive nerve invasion, and R0 resection.

  Jun. 2024, The American surgeon, 90(6) (6), 1279 - 1289, English, International magazine

  Scientific journal


• Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma.

  Ryosuke Fujinaka, Takeshi Urade, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Masato Komatsu, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Spontaneous rupture of a primary hepatocellular carcinoma (HCC) is a frequently observed and fatal complication. However, the rupture of lymph node (LN) metastases from HCC is rare. A 79 year-old male with hepatitis B underwent three liver resections for HCC. Two years and 6 months after the last liver resection, enhanced computed tomography (CT) revealed a nodule with a diameter of 3 cm in the lower pole of the spleen. Splenic metastasis of HCC was suspected, and splenectomy was scheduled. During our hospital stay for a urinary tract infection before the scheduled operation, he complained of acute left-sided abdominal pain, and CT showed intra-abdominal hemorrhage due to rupture of the splenic tumor. Emergency splenectomy was performed, and the postoperative course was uneventful. Histopathological examination revealed a poorly differentiated HCC in the lower splenic pole lesion, which contained LN structures. The ruptured lesion was diagnosed as splenic hilar LN metastasis of HCC. Although laparoscopic partial liver resection was performed for intrahepatic recurrence, and atezolizumab plus bevacizumab therapy was administered for peritoneal metastases, the patient was alive 25 months after the splenectomy. Our case suggests that emergency surgery for LN metastatic rupture can achieve hemostasis and lead to improved survival outcomes.

  Jun. 2024, Clinical journal of gastroenterology, 17(3) (3), 557 - 562, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Optimal cutoff values of drain amylase for predicting pancreatic fistula are different between open and laparoscopic distal pancreatectomy.

  Jun Ishida, Hirochika Toyama, Sadaki Asari, Tadahiro Goto, Yoshihide Nanno, Toshihiko Yoshida, Shinichi So, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  BACKGROUND: Drainage fluid amylase (DFA) is useful for predicting clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP). However, difference in optimal cutoff value of DFA for predicting CR-POPF between open DP (ODP) and laparoscopic DP (LDP) has not been investigated. This study aimed to identify the optimal cutoff values of DFA for predicting CR-POPF after ODP and LDP. METHODS: Data for 294 patients (ODP, n = 127; LDP, n = 167) undergoing DP at Kobe University Hospital between 2010 and 2021 were reviewed. Propensity score matching was performed to minimize treatment selection bias. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff values of DFA for predicting CR-POPF for ODP and LDP. Logistic regression analysis for CR-POPF was performed to investigate the diagnostic value of DFA on postoperative day (POD) three with identified cutoff value. RESULTS: In the matched cohort, CR-POPF rates were 24.7% and 7.9% after ODP and LDP, respectively. DFA on POD one was significantly lower after ODP than after LDP (2263 U/L vs 4243 U/L, p < 0.001), while the difference was not significant on POD three (543 U/L vs 1221 U/L, p = 0.171). ROC analysis revealed that the optimal cutoff value of DFA on POD one and three for predicting CR-POPF were different between ODP and LDP (ODP, 3697 U/L on POD one, 1114 U/L on POD three; LDP, 10564 U/L on POD one, 6020 U/L on POD three). Multivariate analysis showed that DFA on POD three with identified cutoff value was the independent predictor for CR-POPF both for ODP and LDP. CONCLUSIONS: DFA on POD three is an independent predictor for CR-POPF after both ODP and LDP. However, the optimal cutoff value for it is significantly higher after LDP than after ODP. Optimal threshold of DFA for drain removal may be different between ODP and LDP.

  May 2024, Surgical endoscopy, 38(5) (5), 2699 - 2708, English, International magazine

  Scientific journal


• Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.

  Akira Koizumi, Shohei Komatsu, Satoshi Omiya, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Ryosuke Fujinaka, Yuhi Shimura, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: The treatment algorithm for systemic therapies for advanced hepatocellular carcinoma (HCC) has changed dramatically; however, the therapeutic landscape for sequential second-line or later-line treatments, including ramucirumab, remains controversial. This study aimed to investigate the role of ramucirumab for treating HCC. PATIENTS AND METHODS: We retrospectively analyzed data from 17 patients with advanced HCC who received ramucirumab, and 8 of them who received lenvatinib re-administration after ramucirumab treatment failure. RESULTS: The median overall survival of 17 patients treated with ramucirumab was 11.5 months. The median ratios of the 1-month post-treatment α-fetoprotein (AFP) levels and albumin-bilirubin (ALBI) scores to the pre-treatment AFP levels and ALBI scores following ramucirumab treatment were 0.880 and 0.965, respectively. The median ratios of the 1-month post-treatment AFP and ALBI levels to the pre-treatment levels were 1.587 and 0.970 for mALBI grade 1/2a, and 1.313 and 0.936 for mALBI grade 2b/3, respectively. Six of the eight patients who received lenvatinib rechallenge treatment exhibited a decrease in AFP levels one month post-lenvatinib treatment. Deterioration of liver function 3 months post-lenvatinib treatment was noted in five of the eight patients who received lenvatinib rechallenge treatment after ramucirumab. CONCLUSION: Ramucirumab may be equally useful in patients with unresectable HCC who have poor liver function or whose liver function is aggravated by other therapies. Rechallenge treatment with lenvatinib after ramucirumab may be a valid treatment option for HCC.

  May 2024, Anticancer research, 44(5) (5), 2055 - 2061, English, International magazine

  Scientific journal


• The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.

  Hidetoshi Gon, Shohei Komatsu, Satoshi Omiya, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND/AIM: This study aimed to evaluate the utility of the albumin-bilirubin grade for predicting the prognosis after repeat liver resection for patients with recurrent hepatocellular carcinoma. PATIENTS AND METHODS: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat liver resection at our institution between 2005 and 2019 were retrospectively analyzed. Cox proportional-hazards regression models evaluated independent preoperative prognostic factors, including the albumin-bilirubin grade. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method. RESULTS: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (p=0.003) and early recurrence within one year from the initial surgery (p=0.001) were independently associated with poor recurrence-free survival, and albumin-bilirubin grade 2 (p=0.020) was independently associated with poor overall survival. The five-year recurrence-free (31% and 17%, respectively) and overall (86% and 60%, respectively) survival rates after repeat liver resection for patients with albumin-bilirubin grades 1 and 2 were significantly different between groups (both p=0.003). CONCLUSION: The albumin-bilirubin grade is useful for preoperatively predicting favorable survival rates after repeat liver resection for patients with recurrent hepatocellular carcinoma. Patients with an albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma.

  May 2024, Anticancer research, 44(5) (5), 2031 - 2038, English, International magazine

  Scientific journal


• Statement on use of generative artificial intelligence by adolescents.

  Asuka Sakuraya, Masayo Matsumura, Shohei Komatsu, Kotaro Imamura, Mako Iida, Norito Kawakami

  Apr. 2024, Asian journal of psychiatry, 94, 103947 - 103947, English, International magazine


• Utility of plasma D-dimer for diagnosis of venous thromboembolism after hepatectomy.

  Taiichiro Miyake, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Riki Asakura, Keisuke Arai, Toshihiko Yoshida, Shinichi So, Jun Ishida, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Venous thromboembolism (VTE) is a potentially fatal complication of hepatectomy. The use of postoperative prophylactic anticoagulation in patients who have undergone hepatectomy is controversial because of the risk of postoperative bleeding. Therefore, we hypothesized that monitoring plasma D-dimer could be useful in the early diagnosis of VTE after hepatectomy. AIM: To evaluate the utility of monitoring plasma D-dimer levels in the early diagnosis of VTE after hepatectomy. METHODS: The medical records of patients who underwent hepatectomy at our institution between January 2017 and December 2020 were retrospectively analyzed. Patients were divided into two groups according to whether or not they developed VTE after hepatectomy, as diagnosed by contrast-enhanced computed tomography and/or ultrasonography of the lower extremities. Clinicopathological factors, including demographic data and perioperative D-dimer values, were compared between the two groups. Receiver operating characteristic curve analysis was performed to determine the D-dimer cutoff value. Univariate and multivariate analyses were performed using logistic regression analysis to identify significant predictors. RESULTS: In total, 234 patients who underwent hepatectomy were, of whom (5.6%) were diagnosed with VTE following hepatectomy. A comparison between the two groups showed significant differences in operative time (529 vs 403 min, P = 0.0274) and blood loss (530 vs 138 mL, P = 0.0067). The D-dimer levels on postoperative days (POD) 1, 3, 5, 7 were significantly higher in the VTE group than in the non-VTE group. In the multivariate analysis, intraoperative blood loss of > 275 mL [odds ratio (OR) = 5.32, 95% confidence interval (CI): 1.05-27.0, P = 0.044] and plasma D-dimer levels on POD 5 ≥ 21 μg/mL (OR = 10.1, 95%CI: 2.04-50.1, P = 0.0046) were independent risk factors for VTE after hepatectomy. CONCLUSION: Monitoring of plasma D-dimer levels after hepatectomy is useful for early diagnosis of VTE and may avoid routine prophylactic anticoagulation in the postoperative period.

  Jan. 2024, World journal of clinical cases, 12(2) (2), 276 - 284, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Evaluation and Prediction of Post-Hepatectomy Liver Failure Using Imaging Techniques: Value of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.

  Keitaro Sofue, Ryuji Shimada, Eisuke Ueshima, Shohei Komatsu, Takeru Yamaguchi, Shinji Yabe, Yoshiko Ueno, Masatoshi Hori, Takamichi Murakami

  Despite improvements in operative techniques and perioperative care, post-hepatectomy liver failure (PHLF) remains the most serious cause of morbidity and mortality after surgery, and several risk factors have been identified to predict PHLF. Although volumetric assessment using imaging contributes to surgical simulation by estimating the function of future liver remnants in predicting PHLF, liver function is assumed to be homogeneous throughout the liver. The combination of volumetric and functional analyses may be more useful for an accurate evaluation of liver function and prediction of PHLF than only volumetric analysis. Gadoxetic acid is a hepatocyte-specific magnetic resonance (MR) contrast agent that is taken up by hepatocytes via the OATP1 transporter after intravenous administration. Gadoxetic acid-enhanced MR imaging (MRI) offers information regarding both global and regional functions, leading to a more precise evaluation even in cases with heterogeneous liver function. Various indices, including signal intensity-based methods and MR relaxometry, have been proposed for the estimation of liver function and prediction of PHLF using gadoxetic acid-enhanced MRI. Recent developments in MR techniques, including high-resolution hepatobiliary phase images using deep learning image reconstruction and whole-liver T1 map acquisition, have enabled a more detailed and accurate estimation of liver function in gadoxetic acid-enhanced MRI.

  Jan. 2024, Korean journal of radiology, 25(1) (1), 24 - 32, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• A Novel Method Using Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetate Acid-Enhanced Magnetic Resonance Imaging for Predicting Post-Hepatectomy Liver Failure in Hepatocellular Carcinoma Patients with a Major Portal Vein Tumor Thrombus.

  Kosuke Nishio, Shohei Komatsu, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: The usefulness of gadolinium-ethoxybenzyl diethylenetriamine pentaacetate acid-enhanced magnetic resonance imaging (EOB-MRI) in assessing the functional future remnant liver volume (fFRLV) to predict post-hepatectomy liver failure (PHLF) has been previously reported. Herein, we evaluated the efficacy of this technique in patients with hepatocellular carcinoma (HCC) with a major portal vein tumor thrombus (PVTT). METHODS: This study included 21 patients with PVTT in the ipsilateral first-order branch (Vp3) and 30 patients with PVTT in the main trunk/contralateral branch (Vp4). To evaluate fFRLV, the signal intensity (SI) of the remnant liver was determined on T1-weighted images, using both conventional and newly developed methods. The fFRLV was calculated using the SI of the remnant liver and muscle, remnant liver volume, and body surface area. Preoperative factors predicting PHLF (≥grade B) in HCC patients with Vp3/4 PVTT were evaluated. RESULTS: In the Vp3 group, we found fFRLV area under the receiver-operating characteristic curves (AUCs) above 0.70 (AUC = 0.875, 0.750) using EOB-MRI results calculated using either the plot or whole method. None of the parameters in the Vp4 group had an AUC greater than 0.70. CONCLUSION: The fFRLV calculated by EOB-MRI using the whole method can be as useful as the conventional method in predicting PHLF (≥grade B) for HCC patients with Vp3 PVTT.

  2024, Digestive surgery, 41(1) (1), 30 - 36, English, International magazine

  Scientific journal


• Clinical impact of spacer placement surgery with expanded polytetrafluoroethylene sheet for particle therapy.

  Ryosuke Fujinaka, Shohei Komatsu, Kazuki Terashima, Yusuke Demizu, Satoshi Omiya, Masahiro Kido, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Takumi Fukumoto

  BACKGROUND: Spacer placement surgery is useful in particle therapy (PT) for patients with abdominopelvic malignant tumors located adjacent to the gastrointestinal tract. This study aimed to assess the safety, efficacy, and long-term outcomes of spacer placement surgery using an expanded polytetrafluoroethylene (ePTFE) spacer. METHODS: This study included 131 patients who underwent ePTFE spacer placement surgery and subsequent PT between September 2006 and June 2019. The overall survival (OS) and local control (LC) rates were calculated using Kaplan-Meier method. Spacer-related complications were classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). RESULTS: The median follow-up period after spacer placement surgery was 36.8 months. The 3-year estimated OS and LC rates were 60.5% and 76.5%, respectively. A total of 130 patients (99.2%) were able to complete PT. Spacer-related complications of ≥ grade 3 were observed in four patients (3.1%) in the acute phase and 13 patients (9.9%) in the late phase. Ten patients (7.6%) required removal of the ePTFE spacer. CONCLUSIONS: Spacer placement surgery using an ePTFE spacer for abdominopelvic malignant tumors is technically feasible and acceptable for subsequent PT. However, severe spacer-related late complications were observed in some patients. Since long-term placement of a non-absorbable ePTFE spacer is associated with risks for morbidity and infection, careful long-term follow-up and prompt therapeutic intervention are essential when complications associated with the ePTFE spacer occur. TRIAL REGISTRATION: retrospectively registered.

  Oct. 2023, Radiation oncology (London, England), 18(1) (1), 173 - 173, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• The Usefulness of Total Tumor Volume as a Prognostic Factor and in Selecting the Optimal Treatment Strategy of Chemotherapeutic Intervention in Patients with Colorectal Liver Metastases.

  Yuhi Shimura, Shohei Komatsu, Yoshiaki Nagatani, Yohei Funakoshi, Keitaro Sofue, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Hironobu Minami, Takumi Fukumoto

  BACKGROUND: Few reports have discussed the association between total tumor volume (TTV) and prognosis in patients with colorectal liver metastases (CRLM). The present study aimed to evaluate the usefulness of TTV for predicting recurrence-free survival and overall survival (OS) in patients receiving initial hepatic resection or chemotherapy, and to investigate the value of TTV as an indicator for optimal treatment selection for patients with CRLM. PATIENTS AND METHODS: This retrospective cohort study included patients with CRLM who underwent hepatic resection (n = 93) or chemotherapy (n = 78) at the Kobe University Hospital. TTV was measured using 3D construction software and computed tomography images. RESULTS: A TTV of 100 cm3 has been previously reported as a significant cut-off value for predicting OS of CRLM patients receiving initial hepatic resection. For patients receiving hepatic resection, the OS for those with a TTV ≥ 100 cm3 was significantly reduced compared with those with a TTV < 100 cm3. For patients receiving initial chemotherapy, there were no significant differences between the groups divided according to TTV cut-offs. Regarding OS of patients with TTV ≥ 100 cm3, there was no significant difference between hepatic resection and chemotherapy (p = 0.160). CONCLUSIONS: TTV can be a predictive factor of OS for hepatic resection, unlike for initial chemotherapy treatment. The lack of significant difference in OS for CRLM patients with TTV ≥ 100 cm3, regardless of initial treatment, suggests that chemotherapeutic intervention preceding hepatic resection may be indicated for such patients.

  Oct. 2023, Annals of surgical oncology, 30(11) (11), 6603 - 6610, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Risk Factors for Recurrence of Cholangitis After Pancreaticoduodenectomy and Comparison of Stents in Hepaticojejunostomy.

  Hirotaka Fukuoka, Hirochika Toyama, Takuya Mizumoto, Jun Ishida, Sadaki Asari, Tadahiro Goto, Yoshihide Nanno, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Postoperative cholangitis is a common complication of pancreaticoduodenectomy. Frequent cholangitis impairs patients' quality of life after pancreaticoduodenectomy. However, the risk factors for recurrence of cholangitis remain unclear. Hence, this retrospective study aimed to identify risk factors for recurrence of cholangitis after pancreaticoduodenectomy. METHODS: The medical records of patients who underwent pancreaticoduodenectomy between 2015 and 2019 in our institution were retrospectively reviewed. At least two episodes of cholangitis a year after pancreaticoduodenectomy were defined as 'recurrence of cholangitis' in the present study. Univariate and multivariate analyses were performed. RESULTS: The recurrence of cholangitis occurred in 40 of 207 patients (19.3%). Multivariate analysis revealed that internal stent (external, RR: 2.16, P = 0.026; none, RR: 4.76, P = 0.011), firm pancreas (RR: 2.61, P = 0.021), constipation (RR: 3.49, P = 0.008), and postoperative total bilirubin>1.7 mg/dL (RR: 2.94, P = 0.006) were risk factors of recurrence of cholangitis. Among patients with internal stents (n = 54), those with remnant stents beyond 5 months had more frequent recurrence of cholangitis (≥5 months, 75%; <5 months, 30%). CONCLUSIONS: Internal stents, firm pancreas, constipation, and postoperative high bilirubin levels are risk factors for cholangitis recurrence after pancreaticoduodenectomy. In addition, the long-term implantation of internal stents may trigger cholangitis recurrence.

  Oct. 2023, World journal of surgery, 47(10) (10), 2499 - 2506, English, International magazine

  Scientific journal


• ASO Author Reflections: Can the Total Tumor Volume be an Indicator for Optimal Treatment Strategy in Patients with Colorectal Liver Metastases?

  Yuhi Shimura, Shohei Komatsu, Hironobu Minami, Takumi Fukumoto

  Oct. 2023, Annals of surgical oncology, 30(11) (11), 6611 - 6612, English, International magazine

  Scientific journal


• Morbidity after left trisectionectomy for hepato-biliary malignancies: An analysis of the National Clinical Database of Japan.

  Fumihiro Terasaki, Shinya Hirakawa, Hisateru Tachimori, Teiichi Sugiura, Atsushi Nanashima, Shohei Komatsu, Hiroaki Miyata, Yoshihiro Kakeji, Yuko Kitagawa, Masafumi Nakamura, Itaru Endo

  BACKGROUND: The aim of this study was to analyze the nationwide surgical outcome of a left trisectionectomy (LT) and to identify the perioperative risk factors associated with its morbidity. METHODS: Cases of LT for hepato-biliary malignancies registered at the Japanese National Clinical Database between 2013 and 2019 were retrospectively reviewed. Statistical analyses were performed to identify the perioperative risk factors associated with a morbidity of Clavien-Dindo classification (CD) ≥III. RESULTS: Left trisectionectomy was performed on 473 and 238 cases of biliary and nonbiliary cancers, respectively. Morbidity of CD ≥III and V occurred in 45% and 5% of cases with biliary cancer, respectively, compared with 26% and 2% of cases with nonbiliary cancer, respectively. In multivariable analyses, biliary cancer was significantly associated with a morbidity of CD ≥III (odds ratio, 1.87; p = .018). In subgroup analyses for biliary cancer, classification of American Society of Anesthesiologists physical status (ASA-PS) 2, portal vein resection (PVR), and intraoperative blood loss ≥30 mL/kg were significantly associated with a morbidity of CD ≥III. CONCLUSIONS: Biliary cancer induces severe morbidity after LT. The ASA-PS classification, PVR, and intraoperative blood loss indicate severe morbidity after LT for biliary cancer.

  Sep. 2023, Journal of hepato-biliary-pancreatic sciences, 30(12) (12), 1304 - 1315, English, Domestic magazine

  Scientific journal


• Innovative Combination Treatment to Expand the Indications of Particle Therapy: Spacer Placement Surgery Using Bio-Absorbable Polyglycolic Acid Spacer.

  Shohei Komatsu, Tianyuan Wang, Kazuki Terashima, Yusuke Demizu, Makoto Anzai, Masaki Suga, Tomohiro Yamashita, Osamu Suzuki, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  BACKGROUND: Particle therapy (PT) has favorable dose distribution and high curability. However, radiotherapy for malignant tumors adjacent to the gastrointestinal tract is contraindicated owing to its low tolerance. To overcome this, combination treatment with surgery to make a space between the tumor and adjacent gastrointestinal tract followed by PT has been developed. Several materials have been used for the spacer, and we have recently developed the absorbable polyglycolic acid (PGA) spacer, which has been used since 2019. This study is the first report of consecutive case series of spacer placement surgery using the PGA spacer. STUDY DESIGN: Fifty consecutive patients undergoing spacer placement surgery with the PGA spacer were evaluated. Postoperative laboratory data, morbidity related to the treatment, and spacer volume after treatment were evaluated. RESULTS: There were no treatment-related deaths, and all but two patients completed combination treatment. The median ratios of post-operative PGA spacer volume to the pre-treatment volume were 96.9%, 87.7%, and 74.6% at weeks 2, 4, and 8, respectively. The spacer volume was maintained at 80% at 7 weeks and was predicted to be 50% at 15 weeks and 20% in 24 weeks. CONCLUSIONS: Spacer placement surgery using the PGA spacer was feasible and tolerable. The PGA spacers maintained sufficient thickness during the duration of subsequent PT. Combination treatment using the PGA spacer is innovative and has the potential to become a new standard curative local treatment.

  Sep. 2023, Journal of the American College of Surgeons, 238(1) (1), 119 - 128, English, International magazine

  Scientific journal


• ASO Visual Abstract: Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma-A Retrospective Analysis.

  Shigeto Masuda, Kohei Yamakawa, Atsuhiro Masuda, Hirochika Toyama, Keitaro Sofue, Yoshihide Nanno, Shohei Komatsu, Satoshi Omiya, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Shigeto Ashina, Masanori Gonda, Shohei Abe, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  Sep. 2023, Annals of surgical oncology, 30(9) (9), 5790 - 5791, English, International magazine

  Scientific journal


• LC-1000 flow cytometry system complements intraoperative peritoneal cytology for pancreatic and biliary tract cancer.

  Riki Asakura, Tetsuo Ajiki, Shigeki Abe, Hiroaki Yanagimoto, Daisuke Tsugawa, Shohei Komatsu, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: The exfoliative cell analyzer, LC-1000, is medical device that utilizes the principles of flow cytometry, and might provide digital diagnostic information for cytology using a different approach from conventional cytomorphology. In this study, wae examined the usefulness of the LC-1000 as a diagnostic support system for intraoperative peritoneal lavage cytology and its prognostic impact for pancreatic (PC) and biliary tract cancer (BTC). METHODS: Patients with PC and BTC who underwent surgical treatment were included. First, we identified useful indicators of LC-1000 and established cutoff values to discriminate positive cytology. Next, we verified the validity of these cutoff values. RESULTS: In the test set (n = 48), of the LC-1000 indicators examined, only MR-CPIx was significantly different between the negative and positive cytology groups, yielding a cutoff value of 0.86. In the validation set (n = 52), the sensitivity, specificity, positive and negative predictive value of the LC-1000 for cytology results was 1.0, 0.49, 0.11 and 1.0, respectively. In patients who had undergone radical resection, recurrence-free survival rate was significantly higher in the LC-1000 negative group than in the positive group in PC, but not in BTC. CONCLUSION: The LC-1000 was useful as digital support system for peritoneal cytology, and it might have potential as a prognostic factor for PC.

  Sep. 2023, Journal of hepato-biliary-pancreatic sciences, 30(9) (9), 1119 - 1128, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Impact of GLIM criteria-based malnutrition diagnosis on outcomes following liver resection for hepatocellular carcinoma.

  Satoshi Omiya, Takeshi Urade, Shohei Komatsu, Masahiro Kido, Kaori Kuramitsu, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: The Global Leadership Initiative on Malnutrition (GLIM), comprising several of the major global clinical nutrition societies, suggested the world's first criteria for diagnosis of the severity of malnutrition. However, the impact of the resulting diagnosis on patient outcomes for those with hepatocellular carcinoma (HCC) following liver resection (LR) has not been investigated. METHODS: A retrospective analysis of 293 patients with HCC who underwent LR between January 2011 and December 2018 was performed. We compared overall survival (OS) and recurrence-free survival (RFS) and evaluated prognostic factors after LR using Cox proportional hazards regression models. RESULTS: Preoperative patient nutritional status, n (%), was classified as follows: normal, 130 (44%), moderate malnutrition, 116 (40%), and severe malnutrition, 47 (16%). The median OS (129 vs. 43 months, p < 0.001) and median RFS (54 vs. 20 months, p = 0.001) were significantly greater in the normal group than in the severe malnutrition group. Multivariate analysis showed that severe malnutrition was a significant risk factor for OS (p = 0.006) and RFS (p = 0.010) after initial LR. CONCLUSION: Severe malnutrition, as diagnosed by the GLIM criteria, is a significant prognostic factor for survival and recurrence in patients with HCC after LR.

  Aug. 2023, HPB : the official journal of the International Hepato Pancreato Biliary Association, 25(12) (12), 1555 - 1565, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Advantages of the Laparoscopic Approach for the Initial Operation in Patients who Underwent Repeat Hepatectomy.

  Hidetoshi Gon, Shohei Komatsu, Masahiro Kido, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Jun Ishida, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Less intra-abdominal adhesions are expected following laparoscopic surgery. Although an initial laparoscopic approach for primary liver tumors may have advantages in patients who require repeat hepatectomies for recurrent liver tumors, this has not been sufficiently investigated. METHODS: Patients who underwent repeat hepatectomies for recurrent liver tumors at our hospital between 2010 and 2022 were retrospectively analyzed. Of 127 patients, 76 underwent laparoscopic repeat hepatectomy (LRH), of whom 34 patients initially underwent laparoscopic hepatectomy (L-LRH) and 42, open hepatectomy (O-LRH). Fifty-one patients underwent open hepatectomy as both the initial and second operation (O-ORH). We analyzed surgical outcomes between L-LRH and O-LRH groups and between L-LRH and O-ORH groups using propensity-matching analysis for each pattern. RESULTS: Twenty-one patients each were included in L-LRH and O-LRH propensity-matched cohorts. The L-LRH group had a lower rate of postoperative complications than the O-LRH group (0 vs 19%, P = 0.036). When we compared surgical outcomes between L-LRH and O-ORH groups in another matched cohort with 18 patients in each group, in addition to the lower rate of postoperative complications, the L-LRH group had additional favorable surgical outcomes including shorter operation time and lower blood loss volume than the O-ORH group (291 vs 368 min, P = 0.037 and 10 vs 485 mL, P < 0.0001). CONCLUSIONS: An initial laparoscopic approach would be favorable for patients undergoing repeat hepatectomies, as it leads to lower risk of postoperative complications. Compared with O-ORH, the advantage of the laparoscopic approach may be enhanced when it is repeatedly adopted.

  Aug. 2023, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 27(8) (8), 1621 - 1631, English, International magazine

  Scientific journal


• Efficacy and safety of laparoscopic liver resection for hepatocellular carcinoma in segment 8: a propensity score-matched two-center study.

  Nobuaki Yamasaki, Hidetoshi Gon, Hisoka Yamane, Toshihiko Yoshida, Hirotoshi Soyama, Masahiro Kido, Motofumi Tanaka, Shohei Komatsu, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: The safety and efficacy of laparoscopic liver resection (LLR) have been reported worldwide. However, those of LLR for tumors located in Couinaud's segment 8 are not sufficiently investigated. METHODS: We retrospectively analyzed 108 patients who underwent liver resection for hepatocellular carcinoma (HCC) in segment 8 at Kobe University Hospital and Hyogo Cancer Center between January 2010 and December 2021. The patients were categorized in LLR and open liver resection (OLR) groups, and 1:1 propensity score matching (PSM) was performed to compare surgical outcomes between the groups. RESULTS: Forty-seven and 61 patients underwent LLR and OLR, respectively. After PSM, each group contained 34 patients. There was no significant difference in operation time between the groups (331 min vs. 330 min, P = 0.844). Patients in the LLR group had significantly less blood loss (30 mL vs. 468 mL, P < 0.001) and shorter length of postoperative hospital stay (10 days vs. 12 days, P = 0.015) than those in the OLR group. There was no significant difference in the occurrence of postoperative complications between the groups (12% vs. 9%, P = 0.690). Further, the 1-year cumulative incidence of recurrence was not significantly different between the groups (16% vs. 19%, P = 0.734). CONCLUSIONS: The surgical outcomes and short-term prognosis of LLR were similar or better than those of OLR. LLR could be an effective and safe procedure, even for lesions located in segment 8, which is considered a difficult anatomical location for LLR.

  Jul. 2023, Surgical endoscopy, 37(11) (11), 8438 - 8446, English, International magazine

  Scientific journal


• Volume- and quality-controlled certification system promotes centralization of complex hepato-pancreatic-biliary surgery.

  Yoshihiro Mise, Shinya Hirakawa, Hisateru Tachimori, Yoshihiro Kakeji, Yuko Kitagawa, Shohei Komatsu, Atsushi Nanashima, Masafumi Nakamura, Itaru Endo, Akio Saiura

  BACKGROUND: Centralization of complex surgeries has made little progress when it only considers the minimum number of surgical procedures. We aim to assess the impact of certification system of Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS) on centralization and surgical quality of advanced hepato-pancreatic-biliary (HPB) surgery. METHODS: The National Clinical Database was used to review 20 111 patients who underwent pancreatoduodenectomy (PD) and 9666 who underwent advanced hepatectomy defined as hepatectomy of more than one section during 2019 and 2020. JSHPBS certifies hospitals based on the annual number of advanced HPB surgeries and the surgical quality. Minimum numbers of surgeries for board-certified A and B institutions are 50 and 30, respectively. Short-term outcomes were compared among institutions. RESULTS: In 2020, 69.4% (7007/10090) and 72.9% (3433/4710) of patients underwent PD and advanced hepatectomy at board-certified institutions. In-hospital mortality rates after PD was 0.9% at certified A institutions, 1.4% at B institutions, and 2.7% at non-certified institutions (p < .001). The odds ratio (OR) of risk-adjusted mortality after PD compared with non-certified institutions was 0.39 (confidence interval [CI]: 0.30-0.50, p < .001) at certified A institutions, and 0.54 at certified B institutions (CI: 0.40-0.73, p < .001). In-hospital mortality rates after advanced hepatectomy was 1.7% at certified A institutions, 2.3% at B institutions, and 3.2% at non-certified institutions (p < .001). The OR of risk-adjusted mortality after advanced hepatectomy compared with non-certified institutions was 0.57 at certified A institutions (CI: 0.41-0.78, p < .001). CONCLUSION: The volume- and quality-controlled certification system of JSHBPS reduces surgical mortality after advanced HPB surgeries.

  Jul. 2023, Journal of hepato-biliary-pancreatic sciences, 30(7) (7), 851 - 862, English, Domestic magazine

  Scientific journal


• Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma.

  Yoshihiko Yano, Atsushi Yamamoto, Takuya Mimura, Saeko Kushida, Seiya Hirohata, Seitetsu Yoon, Hirotaka Hirano, Soo Ki Kim, Yuri Hatazawa, Kenji Momose, Hiroki Hayashi, Takuo Kado, Katsuhisa Nishi, Hidenori Tanaka, Takanori Matsuura, Ryutaro Yoshida, Naoki Asaji, Eiichiro Yasutomi, Yuuki Shiomi, Akihiro Minami, Shohei Komatsu, Takumi Fukumoto, Yoshihide Ueda, Yuzo Kodama

  BACKGROUND AND AIM: The purpose of this study was to analyze factors associated with the overall survival (OS) of atezolizumab/bevacizumab combination therapy for advanced hepatocellular carcinoma (aHCC). We also assessed the OS of patients with ineffective therapy and those who discontinued treatment owing to adverse events (AEs). METHODS: This retrospective multicenter study involved 139 patients with aHCC who received atezolizumab/bevacizumab combination therapy between November 2020 and September 2022. RESULTS: The median duration of treatment was 136.5 days, and the median observation period was 316 days. The overall response rate was 40%, and the disease control rate was 78% according to mRECIST criteria. Grade ≥2 AEs occurred in 63 patients (43%) and led to treatment discontinuation in 16 patients. Multivariate analysis revealed that treatment response and occurrence of grade ≥2 AEs after therapy, as well as low level of albumin-bilirubin (ALBI) grade and low level of des-gamma carboxy prothrombin (DCP) before therapy, were extracted as factors that contributed to OS. Log-rank tests with the Kaplan-Meier method showed significant differences in OS among these factors. The OS of patients who discontinued owing to AEs was significantly shorter than that of other patients. CONCLUSION: Not only factors before therapy but also treatment response and the appearance of AEs are involved in OS for atezolizumab/bevacizumab combination therapy. Although the development of AEs also contributed to OS, appropriate management of AEs is important to avoid discontinuing treatment with this combination.

  Jul. 2023, JGH open : an open access journal of gastroenterology and hepatology, 7(7) (7), 476 - 481, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Transarterial chemoembolization for liver metastases of a pancreatic neuroendocrine neoplasm: a single-center experience.

  Yoshihide Nanno, Hirochika Toyama, Eisuke Ueshima, Keitaro Sofue, Ippei Matsumoto, Jun Ishida, Takeshi Urade, Kenji Fukushima, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  Transarterial chemoembolization (TACE) is performed for pancreatic neuroendocrine tumor (PanNEN) liver metastases; however, the safety and efficacy of TACE procedures, especially for patients who have undergone previous pancreatic surgery, have not been established. We reviewed 48 TACE procedures (1-6 procedures/patient) performed on 11 patients with PanNEN liver metastases, including 16 TACE procedures (4-6 procedures/patient) for 3 patients with a history of biliary-enteric anastomosis. The overall tumor objective response rate was 94%. The incidence of Clavien‒Dindo grade ≥ 2 complications was 1/16 (6%) and 1/32 (3%), and the median time to untreatable progression was 31 (14-41) and 27 (2-60) months among patients with and without a history of biliary-enteric anastomosis, respectively. Although validation is needed in future studies, our experiences have shown that TACE treatment is a viable treatment option for PanNEN liver metastases, even after biliary-enteric anastomosis with experienced teams and careful patient follow-up.

  Jun. 2023, Surgery today, 53(12) (12), 1396 - 1400, English, Domestic magazine

  Scientific journal


• Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning Pancreatic Neuroendocrine Tumors.

  Yoshihide Nanno, Hirochika Toyama, Ippei Matsumoto, Jun Uemura, Sadaki Asari, Tadahiro Goto, Dongha Lee, Tomomasa Murakami, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Keiichi Okano, Yoshifumi Takeyama, Takumi Fukumoto

  BACKGROUND: Optimal management of non-functioning pancreatic neuroendocrine tumors (PanNETs) ≤20 mm is controversial. The biological heterogeneity of these tumors poses challenges when deciding between resection and observation. METHODS: In this multicenter, retrospective cohort study, we analyzed all patients (n = 78) who underwent resection of non-functioning PanNETs ≤20 mm at three tertiary medical centers from 2004 to 2020 to assess the utility of preoperatively available radiological features and serological biomarkers of non-functioning PanNETs in choosing an optimal surgical indication. The radiological features included non-hyper-attenuation pattern on enhancement computed tomography (CT; hetero/hypo-attenuation) and main pancreatic duct (MPD) involvement, and serological biomarkers included elevation of serum elastase 1 and plasma chromogranin A (CgA) levels. RESULTS: Of all small non-functioning PanNETs, 5/78 (6%) had lymph node metastasis, 11/76 (14%) were WHO grade II, and 9/66 (14%) had microvascular invasion; 20/78 (26%) had at least one of these high-risk pathological factors. In the preoperative assessment, hetero/hypo-attenuation and MPD involvement were observed in 25/69 (36%) and 8/76 (11%), respectively. Elevated serum elastase 1 and plasma CgA levels were observed in 1/33 (3%) and 0/11 (0%) patients, respectively. On multivariate logistic regression analysis, hetero/hypo-attenuation (odds ratio [OR] 6.1, 95% confidence interval [CI] 1.7-22.2) and MPD involvement (OR 16.8, 95% CI 1.6-174.3) were significantly associated with the high-risk pathological factors. The combination of the two radiological worrisome features correctly predicted non-functioning PanNETs with high-risk pathological factors, with about 75% sensitivity, 79% specificity, and 78% accuracy. CONCLUSIONS: This combination of radiological worrisome features can accurately predict non-functioning PanNETs that may require resection.

  Jun. 2023, Annals of surgical oncology, 30(6) (6), 3493 - 3500, English, International magazine

  Scientific journal


• ASO Visual Abstract: Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning Pancreatic Neuroendocrine Tumors.

  Yoshihide Nanno, Hirochika Toyama, Ippei Matsumoto, Jun Uemura, Sadaki Asari, Tadahiro Goto, Dongha Lee, Tomomasa Murakami, Shohei Komatsu, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Keiichi Okano, Yoshifumi Takeyama, Takumi Fukumoto

  Jun. 2023, Annals of surgical oncology, 30(6) (6), 3503 - 3504, English, International magazine

  Scientific journal


• Association of Sarcopenia with a Poor Prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.

  Shigeto Masuda, Kohei Yamakawa, Atsuhiro Masuda, Hirochika Toyama, Keitaro Sofue, Yoshihide Nanno, Shohei Komatsu, Satoshi Omiya, Arata Sakai, Takashi Kobayashi, Takeshi Tanaka, Masahiro Tsujimae, Shigeto Ashina, Masanori Gonda, Shohei Abe, Hisahiro Uemura, Shinya Kohashi, Noriko Inomata, Kae Nagao, Yoshiyuki Harada, Mika Miki, Yosuke Irie, Noriko Juri, Maki Kanzawa, Tomoo Itoh, Takumi Fukumoto, Yuzo Kodama

  BACKGROUND: Sarcopenia, defined as a loss of skeletal muscle mass and quality, is found in 30-65% of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis, and is a poor prognostic factor. However, it is yet to be evaluated why sarcopenia is associated with poor prognosis. Therefore, this study elucidated the tumor characteristics of PDAC with sarcopenia, including driver gene alterations and tumor microenvironment. PATIENTS AND METHODS: We retrospectively analyzed 162 patients with PDAC who underwent pancreatic surgery between 2008 and 2017. We defined sarcopenia by measuring the skeletal muscle mass at the L3 level using preoperative computed tomography images and evaluated driver gene alteration (KRAS, TP53, CDKN2A/p16, and SMAD4) and tumor immune (CD4+, CD8+, and FOXP3+) and fibrosis status (stromal collagen). RESULTS: In localized-stage PDAC (stage ≤ IIa), overall survival (OS) and recurrence-free survival were significantly shorter in the sarcopenia group than in the non-sarcopenia group (2-year OS 89.7% versus 59.1%, P = 0.03; 2-year RFS 74.9% versus 50.0%, P = 0.02). Multivariate analysis revealed that sarcopenia was an independent poor prognostic factor in localized-stage PDAC. Additionally, tumor-infiltrating CD8+ T cells in the sarcopenia group were significantly less than in the non-sarcopenia group (P = 0.02). However, no difference was observed in driver gene alteration and fib.rotic status. These findings were not observed in advanced-stage PDAC (stage ≥ IIb). CONCLUSIONS: Sarcopenia was associated with a worse prognosis and decreased tumor-infiltrating CD8+ T cells in localized-stage PDAC. Sarcopenia may worsen a patient's prognosis by suppressing local tumor immunity.

  May 2023, Annals of surgical oncology, 30(9) (9), 5776 - 5787, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Prognostic Impact of Malnutrition Diagnosed by the GLIM Criteria for Resected Extrahepatic Cholangiocarcinoma.

  Yuki Okazoe, Hiroaki Yanagimoto, Daisuke Tsugawa, Masayuki Akita, Riki Asakura, Satoshi Omiya, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND/AIM: Recently, the Global Leadership Initiative on Malnutrition (GLIM), which includes the world's leading clinical nutrition societies, proposed the first global diagnostic criteria for malnutrition. However, the association between malnutrition diagnosed by the GLIM criteria and prognosis in patients with resected extrahepatic cholangiocarcinoma (ECC) remains unknown. This study aimed to investigate the predictive validity of the GLIM criteria for the prognosis of patients with resected ECC. PATIENTS AND METHODS: Between 2000 and 2020, 166 patients who underwent curative-intent resection for ECC were retrospectively analyzed. Prognostic significance of preoperative malnutrition diagnosed by the GLIM criteria was investigated using a multivariate Cox proportional hazards model. RESULTS: Eighty-five (51.2%) and 46 (27.7%) patients were diagnosed with moderate and severe malnutrition, respectively. Increased malnutrition severity tended to be correlated with increased lymph node metastasis rate (p-for-trend=0.0381). The severe malnutrition group had worse 1-, 3-, and 5-year overall survival rates than the normal (without malnutrition) group (82.2% vs. 91.2%, 45.6% vs. 65.1%, 29.3% vs. 61.5%, respectively, p=0.0159). In multivariate analysis, preoperative severe malnutrition was an independent predictor for poor prognosis (hazard ratio=1.68, 95% confidence interval=1.06-2.66, p=0.0282), along with intraoperative blood loss >1,000 ml, lymph node metastasis, perineural invasion, and curability. CONCLUSION: Severe preoperative malnutrition diagnosed by the GLIM criteria was associated with poor prognosis in patients who underwent curative-intent resection for ECC.

  May 2023, Anticancer research, 43(5) (5), 2299 - 2308, English, International magazine

  Scientific journal


• Factors Predicting Over-Time Weight Increase After Liver Transplantation: A Retrospective Study.

  Yuhi Shimura, Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Daisuke Tsugawa, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Post-transplantation weight control is important for long-term outcomes; however, few reports have examined postoperative weight change. This study aimed to identify perioperative factors contributing to post-transplantation weight change. METHODS: Twenty-nine patients who underwent liver transplantation between 2015 and 2019 with an overall survival of >3 years were analyzed. RESULTS: The median age, model for end-stage liver disease score, and preoperative body mass index (BMI) of the recipients were 57, 25, and 23.7, respectively. Although all but one recipient lost weight, the percentage of recipients who gained weight increased to 55% (1 month), 72% (6 months), and 83% (12 months). Among perioperative factors, recipient age ≤50 years and BMI ≤25 were identified as risk factors for weight gain within 12 months (P < .05), and patients with age ≤50 years or BMI ≤25 recipients gained weight more rapidly (P < .05). The recovery time of serum albumin level ≥4.0 mg/dL was not statistically different between the 2 groups. The weight change during the first 3 years after discharge was represented by an approximately straight line, with 18 and 11 recipients showing a positive and negative slope, respectively. Body mass index ≤23 was identified as a risk factor for a positive slope of weight gain (P <.05). CONCLUSIONS: Although postoperative weight gain implies recovery after transplantation, recipients with a lower preoperative BMI should strictly manage body weight as they may be at higher risk of rapid weight increase.

  Apr. 2023, Transplantation proceedings, 55(4) (4), 924 - 929, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Improved diagnosis of histological capsule in hepatocallular carcinoma by using nonenhancing capsule appearance in addition to enhancing capsule appearance in gadoxetic acid-enhanced MRI.

  Eiko Nishioka, Keitaro Sofue, Koji Maruyama, Eisuke Ueshima, Yoshiko Ueno, Masakatsu Tsurusaki, Shohei Komatsu, Takumi Fukumoto, Takamichi Murakami

  To assess the value of nonenhancing capsule by adding to enhancing capsule in gadoxetic acid-enhanced MRI (EOB-MRI) in comparison with contrast-enhanced CT (CE-CT) for diagnosing histological capsule in hepatocellular carcinoma (HCC). One-hundred fifty-one patients with HCC who underwent both CE-CT and EOB-MRI were retrospectively reviewed. Liver Imaging-Reporting and Data System (LI-RADS) v2018 imaging features, including enhancing and nonenhancing capsule were evaluated by two readers in CE-CT and EOB-MRI. Frequencies of each imaging feature were compared between CE-CT and EOB-MRI. The area under the receiver operating characteristic (AUC) curve for the diagnosis of histological capsule was compared across the following three imaging criteria: (1) enhancing capsule in CE-CT, (2) enhancing capsule in EOB-MRI, and (3) enhancing/nonenhancing capsule in EOB-MRI. Enhancing capsule in EOB-MRI was significantly less frequently depicted than that in CE-CT (p < 0.001 and = 0.016 for reader 1 and 2). Enhancing/nonenhancing capsule in EOB-MRI achieved a similar frequency of enhancing in CE-CT (p = 0.590 and 0.465 for reader 1 and 2). Adding nonenhancing capsule to enhancing capsule in EOB-MRI significantly increased AUCs (p < 0.001 for both readers) and achieved similar AUCs compared with enhancing capsule in CE-CT (p = 0.470 and 0.666 for reader 1 and 2). Adding nonenhancing capsule to the definition of capsule appearance can improve the diagnosis of capsule in EOB-MRI for the diagnosis of histological capsule in HCC and decrease discordance of capsule appearance between EOB-MRI and CE-CT.

  Apr. 2023, Scientific reports, 13(1) (1), 6113 - 6113, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.

  Daichi Enomoto, Kazuhiro Yamamoto, Yuki Matsumoto, Asami Morioka, Tomohiro Omura, Shohei Komatsu, Yoshihiko Yano, Takumi Fukumoto, Ikuko Yano

  BACKGROUND/AIM: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver function. The albumin-bilirubin (ALBI) grade is a novel indicator for predicting liver function in patients with hepatic disease. This study aimed to investigate the relationship between ALBI grade and HCC patients' lenvatinib treatment duration. PATIENTS AND METHODS: This is a retrospective cohort study of patients with HCC and Child-Pugh A treated with lenvatinib between April 2018 and December 2019. The baseline liver function was determined using the ALBI grade. The primary outcome was discontinuation owing to adverse events. The risk factors for discontinuation owing to adverse effects were analyzed using logistic regression. RESULTS: This investigation included 48 HCC patients. Patients with ALBI grade 2 had a significantly shorter time of discontinuation due to adverse events than those with grade 1 (p=0.036). However, the time of treatment failure did not differ between the groups. Multiple logistic regression analysis showed that ALBI grade 2 and non-use of antihypertensive drugs were independent factors for discontinuation due to adverse events [odds ratio (OR)=14.1, 95% confidence interval (CI)=1.46-135, p=0.022 and OR=5.48, 95% CI=1.13-23.9, p=0.024, respectively]. CONCLUSION: The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child-Pugh A.

  Mar. 2023, Anticancer research, 43(3) (3), 1317 - 1323, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Outcomes of the Sequential Treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib.

  Daisuke Nakagawa, Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Atsushi Yamamoto, Satoshi Omiya, Yuhi Shimura, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: The chemotherapeutic landscape for hepatocellular carcinomas (HCCs) has changed dramatically with the availability of several treatment options. This study aimed to assess the long-term outcomes of lenvatinib treatment and analyze its feasibility in the sequential treatment of HCCs. PATIENTS AND METHODS: Eighty-five consecutive patients who received lenvatinib for unresectable HCCs were investigated retrospectively. Survival was assessed based on when the patients were first radiologically diagnosed with progressive disease. Among those with radiologically diagnosed stable or progressive disease at 3 months after lenvatinib administration, the cutoff α-fetoprotein (AFP) ratio (ratio of the AFP level after lenvatinib treatment to the pretreatment AFP level) that was predictive of survival was determined using receiver operating characteristic analysis. RESULTS: The median survival time (MST) was significantly worse among patients diagnosed with progressive disease at 1 month after treatment than among those diagnosed at 2-3 or 3-4 months after treatment [MSTs at 1, 2-3, and 3-4 months: 2.2, 10.2, and 17.3 months, respectively (p<0.001)]. An AFP ratio of 1.36 (computed using the AFP level at 3 months after lenvatinib treatment) was significantly predictive of survival in patients with stable or progressive disease (26.3 vs. 11.3 months, p=0.0024). CONCLUSION: The prognosis of patients on lenvatinib who develop early progressive disease is dismal. Thus, their treatment should be ceased or switched. The 3-month AFP ratio of 1.36 may be a potentially useful cutoff for considering a switch to other treatments in patients radiologically diagnosed with stable or progressive disease.

  Feb. 2023, Anticancer research, 43(2) (2), 911 - 918, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Successful Management of Refractory Autoimmune Hemolytic Anemia with Cold Agglutinin Disease with Splenectomy: A Case Report with Review of Literature.

  Shuji Okamoto, Takeshi Urade, Kimikazu Yakushijin, Masahiro Kido, Kaori Kuramitsu, Shohei Komatsu, Hidetoshi Gon, Hironori Yamashita, Sachiyo Shirakawa, Daisuke Tsugawa, Sachio Terai, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia characterized by agglutination of red blood cells at temperatures below the normal core body temperature. In patients with CAD, splenectomy is not indicated because of its low therapeutic effect on hemolytic anemia induced by extravascular hemolysis. Herein, we report a case of refractory hemolytic anemia with CAD successfully managed with splenectomy. CLINICAL CASE: A 60-year-old man visited a municipal hospital with the chief complaint of fatigue. He was found to have hemolytic anemia and icterus with increased cold agglutination and was diagnosed with CAD. Malignant lymphoma was suspected as the underlying disease; however, no clear underlying disease was identified. Hemolytic anemia progressed during the subsequent winter seasons, and he was treated with temperature control, warming, and weekly blood transfusions. However, despite the blood transfusions, his hemoglobin level did not improve during the summer 2 years after diagnosis, and his previously observed splenomegaly had progressed. He was referred to our department, and a splenectomy was performed to diagnose any occult malignant lymphoma and improve the refractory hemolytic anemia. Because histopathological examination revealed no evidence of malignant lymphoma, a diagnosis of primary CAD was made. The hemolytic anemia improved, and no blood transfusion was required after splenectomy. CONCLUSIONS: Splenectomy significantly improved the patient's refractory hemolytic anemia due to primary CAD. Thus, it may be an effective treatment option in such cases, although further cases and studies are required to evaluate the effects of splenectomy.

  Jan. 2023, The Kobe journal of medical sciences, 68(1) (1), E30-E34, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Assessment of serum and drain fluid bilirubin concentrations in liver transplantation patients.

  Hirotoshi Soyama, Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Hiroaki Yanagimoto, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Bile leakage is a major complication after liver transplantation and remains as a significant source of morbidity and mortality. In 2011, the International Study Group of Liver Surgery (ISGLS) defined bile leakage as a drain/serum bilirubin ratio ≥3. However, to our knowledge there is no literature assessing serum and drain bilirubin concentrations after liver transplantation. The aim of this study was to describe the natural postoperative changes in serum and drain fluid bilirubin concentrations in patients after liver transplantation. METHODS: We included 32 patients who underwent liver transplantation at Kobe University Hospital from January 2007 to December 2020. We enrolled 34 living donors who had no complications as the control group. RESULTS: The recipient serum total/direct bilirubin concentration were higher compared with the donors from postoperative day (POD) 1 to 5 with a statistical difference (P < .05). The recipient drain/serum total bilirubin ratio was lower than donors on POD 3 (0.89 ± 0.07 vs 1.53 ± 0.07: P < .0001), which was also confirmed by the recipient drain/serum direct bilirubin ratio (0.64 ± 0.10 vs 1.18 ± 0.09: P < .0001). On POD 3, the drain fluid volume (647.38 ± 89.47 vs 113.43 ± 86.8 mL: P < .001) and serum total bilirubin concentration (6.73 ± 0.61 vs 1.23 ± 0.60 mg/dL: P < .001) was higher in the recipients than in donors. Categorized in 2 groups, the higher drain fluid volume and bilirubin concentration recipients showed lower drain/serum total bilirubin ratio compared with the other group (P = .03) CONCLUSION: The drain/serum bilirubin ratio in the transplanted patients could be calculated lower compared with the hepatectomy patients because of high drain fluid volume and hyperbilirubinemia. Great care should be taken when assessing the bile leakage in liver transplant recipients using the ISGLS definition.

  Jan. 2023, Transplantation proceedings, 55(1) (1), 184 - 190, English, International magazine

  Scientific journal


• 外科発展の礎 外科志望者増加のための取り組み 外科医獲得にむけた神戸大学外科学講座の取り組み

  小松 昇平, 岡田 健次, 掛地 吉弘, 國久 智成, 尾藤 祐子, 眞庭 謙昌, 福本 巧

  (一社)日本外科学会, Jan. 2023, 日本外科学会雑誌, 124(1) (1), 106 - 108, Japanese


• Hepatic Resection vs Particle Therapy as an Initial Treatment for Single Hepatocellular Carcinoma: Bi-Institutional Propensity Score-Matched Analysis.

  Satoshi Omiya, Shohei Komatsu, Kazuki Terashima, Nobuaki Yamasaki, Yoshiro Matsuo, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Takumi Fukumoto

  BACKGROUND: Curative treatment for hepatocellular carcinoma (HCC) is limited to hepatic resection (HR), radiofrequency ablation, and liver transplantation, while the value of particle therapy (PT) as an initial treatment remains unclear. This study aimed to compare the outcomes of HR and PT for single HCC. STUDY DESIGN: A total of 554 patients with single HCC without vascular invasion were enrolled from January 2000 to December 2015. Patients underwent either HR (n = 279) or PT (n = 275) as initial treatments. A one-to-one propensity score matching (PSM) analysis was performed to evaluate the overall survival (OS) and progression-free survival (PFS) after dividing patients according to liver function as assessed by the modified albumin-bilirubin (mALBI) grade. RESULTS: The median OS (130 vs. 85 month, p = 0.001) and PFS (47 vs. 30 month, p = 0.004) of HR were also significantly better than that of PT in the PSM cohort with mALBI grade 1/2a (n = 145 per group). Meanwhile, in a PSM cohort with mALBI grade 2b/3 (n = 53 per group), there were no significant differences in median OS and PFS between HR and PT. CONCLUSION: HR may be preferable as an initial treatment for patients with single HCC without vascular invasion, especially those with preserved liver function. PT can be an acceptable alternative to HR for patients without surgical indication and/or impaired liver function.

  Dec. 2022, Journal of the American College of Surgeons, 236(5) (5), 972 - 981, English, International magazine

  Scientific journal


• Successful left hepatic trisectionectomy after portal vein embolization for colon cancer liver metastasis in a patient with right-sided ligamentum teres.

  Takeshi Urade, Masahiro Kido, Kaori Kuramitsu, Shohei Komatsu, Takuya Mizumoto, Eisuke Ueshima, Koji Sasaki, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Right-sided ligamentum teres (RSLT) is a rare congenital anomaly in which the fetal umbilical vein is connected to the right paramedian trunk of the portal vein. An 80-year-old woman underwent curative sigmoidectomy for sigmoid cancer 3 years prior to presentation. After 1 year, small solitary liver metastasis was noted in segment 4. Because the patient experienced recurrence of the same lesion after chemotherapy and radiofrequency ablation, she was referred to our hospital. CT revealed an anomaly of the liver with RSLT, classified as an independent posterior branch type. The tumor in the left paramedian section was located in the right umbilical portion (RUP), and BDTT was advanced to the common bile duct. Because the estimated future remnant liver volume was 35.2%, transileocecal portal vein embolization (PVE) for the portal branches from the RUP increased it to 43.5% in 3 weeks. Left trisectionectomy with extrahepatic bile duct resection and hepaticojejunostomy were performed. The patient was discharged on postoperative day 75. We successfully performed a left trisectionectomy after PVE in a patient with RSLT. Understanding the vascular and biliary anomalies of patients with RSLT is essential. When the future remnant liver is small, PVE can be considered for safe hepatectomy.

  Dec. 2022, Clinical journal of gastroenterology, 15(6) (6), 1130 - 1135, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Potential Role of Surgical Resection for Gallbladder Cancer in Elderly Patients.

  Yasuhiro Ueda, Hiroaki Yanagimoto, Tetsuo Ajiki, Daisuke Tsugawa, Riki Asakura, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Masahiro Kido, Takumi Fukumoto

  INTRODUCTION: With the aging of the population in Japan, gallbladder cancer (GBC) in the elderly is increasing. However, the available clinical data are limited, and the optimal treatment is still controversial. The aim of this study was to evaluate the benefit of surgical resection in GBC patients ≥75 years of age. METHODS: A retrospective single center analysis of patients who had undergone surgical resection for GBC between 2000 and 2019 was carried out. Patients aged ≥75 years (elderly group, n = 24) or <75 years (younger group, n = 50) were compared. RESULTS: Both younger and elderly patients exhibited similar clinicopathological characteristics, but comorbidity in the latter was significantly greater, as was the frequency of less invasive surgery. Nonetheless, the incidence of postoperative complications was similar in elderly and younger patients. The proportion of patients receiving adjuvant chemotherapy was lower in the elderly. Overall survival of elderly and younger patients was not significantly different (65.0 vs 62.4% at 5 years, P = .600). In multivariate analysis, residual tumor status but not age was an independent prognostic factor. DISCUSSION: This study demonstrated that appropriate surgical treatment of elderly GBC patients was safe and effective, despite their having more comorbidities and lower rates of adjuvant chemotherapy than younger patients.

  Nov. 2022, The American surgeon, 89(12) (12), 31348221136570 - 31348221136570, English, International magazine

  Scientific journal


• 進行肝細胞癌におけるconversion surgeryの妥当性

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 蔵満 薫, 権 英寿, 福島 健司, 浦出 剛史, 宗 慎一, 山本 淳史, 藤島 佳未, 石田 淳, 津川 大介, 後藤 直大, 浅利 貞毅, 柳本 泰明, 外山 博近, 上田 佳秀, 味木 徹夫, 福本 巧

  (株)医薬情報研究所, Nov. 2022, 新薬と臨牀, 71(11) (11), 1234 - 1234, Japanese


• 進行肝細胞癌におけるconversion surgeryの妥当性

  石原 伸朗, 小松 昇平, 矢野 嘉彦, 木戸 正浩, 蔵満 薫, 権 英寿, 福島 健司, 浦出 剛史, 宗 慎一, 山本 淳史, 藤島 佳未, 石田 淳, 津川 大介, 後藤 直大, 浅利 貞毅, 柳本 泰明, 外山 博近, 上田 佳秀, 味木 徹夫, 福本 巧

  (株)医薬情報研究所, Nov. 2022, 新薬と臨牀, 71(11) (11), 1234 - 1234, Japanese


• Standardization of laparoscopic anatomic liver resection of segment 2 by the Glissonean approach.

  Takeshi Urade, Masahiro Kido, Kaori Kuramitsu, Shohei Komatsu, Hidetoshi Gon, Kenji Fukushima, Shinichi So, Takuya Mizumoto, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Anatomic liver resection (ALR) has been established to eliminate the tumor-bearing hepatic region with preservation of the remnant liver volume for liver malignancies. Recently, laparoscopic ALR has been widely applied; however, there are few reports on laparoscopic segmentectomy 2. This study aimed to present the standardization of laparoscopic segmentectomy 2 with surgical outcomes. METHODS: This study included seven patients who underwent pure laparoscopic segmentectomy 2 by the Glissonean approach from January 2020 to December 2021. Four of them had hepatocellular carcinoma, two had colorectal liver metastasis, and one had hepatic angiomyolipoma, which was preoperatively diagnosed with hepatocellular carcinoma. In all patients, preoperative three-dimensional (3D) simulation images from dynamic CT were reconstructed using a 3D workstation. The layer between the hepatic parenchyma and the Glissonean pedicle of segment 2 (G2) was dissected to encircle the root of G2. After clamping or ligation of the G2, 2.5 mg of indocyanine green was injected intravenously to identify the boundaries between segments 2 and 3 with a negative staining method under near-infrared light. Parenchymal transection was performed from the caudal side to the cranial side according to the demarcation on the liver surface, and the left hepatic vein was exposed on the cut surface if possible. RESULTS: The mean operative time for all patients was 281 min. The mean blood loss was 37 mL, and no transfusion was necessary. Estimated liver resection volumes significantly correlated with actual liver resection volumes (r = 0.61, P = 0.035). After the operation, one patient presented with asymptomatic deep venous and pulmonary thrombosis, which was treated with anticoagulant therapy. The mean length of hospital stay was 8.9 days. CONCLUSION: Laparoscopic segmentectomy 2 by the Glissonean approach is a feasible and safe procedure with the preservation of the nontumor-bearing segment 3 for liver tumors in segment 2.

  Nov. 2022, Surgical endoscopy, 36(11) (11), 8600 - 8606, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab Treatment for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Atsushi Yamamoto, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab and lenvatinib are the key drugs in the current systemic chemotherapeutic regimen for hepatocellular carcinoma (HCC). Studies have reported the potential effectiveness of lenvatinib introduction after an atezolizumab plus bevacizumab treatment; however, the therapeutic effectiveness of a lenvatinib rechallenge after an atezolizumab plus bevacizumab treatment remains unclear. PATIENTS AND METHODS: Thirteen consecutive patients who were rechallenged with lenvatinib after clinical failure following treatments with lenvatinib and atezolizumab plus bevacizumab were included. A comparative study was conducted on the duration and treatment efficacy of the first and second lenvatinib treatments and on the pre- and post-treatment liver function. RESULTS: The median ratios of the 1-month post-treatment alpha-fetoprotein (AFP) levels to the pretreatment AFP levels were 0.750 and 0.667 for the first and second lenvatinib treatments, respectively, without significant difference (p=0.9327). Meanwhile, the median ratios of the 1-month post-treatment albumin-bilirubin (ALBI) scores to the pretreatment ALBI scores were 1.063 and 0.827 for the first and second lenvatinib treatments, respectively, with significant difference (p=0.015). The median duration of the second lenvatinib treatment was significantly shorter than that of the first lenvatinib treatment [2.8 months (range=0.9-4.7 months) vs. 8.7 months (range=3.1-29.7 months)]. CONCLUSION: Lenvatinib re-administration after atezolizumab plus bevacizumab treatment can act as a double-edged sword, as it exerts an anti-tumor effect while being associated with potential liver function deterioration. However, this treatment sequence can be useful, and requires careful monitoring of the transitions in the liver function and the patient's performance status.

  Nov. 2022, Anticancer research, 42(11) (11), 5479 - 5486, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Safe Laparoscopic Resection of Hepatocellular Carcinoma in the Spiegel Lobe of the Liver Using a Medial-to-Lateral Approach.

  Hidetoshi Gon, Masahiro Kido, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  Oct. 2022, Annals of surgical oncology, 30(1) (1), 383 - 383, English, International magazine

  Scientific journal


• Laparoscopic Medial-to-Lateral Approach for the Resection of Hepatocellular Carcinoma Located at the Spiegel Lobe of the Liver.

  Hidetoshi Gon, Masahiro Kido, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yoshihide Nanno, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Laparoscopic caudate lobe resection is a challenging procedure. Several researchers have reported the safety of laparoscopic liver resections;1.Transl Gastroenterol Hepatol. 1:56;2.Asian J Endosc Surg. 12:232-236;3.Ann Surg Oncol. 26:2980; however, a standardized procedure has not yet been established. Herein, we present a video showing laparoscopic Spiegel lobectomy in a patient with 6-cm hepatocellular carcinoma (HCC) using a novel approach. PATIENT AND METHODS: A 63-year-old man with a caudate lobe HCC was referred to our hospital. Computed tomography showed a 5 × 6 cm2 HCC located in the Spiegel lobe, which profoundly displaced the inferior vena cava (IVC) to the lower right side, and mobilization of the Spiegel lobe was considered difficult. To perform the dissection between the Siegel lobe and IVC safely, we performed parenchymal transection along the ventral side of the IVC initially. The Spiegel lobe was then dislocated to the left side of the IVC. We dissected the left lateral side of the IVC, including the proper hepatic vein draining the caudate lobe and the left IVC ligament with a safe operative field, and successfully removed the Spiegel lobe with large HCC. RESULTS: The operation time was 383 min. The blood loss was 10 mL. The patient was discharged on the seventh postoperative day without any complications. Histopathological examination revealed well-differentiated HCC with a negative surgical margin. CONCLUSIONS: Laparoscopic medial-to-lateral approach with initial parenchymal transection at the medial side of the Spiegel lobe followed by dissection of the left lateral side of the IVC is considered as a safe and effective procedure for large tumors in the Spiegel lobe.

  Oct. 2022, Annals of surgical oncology, 30(1) (1), 381 - 382, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Correction to: Use of a short cartridge stapler is beneficial in pancreatic transection at the neck during laparoscopic distal pancreatectomy.

  Jun Ishida, Hirochika Toyama, Sadaki Asari, Tadahiro Goto, Yoshihide Nanno, Takuya Mizumoto, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  Sep. 2022, Surgery today, 53(1) (1), 158 - 158, English, Domestic magazine


• Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: a bi-institutional propensity-matched cohort study.

  Shohei Komatsu, Kazuomi Ueshima, Masahiro Kido, Kaori Kuramitsu, Daisuke Tsugawa, Hiroaki Yanagimoto, Hirochika Toyama, Yonson Ku, Masatoshi Kudo, Takumi Fukumoto

  AIM: Sorafenib was previously considered a first-line treatment for hepatocellular carcinoma (HCC) patients with macroscopic portal vein tumor thrombus (PVTT). This case-matched analysis was performed to evaluate the best first-line treatment for HCC in patients with macroscopic PVTT. METHODS: The HCC patients with Vp2 (PVTT invaded into a second-order portal branch), Vp3 (first-order portal branch), and Vp4 (main trunk or contralateral portal vein) PVTT who underwent hepatectomy and those treated with sorafenib were included. Treatment results were compared between the two modalities for each PVTT category, and a propensity analysis was performed for patients with Vp3 and Vp4 (Vp3/4). RESULTS: The median survival times (MSTs) of patients with Vp2, Vp3, and Vp4 PVTT who underwent hepatectomy were 21.4, 13.6, and 14.9 months, respectively; the MSTs for those with Vp2, Vp3, and Vp4 PVTT who received sorafenib treatment were 6.9, 5.5, and 3.6 months, respectively, with a significant difference. In a propensity-matched cohort of patients with Vp3/4 PVTT (36 patients in each), the MST of patients who underwent hepatectomy (15.1 months) was significantly better than the patients treated with sorafenib (4.5 months). CONCLUSION: Hepatectomy can be associated with prolonged survival in HCC patients with macroscopic PVTT.

  Sep. 2022, Journal of hepato-biliary-pancreatic sciences, 30(3) (3), 303 - 314, English, Domestic magazine

  Scientific journal


• Use of a short cartridge stapler is beneficial in pancreatic transection at the neck during laparoscopic distal pancreatectomy.

  Jun Ishida, Hirochika Toyama, Sadaki Asdari, Tadahiro Goto, Yoshihide Nanno, Takuya Mizumoto, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Hiroaki Yanagimoto, Masahiro Kido, Takumi Fukumoto

  Stapling is the standard method for pancreatic transection during laparoscopic distal pancreatectomy. Although most surgeons use a 60 mm cartridge stapler, space limitations created by laparoscopic surgery make the instrument difficult to handle, especially during pancreatic transection at the neck. Therefore, we currently use a 45 mm cartridge stapler for laparoscopic pancreatic transection at the neck. Between October 2019 and December 2020, we performed pancreatic transection using a 45 mm cartridge stapler in 27 patients. Fifteen patients experienced biochemical leakage, but no patients developed clinically relevant pancreatic fistula. The compactness of the 45 mm cartridge has several benefits: (1) less space is required for flexing, opening, and closing the device; (2) it enables easy insertion of the lower jaw behind the pancreas, even if the dissected space behind the pancreas is narrow; (3) less obstruction of the surgeons' view prevents accidental injury to the surrounding tissues and vessels. These benefits may enable safe pancreatic transection.

  Jul. 2022, Surgery today, 53(1) (1), 153 - 157, English, Domestic magazine

  Scientific journal


• Suitability of Laparoscopic Liver Resection of Segment VII: a Retrospective Two-Center Study.

  Hidetoshi Gon, Hisoka Yamane, Toshihiko Yoshida, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Shinichi So, Yoshihide Nanno, Daisuke Tsugawa, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Resecting liver tumors located in Couinaud's segment VII is challenging; the efficacy and safety of laparoscopic liver resection for segment VII lesions compared to open liver resection remain unclear. METHODS: Medical records of 84 patients who underwent liver resection of segment VII at Kobe University Hospital and Hyogo Cancer Center between 2010 and 2021 were retrospectively analyzed. Surgical outcomes were compared between laparoscopic liver resection and open liver resection groups using propensity matching analysis. RESULTS: Thirty-one and 53 patients underwent laparoscopic liver resection and open liver resection, respectively. After propensity matching, 29 patients were included in each group. The laparoscopic liver resection group had a significantly longer operation time (407 vs. 305 min, P = 0.002), lower blood loss (100 vs. 230 mL, P = 0.004), and higher postoperative alanine aminotransferase levels (436 vs. 252 IU/L, P = 0.008) than the open liver resection group. In patients with liver cirrhosis, the proportion of patients with postoperative liver-specific complications was higher in the laparoscopic liver resection group than in the open liver resection group (57% vs 11%, P = 0.049), although there was no significant difference in postoperative liver-specific complication rates between the groups in patients without liver cirrhosis. CONCLUSIONS: For liver resection of segment VII, laparoscopic liver resection led to higher postoperative liver damage than open liver resection. Open liver resection may be better for patients with liver cirrhosis to avoid postoperative liver-specific complications. Laparoscopic liver resection could be an acceptable procedure for patients without liver cirrhosis, with some merits such as less blood loss.

  Jun. 2022, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(11) (11), 2274 - 2281, English, International magazine

  Scientific journal


• Space-making particle therapy for unresectable hilar cholangiocarcinoma.

  Yu Hashimoto, Shohei Komatsu, Kazuki Terashima, Daisuke Tsugawa, Hiroaki Yanagimoto, Masaki Suga, Yusuke Demizu, Sunao Tokumaru, Tomoaki Okimoto, Ryohei Sasaki, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Particle therapy (PT) holds a great potential for unresectable hilar cholangiocarcinoma (HC), even though the anatomical proximity to the gastrointestinal tract prevents delivering a radical dose to the tumor. Space-making PT (SMPT), consisting of spacer placement surgery and subsequent PT, has been developed to minimize complications and maximize the therapeutic benefit of dose escalation for HC. This study aimed to examine the effectiveness of SMPT for the treatment of HC. METHODS: Between 2007 and 2018, 12 patients with unresectable HC treated with SMPT were enrolled. The treatment outcomes and effectiveness of spacer placement surgery were evaluated through analyses of pre- and post- surgical parameters of dose volume histograms. RESULTS: The median survival time was 29.6 months, and the 1- and 3-year overall survival rates were 82.5% and 45.8%, respectively. The mean V95% value (volume irradiated with 95% of the planned treatment dose) of the gross tumor volume and clinical target volume after spacer placement surgery improved to 98.5% and 96.6% from preoperative values of 85.6% and 78.1%, respectively (p = 0.0196 and p = 0.0053 respectively). Grade 3 or higher adverse events after SMPT were seen in 6 patients. CONCLUSIONS: SMPT led to improvements in dosimetric parameters and showed good feasibility and excellent outcomes. SMPT can be a promising novel alternative for unresectable HC.

  Apr. 2022, Digestive surgery, 39(2-3) (2-3), 99 - 108, English, International magazine

  Scientific journal


• Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma.

  Yu Asakura, Hirochika Toyama, Jun Ishida, Sadaki Asari, Sachio Terai, Sachiyo Shirakawa, Hironori Yamashita, Takashi Shimizu, Yuta Ogura, Ippei Matsumoto, Hidetoshi Gon, Daisuke Tsugawa, Shohei Komatsu, Kaori Kuramitsu, Hiroaki Yanagimoto, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate even after curative resection. Lung recurrence may have better outcomes than other recurrences. However, its detailed clinicopathological features are unclear. We investigated the clinicopathological features and risk factors for lung recurrence after pancreatectomy for PDAC. METHODS: The study included 161 patients with potentially and borderline resectable PDAC who had undergone R0 or R1 pancreatectomy between January 2008 and December 2016. We retrospectively examined the prognosis and predictors for lung recurrence after curative resection. RESULTS: Seventeen patients (10.6%) had isolated lung recurrence. The median overall and recurrence-free survivals were 38.0 and 16.1 months, respectively. In multivariate analysis, para-aortic lymph node (PALN) metastasis (p = 0.006) and female sex (p = 0.027) were independent factors for lung recurrence. CONCLUSION: Lung recurrence had a better prognosis than other recurrences. PALN metastasis and female sex are independent risk factors for lung recurrence after curative resection for PDAC.

  Mar. 2022, Asian journal of surgery, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Kaori Kuramitsu, Atsushi Yamamoto, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: Atezolizumab plus bevacizumab therapy is the new standard treatment option for advanced hepatocellular carcinoma (HCC). The clinical details and sequential course after atezolizumab plus bevacizumab therapy remain to be determined. PATIENTS AND METHODS: Thirty-four consecutive patients who received atezolizumab plus bevacizumab therapy were evaluated. Their clinical outcomes were assessed according to liver function classified by modified albumin-bilirubin (ALBI) grade 1 and 2a (1/2a) versus 2b and treatment line (first-line versus second- or later-line). Furthermore, the treatment sequence after atezolizumab plus bevacizumab therapy was also assessed. RESULTS: The objective response and disease control rates were 15.6% and 93.8%, respectively. The median proportions of ALBI scores at 1, 2, and 3 months relative to the baseline scores were 0.94, 0.97, and 0.93, respectively. The median proportions of α-fetoprotein (AFP) scores at 1, 2, and 3 months relative to the baseline scores were 0.98, 1.12, and 1.83, respectively. There were no significant differences in the changes in the proportions of AFP and ALBI scores according to both liver function and treatment line. Twelve patients were administered lenvatinib treatment after the failure of atezolizumab plus bevacizumab therapy. The proportions of AFP and ALBI scores at 1 month relative to the baseline scores were 0.55 and 0.81, respectively. CONCLUSION: Atezolizumab plus bevacizumab therapy can be effective for advanced HCC irrespective of the patients' liver function and treatment line. Lenvatinib administration after atezolizumab plus bevacizumab therapy can be effective, although special attention should be paid to the deterioration of liver function.

  Mar. 2022, Anticancer research, 42(3) (3), 1403 - 1412, English, International magazine

  Scientific journal


• 未分化多形肉腫膵転移に対して腹腔鏡下尾側膵切除を行った1例

  福岡 裕貴, 外山 博近, 浅利 貞毅, 寺井 祥雄, 山下 博成, 石田 潤, 小倉 佑太, 権 英寿, 津川 大介, 小松 昇平, 蔵満 薫, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  (株)癌と化学療法社, Jan. 2022, 癌と化学療法, 49(1) (1), 80 - 82, Japanese


• Prognostic Impact of Inflammation-Based Scores for Extrahepatic Cholangiocarcinoma.

  Riki Asakura, Hiroaki Yanagimoto, Tetsuo Ajiki, Daisuke Tsugawa, Takuya Mizumoto, Shinichi So, Takeshi Urade, Yoshihide Nanno, Kenji Fukushima, Hidetoshi Gon, Shohei Komatsu, Kaori Kuramitsu, Tadahiro Goto, Sadaki Asari, Masahiro Kido, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: Although the relationship between systemic inflammatory responses and prognosis has been known in various cancers, it remains unclear which scores are most valuable for determining the prognosis of extrahepatic cholangiocarcinoma. We aimed to verify the usefulness of various inflammation-based scores as prognostic factors in patients with resected extrahepatic cholangiocarcinoma. METHODS: We analyzed consecutive patients undergoing surgical resection for extrahepatic cholangiocarcinoma at our institution between January 2000 and December 2019. The usefulness of the following inflammation-based scores as prognostic factor was investigated: glasgow prognostic score (GPS), modified GPS, neutrophil-to-lymphocyte ratio, platelet to lymphocyte ratio, lymphocyte-to-monocyte ratio, prognostic nutrition index, C-reactive protein to albumin ratio (CAR), controlling nutritional status (CONUT), and prognostic index. RESULTS: A total of 169 patients were enrolled in this study. Of the nine scores, CAR and CONUT indicated prognostic value. Furthermore, multivariate analysis for overall survival revealed that high CAR (>0.23) was an independent prognostic factor (hazard ratio: 1.816, 95% confidence interval: 1.135-2.906, p = 0.0129), along with lymph node metastasis and curability. There was no difference in tumor staging and short-term outcomes between the low CAR (≤0.23) and high CAR groups. CONCLUSIONS: CAR was the most valuable prognostic score in patients with resected extrahepatic cholangiocarcinoma.

  2022, Digestive surgery, 39(2-3) (2-3), 65 - 74, English, International magazine

  Scientific journal


• Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report.

  Shohei Komatsu, Yoshimi Fujishima, Masahiro Kido, Kaori Kuramitsu, Tadahiro Goto, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Hepatocellular carcinoma (HCC) with major portal vein tumor thrombus (Vp4 PVTT) is an extremely advanced tumor with limited treatment options. Systemic chemotherapy is the only recommended treatment option, and atezolizumab plus bevacizumab has recently emerged as a first-line treatment option. CASE PRESENTATION: We describe the case of an 82-year-old man with unresectable advanced HCC with Vp4 PVTT who achieved a significant response to atezolizumab plus bevacizumab treatment. A single administration of atezolizumab plus bevacizumab ensured significant anti-tumor effects (regression in the tumor size and PVTT, portal vein recanalization, and serum alfa-fetoprotein levels decreased from 90,770 to 89 ng/mL). The patient continued with atezolizumab monotherapy, and after nine consecutive regimens, there was no apparent sign of residual tumor. CONCLUSIONS: This case demonstrates the powerful anti-tumor effect of atezolizumab plus bevacizumab treatment for advanced HCC with Vp4 PVTT, suggesting that these agents can be a promising treatment option for such refractory tumors.

  Dec. 2021, BMC gastroenterology, 21(1) (1), 470 - 470, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 腹腔鏡下膵体尾部切除後、Needle Tract Seedingによる胃壁再発を来した膵癌の1例

  小倉 佑太, 外山 博近, 寺井 祥雄, 山下 博成, 石田 潤, 福岡 裕貴, 権 英寿, 津川 大介, 小松 昇平, 蔵満 薫, 柳本 泰明, 浅利 貞毅, 木戸 正浩, 味木 徹夫, 福本 巧

  (株)癌と化学療法社, Dec. 2021, 癌と化学療法, 48(13) (13), 2011 - 2013, Japanese


• Standardization of the Side-to-Side Cavo-Caval Anastomosis in Orthotopic Liver Transplantation Based on the Causal Analysis of Outflow Obstruction.

  Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Daisuke Tsugawa, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Takuya Mizumoto, Yoshihide Nanno, Hironori Yamashita, Tadahiro Goto, Hiroaki Yanagimoto, Sadaki Asari, Tetsuo Ajiki, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Although liver transplantation is widely accepted as the therapeutic strategy for end-stage liver failure, complication of hepatic venous outflow obstruction remains lethal. Currently, ensuring a single wide orifice in both the graft and recipient inferior vena cava has been proposed to avoid hepatic venous outflow obstruction with no theoretical concept. METHODS: We herein report a standardization technique for the reconstruction of the hepatic vein based on the causal analysis. RESULTS: During the put-in process, the graft must be positioned in contact with the recipient diaphragm and slightly pushed to the cranial direction to simulate the state after abdominal closure. Because there is no extra space between the graft and diaphragm, the graft could not rotate about the anastomotic site of the inferior vena cava toward the diaphragm after abdominal closure as the intestinal pressure increases, and accordingly hepatic venous outflow obstruction does not develop. CONCLUSIONS: With this concept, all transplant surgeons can successfully and easily perform hepatic vein reconstruction without total clamping of the inferior vena cava and without outflow block.

  Dec. 2021, Transplantation proceedings, 53(10) (10), 2934 - 2938, English, International magazine

  Scientific journal


• Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.

  Satoshi Omiya, Shohei Komatsu, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Keitaro Sofue, Yoshihiko Yano, Yoshitada Sakai, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND/AIM: Sarcopenia has been reported to be a significant prognostic factor in patients with hepatocellular carcinoma in recent years. This study aimed to clarify the prognostic significance of sarcopenia in advanced hepatocellular carcinoma treated with reductive hepatectomy. PATIENTS AND METHODS: We retrospectively analyzed 93 patients who underwent reductive hepatectomy for advanced hepatocellular carcinoma. RESULTS: Median survival time of the sarcopenia group (16.4 months) was significantly shorter than that of the non-sarcopenia group (20.4 months). The overall survival rates at 1, 3, and 5 years of the sarcopenia group were significantly lower than those of the non-sarcopenia group (57.9%, 8.6%, and 2.9% vs. 67.3%, 29.2%, and 15.7%, respectively; p=0.035). On multivariate analysis, sarcopenia was a significant risk factor of overall survival (hazard ratio=1.60, 95% confidence interval=1.00-2.56, p=0.049). CONCLUSION: Sarcopenia was a significant prognostic factor of survival after reductive hepatectomy in advanced hepatocellular carcinoma.

  Nov. 2021, Anticancer research, 41(11) (11), 5775 - 5783, English, International magazine

  Scientific journal


• Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus.

  Shohei Komatsu, Masahiro Kido, Kaori Kuramitsu, Daisuke Tsugawa, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: Optimal treatment strategies for advanced hepatocellular carcinoma (HCC) with macroscopic portal vein tumor thrombus (PVTT) remain controversial. Therefore, this study aimed to assess the impact and predictive factors of hepatectomy for HCC with macroscopic PVTT. METHODS: This study included 100 patients who presented with intraoperatively confirmed PVTT extending to the first portal branch (Vp3), main portal trunk, or opposite-side portal branch (Vp4) between June 2000 and December 2019. Their postoperative outcomes and predictive factors for survival were evaluated. RESULTS: Of the 100 patients, 37 (37%) and 63 (63%) had Vp3 and Vp4 PVTTs, respectively. Moreover, 42 (42%) and 58 (58%) patients underwent R0/1 and R2 hepatectomies, respectively. The median survival time (MST) of all patients with Vp3/4 PVTT was 14.5 months; the 1- and 3-year overall survival rates were 59.6 and 16.8%, respectively. The MSTs of patients with Vp3 and Vp4 PVTTs were 16.1 and 14.3 months, respectively (P = 0.7098). The MSTs of patients who underwent R0/1 and R2 hepatectomies were 14.3 and 14.9 months, respectively (P = 0.3831). All assessed tumor factors (including the Vp status [Vp3 or Vp4], type of resection [R0/1 or R2], intrahepatic maximal tumor size, intrahepatic tumor number, and the existence of extrahepatic metastasis) did not influence the overall survival significantly. CONCLUSIONS: Tumor factors, such as the presence of a Vp3/4 PVTT, have a strong impact on survival; however, other multiple tumor factors have a limited impact. Hepatectomy can be an effective treatment option for HCC with Vp3/4 PVTT, and its indications should be considered.

  Oct. 2021, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 26(4) (4), 822 - 830, English, International magazine

  Scientific journal


• Salvage hepatectomy for local recurrence after particle therapy using proton and carbon ion beams for liver cancer.

  Motofumi Tanaka, Shohei Komatsu, Masahiro Kido, Hirochika Toyama, Masahiro Tominaga, Yoichiro Uchida, Kazuki Terashima, Yusuke Demizu, Tomoaki Okimoto, Takumi Fukumoto

  Aim: With the increased use of particle therapy for liver cancer, local recurrence after particle therapy increased. Salvage hepatectomy is an acceptable treatment option for local recurrence following particle therapy; however, its safety and effectiveness remain unclear. Therefore, this multi-center study aimed to verify the feasibility and efficacy of salvage hepatectomy and assess clinical issues associated with its application. Methods: We retrospectively assessed the perioperative outcomes, prognosis, and pathological characteristics of 15 patients who underwent salvage hepatectomy for local recurrence after particle therapy between 2006 and 2019. Results: Hepatocellular carcinoma and metastatic liver tumors were noted in eight and seven patients, respectively. The mean total dose and number of fractions were 66.5 Gy and 12, respectively, and the mean interval between particle therapy and surgery was 30.1 months. Major hepatectomy was performed in seven cases. Moreover, the mortality rate was 0%, and surgical complications of Clavien-Dindo grade IIIa or higher were observed in four cases (27%)-two bile leakages, one pleural effusion, and one refractory skin fistula. The median overall survival time and 5-year overall survival rate after salvage hepatectomy were 29.9 months and 43.1%, respectively. Histological examination of the irradiated liver tissue surrounding the tumor showed sinusoidal dilatation, loss of hepatocyte, and fibrosis in most cases. Conclusion: Salvage hepatectomy after particle therapy is a feasible therapy; however, the risk of refractory complications associated with particle therapy is relatively high. Therefore, the first-line treatment for resectable liver cancer should be carefully determined considering second-line treatment after local recurrence.

  Sep. 2021, Annals of gastroenterological surgery, 5(5) (5), 711 - 719, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.

  Shohei Komatsu, Yoshihiko Yano, Masahiro Kido, Kaori Kuramitsu, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Shinichi So, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto

  BACKGROUND/AIM: While there is increasing evidence supporting the role of several first- and second-line treatment regimens for advanced hepatocellular carcinomas (HCC), the clinical relevance of rechallenge treatment with previously administered drugs, however, remains to be explored. PATIENTS AND METHODS: Five consecutive patients with advanced HCC who received lenvatinib rechallenge treatment after ramucirumab were assessed. RESULTS: All patients were clinically diagnosed with failure after ramucirumab treatment, and the frequencies of ramucirumab administration before lenvatinib re-administration ranged from 3 to 11. The alfa-fetoprotein level in four of five patients decreased 1 month after the lenvatinib rechallenge. Radiological findings via the modified Response Evaluation Criteria in Solid Tumors showed stable diseases in four patients and a partial response in one. CONCLUSION: Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.

  Sep. 2021, Anticancer research, 41(9) (9), 4555 - 4562, English, International magazine

  Scientific journal


• Indication of Surgical Hepatectomy for the Patients of Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombosis.

  Yusuke Nishizawa, Kaori Kuramitsu, Masahiro Kido, Shohei Komatsu, Hidetoshi Gon, Takeshi Urade, Shinichi So, Jun Ishida, Sachiyo Shirakawa, Hironori Yamashita, Daisuke Tsugawa, Sachio Terai, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  The prognosis of hepatocellular carcinoma (HCC) presenting with inferior vena cava tumor thrombus (IVCTT) is extremely poor. The aim of this study was to reveal the postoperative course and to identify patients who have survived surgical hepatectomy among HCC patients with IVCTT. Between January 2006 and December 2018, 643 patients underwent surgical hepatectomy for HCC at Kobe University Hospital. Among them, 20 patients were categorized as Vv3 according to the Japanese staging system. We retrospectively collected detailed data on these patients. The statistical, clinical, and pathological data were recorded prospectively and analyzed retrospectively. The median survival time was 9.8 months. Among all patients, 11 (55%) achieved R0 resection, and only two survivors were from this group. The number of tumors (solitary vs. multiple; p=0.050) and pathological Vp (pVp0 vs. other; p=0.009) were identified as risk factors for overall survival in the univariate analysis. In the multivariate analysis, pathological Vp (pVp0 vs. other; p=0.037) was identified as a significant prognostic factor for survival. Pathological Vp affected overall survival among IVCTT patients; the median survival time was 53.7 months with pVp0, 10.2 months with pVp1, and 8.8 months with pVp2-4 (p=0.035). For patients with IVCTT, surgical hepatectomy should be indicated only for those who do not have portal vein invasion and could achieve R0 resection.

  Jun. 2021, The Kobe journal of medical sciences, 67(1) (1), E10-E17, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Indication of Liver Transplantation in the Treatment of Newly Categorized Acute-on-Chronic Liver Failure In Japan.

  Kaori Kuramitsu, Yoshihiko Yano, Shohei Komatsu, Motofumi Tanaka, Masahiro Kido, Takumi Fukumoto

  AIM: This study aims to validate Japanese diagnostic criteria for acute-on-chronic liver failure (ACLF) and confirm the feasibility of performing transplantation. METHODS: We included 60 patients with acute liver injury. Demographic and clinical features were retrospectively collected, and the primary outcome was compared among 4 types: acute liver failure (ALF) with hepatic coma (n = 23), ALF without hepatic coma (n = 12), acute liver injury (n = 20), and ACLF (n = 5). Moreover, 80 transplanted patients were enrolled to compare the difficulty of transplantation between ALF (n = 8) vs non-ALF (n = 72) patients. RESULTS: Seven patients in the ALF with hepatic coma group and 1 patient in the ACLF with hepatic coma group were transplanted. Ten patients who could not be registered for transplantation died. In univariate analysis, liver failure type (P < .0001), total bilirubin level (P = .05), and prothrombin time internationalized ratio (P < .0001) were associated with patient survival. In multivariate analysis, liver failure type was associated with patient survival (P < .0001). The respective 1-, 3-, and 5-year patient survival rates were 45.9%, 45.9%, and 45.9% for ALF patients with hepatic coma; 100.0%, 100.0%, and 100.0% for ALF patients without hepatic coma and acute liver injury; and 80.0%, 80.0%, and 80.0% for ACLF patients (P < .0001). Chronic liver disease did not affect operation time (P = .46) and bleeding volume (P = .49). CONCLUSION: Patients diagnosed with ACLF via Japanese criteria presented significantly higher survival rates than ALF patients with hepatic coma.

  Jun. 2021, Transplantation proceedings, 53(5) (5), 1611 - 1615, English, International magazine

  Scientific journal


• Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma.

  Yuki Yasuhara, Shohei Komatsu, Kaori Kuramitsu, Masahiro Kido, Motofumi Tanaka, Hidetoshi Gon, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND/AIM: Few studies have established a definite conclusion regarding the limitation of surgical treatment for patients with Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A retrospective analysis was performed on 717 consecutive patients who underwent initial hepatectomy for HCC. RESULTS: Reductive hepatectomy was performed in 103 patients, with a median survival time (MST) of 18.0 months. Total bilirubin and albumin levels were identified as independent prognostic factors. The predictive score of these factors ranged from 0 to 2. Subsequent local treatment was performed in 91.0, 75.0, and 25.0% of patients who scored 0, 1, and 2, respectively. The MST for patients with a score of 0, 1, and 2 was 20.1, 14.8, and 2.7 months, respectively, with a significant difference. CONCLUSION: Patients with BCLC stage B and C could be properly treated with reductive hepatectomy and subsequent local treatments.

  Apr. 2021, Anticancer research, 41(4) (4), 1975 - 1983, English, International magazine

  Scientific journal


• 【特集 肝胆膵外科における再切除と再手術―最新の治療戦略】粒子線治療後再発に対するサルベージ肝切除

  田中 基文, 小松 昇平, 木戸 正浩, 福本 巧

  金原出版(株), Mar. 2021, 手術, 75(3) (3), 273 - 279, Japanese


• Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results.

  Dongha Lee, Shohei Komatsu, Kazuki Terashima, Hirochika Toyama, Yoshiro Matsuo, Daiki Takahashi, Masaki Suga, Naoko Nishimura, Kentaro Tai, Masahiro Kido, Yusuke Demizu, Sunao Tokumaru, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  BACKGROUND: Particle radiotherapy has increasingly gained acceptance for locally advanced pancreatic cancers owing to superior tumor conformity and dosimetry compared to conventional photon radiotherapy. However, the close proximity of the pancreas to the stomach and duodenum leads to radiation-induced gastrointestinal toxicities, which hinder the delivery of curative doses to the tumor. To overcome this problem, a surgical spacer was placed between the tumor and gastrointestinal tract, and subsequent proton radiotherapy was performed in this study. METHODS: Data from 9 patients who underwent surgical spacer placement and subsequent proton radiotherapy were analyzed. The safety and feasibility of the spacer placement surgery were evaluated; the impact of the spacer on dosimetry was also assessed using dose volume histogram (DVH) analyses, before and after surgical spacer placement. RESULTS: Surgical spacer placement and subsequent proton radiotherapy were successfully completed in all cases. Surgical spacer placement significantly improved the dose intensity covering 95%, mean, and minimum doses for the gross tumor volume, and the clinical and planning target volume based on the DVH, while respecting the dose constraints of the gastrointestinal tract. Based on the Common Terminology Criteria for Adverse Events, two patients (22.2%) developed gastrointestinal ulcer (Grade 2) at 1 and 35 months, and one patient (11.1%) developed gastric perforation (Grade 4) at 4 months after proton radiotherapy. CONCLUSIONS: Surgical spacer placement in the locally advanced pancreatic body and tail cancers is relatively safe and technically feasible. Comparing radiation plans, surgical spacer placement seems to improve the dose distribution in the locally advanced pancreatic body and tail cancers, which are close to the gastrointestinal tract.

  Jan. 2021, Radiation oncology (London, England), 16(1) (1), 3 - 3, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Efficacy of Spacers in Radiation Therapy for Locally Advanced Pancreatic Cancer: A Planning Study.

  Hiroki Kawaguchi, Yusuke Demizu, Naritoshi Mukumoto, Takeaki Ishihara, Daisuke Miyawaki, Shohei Komatsu, Hiroaki Akasaka, Makoto Shinoto, Yoshiyuki Shioyama, Katsumasa Nakamura, Takumi Fukumoto, Ryohei Sasaki

  BACKGROUND/AIM: We aimed to investigate the dosimetric effects of a spacer placed between the pancreas and surrounding gastrointestinal structures in intensity-modulated radiation therapy (IMRT) planning to provide more effective radiation therapy for locally advanced pancreatic cancer (LAPC). PATIENTS AND METHODS: Treatment planning was performed for six patients with LAPC based on computed tomography images without spacers and with 5-mm or 10-mm spacers virtually inserted under the supervision of a hepatobiliary pancreatic surgeon. The prescription dose was 63 Gy in 28 fractions. RESULTS: With the exception of one case of pancreatic head cancer, planning target volume receiving ≥95% of the prescribed dose (PTV V95) was achieved by 90% or more by inserting a spacer, and by 95% or more in all 3 cases of pancreatic body and tail cancer by inserting a 10-mm spacer. CONCLUSION: IMRT with appropriate spacer placement may help provide high-dose treatment for LAPC and improve associated patient outcomes.

  Jan. 2021, Anticancer research, 41(1) (1), 503 - 508, English, International magazine

  Scientific journal


• Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib.

  Kei Saito, Hideki Fujii, Keiji Kono, Ken Hirabayashi, Satoshi Yamatani, Kentaro Watanabe, Shunsuke Goto, Shohei Komatsu, Takumi Fukumoto, Shinichi Nishi

  Background: Within the class of tyrosine kinase inhibitors (TKIs), which are used for the treatment of numerous advanced cancers, lenvatinib is associated with a higher prevalence of hypertension (HT) compared with other TKIs. In this study, we investigated the effect of lenvatinib on blood pressure (BP) and associated factors. Methods: This single-centre, retrospective observational study included 25 consecutive patients treated with lenvatinib for unresectable hepatocellular carcinoma from April 2018 to December 2018 at the study institution. We assessed changes in BP using ambulatory BP monitoring, urinary sodium excretion, kidney function, use of antihypertensive agents and diuretics, and fluid retention following treatment initiation with lenvatinib. Results: At 1 week after treatment initiation, the mean BP and the percentage of patients with riser pattern significantly increased compared with those at the baseline. Although there were no significant changes at 1 week, urinary sodium excretion (153.4 ± 51.7 and 112.5 ± 65.0 mEq/day at 1 and 3 weeks, respectively, P < 0.05) and estimated glomerular filtration rate significantly decreased and the number of patients with fluid retention increased at 3 weeks. Furthermore, patients with fluid retention had significantly higher BP or required more intensive BP treatment compared with those without fluid retention. Conclusions: Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention.

  Jan. 2021, Clinical kidney journal, 14(1) (1), 325 - 331, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Extraluminal recanalization for postoperative biliary obstruction using transseptal needle.

  Hiroki Horinouchi, Eisuke Ueshima, Keitaro Sofue, Shohei Komatsu, Takuya Okada, Masato Yamaguchi, Takumi Fukumoto, Koji Sugimoto, Takamichi Murakami

  BACKGROUND: Postoperative biliary strictures are commonly related to accidental bile duct injuries or occur at the site of biliary anastomosis. The first-line treatment for benign biliary strictures is endoscopic therapy, which is less invasive and repeatable. However, recanalization for biliary complete obstruction is technically challenging to treat. The present report describes a successful case of treatment by extraluminal recanalization for postoperative biliary obstruction using a transseptal needle. CASE PRESENTATION: A 66-year-old woman had undergone caudal lobectomy for the treatment of hepatocellular carcinoma. The posterior segmental branch of the bile duct was injured and repaired intraoperatively. Three months after the surgery, the patient had developed biliary leakage from the right hepatic bile duct, resulting in complete biliary obstruction. Since intraluminal recanalization with conventional endoscopic and percutaneous approaches with a guidewire failed, extraluminal recanalization using a transseptal needle with an internal lumen via percutaneous approach was performed under fluoroscopic guidance. The left lateral inferior segmental duct was punctured, and an 8-F transseptal sheath was introduced into the ostium of right hepatic duct. A transseptal needle was advanced, and the right hepatic duct was punctured by targeting an inflated balloon that was placed at the end of the obstructed right hepatic bile duct. After confirming successful puncture using contrast agent injected through the internal lumen of the needle, a 0.014-in. guidewire was advanced into the right hepatic duct. Finally, an 8.5-F internal-external biliary drainage tube was successfully placed without complications. One month after the procedure, the drainage tube was replaced with a 10.2-F drainage tube to dilate the created tract. Subsequent endoscopic internalization was performed 5 months after the procedure. At the 1-year follow-up examination, there was no sign of biliary obstruction and recurrence of hepatocellular carcinoma. CONCLUSIONS: Recanalization using a transseptal needle can be an alternative technique for rigid biliary obstruction when conventional techniques fail.

  Dec. 2020, Surgical case reports, 6(1) (1), 304 - 304, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 【肝癌治療の最前線】脈管侵襲陽性進行肝細胞癌に対する治療

  小松 昇平, 宗 慎一, 権 英寿, 蔵満 薫, 田中 基文, 木戸 正浩, 福本 巧

  (株)南江堂, Nov. 2020, 外科, 82(12) (12), 1228 - 1233, Japanese


• Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis.

  Shohei Komatsu, Yoshihiko Yano, Keitaro Sofue, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Masahide Awazu, Hidetoshi Gon, Atsushi Yamamoto, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto

  BACKGROUND: The present study aimed to assess the clinical features of patients who received lenvatinib treatment for unresectable hepatocellular carcinoma (HCC). METHODS: The clinical characteristics, adverse events, and radiological responses were evaluated for 51 consecutive patients. RESULTS: Of the study subjects, 37 patients had Child-Pugh class A (CPA) liver function, and 14 patients had Child-Pugh class B (CPB) liver function. The overall response rates in the CPA and CPB groups were 42.9% and 25.0%, respectively, and disease control rates were 82.9% and 83.3%, respectively, without significant difference (p = 0.2621 and 0.9697). There was no significant difference between CPA and CPB groups regarding the incidence of adverse events, except for hepatic coma. No significant difference was observed in the relative dose intensity between the CPA and CPB groups, for the first month, 1-2 months, or 2-3 months (p = 0.2368, 0.9368, and 0.9293). CONCLUSION: The comparable outcomes between the CPA and CPB groups suggest the acceptability of lenvatinib treatment in patients with impaired liver function, at least in the acute phase. With careful follow-up, the dose can be relatively intensified, even in patients with impaired liver function and this may contribute to offering comparable treatment.

  Oct. 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association, 22(10) (10), 1450 - 1456, English, International magazine

  [Refereed]

  Scientific journal


• Prediction of post-hepatectomy liver failure using gadoxetic acid-enhanced magnetic resonance imaging for hepatocellular carcinoma with portal vein invasion.

  Yushi Tsujita, Keitaro Sofue, Shohei Komatsu, Takeru Yamaguchi, Eisuke Ueshima, Yoshiko Ueno, Tomonori Kanda, Takuya Okada, Munenobu Nogami, Masato Yamaguchi, Masakatsu Tsurusaki, Masatoshi Hori, Takumi Fukumoto, Takamichi Murakami

  PURPOSE: Accurate prediction of post-hepatectomy liver failure (PHLF) is important in advanced hepatocellular carcinoma (HCC). We aimed to retrospectively evaluate the utility of gadoxetic acid-enhanced MRI for predicting PHLF in patients who underwent anatomic hepatectomy for HCC with portal vein invasion. METHODS: Forty-one patients (32 men, 9 women) were included. Hepatobiliary-phase MR images were acquired 20 min after injection of gadoxetic acid using a 3D fat-suppressed T1-weighted spoiled gradient-echo sequence. Liver-spleen ratio (LSR), remnant hepatocellular uptake index (rHUI), and HUI were calculated. The severity of PHLF was defined according to the International Study Group of Liver Surgery. Differences in LSR between the resected liver and the remnant liver, and HUI and rHUI/HUI between no/mild and severe PHLF were compared using the Wilcoxon signed-rank test and Wilcoxon rank-sum test, respectively. Univariate and multivariate logistic regression analyses were performed to identify predictors of severe PHLF. Areas under the receiver operating characteristic curves (AUCs) of rHUI and rHUI/HUI were calculated for predicting severe PHLF. RESULTS: Nine patients developed severe PHLF. LSR of the remnant liver was significantly higher than that of the resected liver (P < 0.001). Severe PHLF demonstrated significantly lower rHUI (P < 0.001) and rHUI/HUI (P < 0.001) compared with no/mild PHLF. Multivariate logistic regression analysis showed that decreased rHUI (P = 0.012, AUC=0.885) and rHUI/HUI (P = 0.002, AUC=0.852) were independent predictors of severe PHLF. CONCLUSION: Gadoxetic acid-enhanced MRI can be a promising noninvasive examination for assessing global and regional liver function, allowing estimation of the functional liver remnant and accurate prediction of severe PHLF before hepatic resection.

  Sep. 2020, European journal of radiology, 130, 109189 - 109189, English, International magazine

  [Refereed]

  Scientific journal


• Laparoscopic repeat hepatectomy is a more favorable treatment than open repeat hepatectomy for contralateral recurrent hepatocellular carcinoma cases.

  Hidetoshi Gon, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Shohei Komatsu, Masahide Awazu, Shinichi So, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: We compared surgical outcomes, with a focus on tumor characteristics, of laparoscopic repeat hepatectomy (LRH) and open repeat hepatectomy (ORH) to identify recurrent hepatocellular carcinoma (HCC) cases where the LRH procedure would be more favorable than ORH. METHODS: Eighty-one HCC patients who underwent repeat hepatectomy in our hospital from 2008 to 2019 were retrospectively analyzed in this study. Of these patients, 30 and 51 patients underwent LRH and ORH, respectively. We analyzed surgical outcomes of LRH and ORH, focusing on tumor characteristics such as tumor size, location, distance from major vessels, and contralateral or ipsilateral tumor recurrence to determine what factors could affect surgical outcomes. Subsequently, using a propensity-matched cohort, we compared the impact of those factors on LRH and ORH outcomes. RESULTS: In the entire cohort, the LRH operation time was significantly shorter in contralateral recurrent HCC cases than in ipsilateral recurrent HCC cases (252 vs. 398 min, P = 0.008); however, such a difference was not observed in the ORH operation time. We subsequently compared the surgical outcomes, in terms of the location of tumor recurrence, between the LRH and ORH groups in a propensity-matched cohort. In total, 23 patients were included in each of these groups. We found that the LRH procedure had significantly shorter operative time than the ORH procedure in the contralateral recurrent HCC cases (253 vs. 391 min, P = 0.018); however, we did not observe such a difference in the ipsilateral recurrent HCC cases (372 vs. 333 min, P = 0.669). LRH had lower blood loss, similar postoperative complications and shorter hospital stay than ORH in both contralateral and ipsilateral recurrent HCC cases. CONCLUSIONS: LRH is likely considered a more favorable approach than ORH in treating patients with contralateral recurrent HCC.

  Jun. 2020, Surgical endoscopy, 35(6) (6), 2896 - 2906, English, International magazine

  [Refereed]

  Scientific journal


• Space-making particle therapy for sarcomas derived from the abdominopelvic region.

  Shohei Komatsu, Yusuke Demizu, Nor Shazrina Sulaiman, Kazuki Terashima, Masaki Suga, Masahiro Kido, Hirochika Toyama, Sunao Tokumaru, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  BACKGROUND: The primary definitive treatment for abdominopelvic sarcomas (APSs) is resection, although incomplete resection has a negative prognostic impact. Although the effectiveness of particle therapy (PT) as a treatment for APS has already been demonstrated, its application for tumors adjacent to the gastrointestinal tract is frequently restricted, due to extremely low tolerance. Space-making PT, consisting of surgical spacer placement and subsequent PT, has been developed to overcome this limitation. MATERIALS AND METHODS: Between June 2006 and June 2018, a total of 75 patients with 12 types of APS underwent space-making PT. RESULTS: The 3-year local control rate of all patients was 90.3%. Fourteen surgery-related complications were observed in 12 patients (16%), and complications of Grade 3b or higher were observed in 3 patients. Ninety-five PT-related complications were seen in 66 patients (88.0%), and 13 patients (17.3%) had complications of Grade 3 or higher. The median V95% (volume irradiated with 95% of the treatment planning dose) of the gross tumor volume and clinical target volume were 99.9% and 99.5%, respectively. The median D95% (dose intensity covering 95% of the target volume) of the gross tumor volume/planned dose and clinical target volume/planned dose were 99.4%, and 99.1%, respectively. CONCLUSION: The feasibility and effectiveness of space-making PT have been demonstrated via dosimetric evaluation, and our results indicate that this new strategy may potentially provide an effective and innovative treatment option for advanced APS.

  May 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 146, 194 - 199, English, International magazine

  [Refereed]

  Scientific journal


• Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.

  Tai K, Komatsu S, Sofue K, Kido M, Tanaka M, Kuramitsu K, Awazu M, Gon H, Tsugawa D, Yanagimoto H, Toyama H, Murakami S, Murakami T, Fukumoto T

  BACKGROUND: Although total tumour volume (TTV) may have prognostic value for hepatic resection in certain solid cancers, its importance in colorectal liver metastases (CRLM) remains unexplored. This study investigated its prognostic value in patients with resectable CRLM. METHOD: This was a retrospective review of patients who underwent hepatic resection for CRLM between 2008 and 2017 in a single institution. TTV was measured from CT images using three-dimensional construction software; cut-off values were determined using receiver operating characteristic (ROC) curve analyses. Potential prognostic factors, overall survival (OS) and recurrence-free survival (RFS) were determined using multivariable and Kaplan-Meier analyses. RESULTS: Some 94 patients were included. TTV cut-off values for OS and RFS were 100 and 10 ml respectively. Right colonic primary tumours, primary lymph node metastasis and bilobar liver metastasis were included in the multivariable analysis of OS; a TTV of 100 ml or above was independently associated with poorer OS (hazard ratio (HR) 6·34, 95 per cent c.i. 2·08 to 17·90; P = 0·002). Right colonic primary tumours and primary lymph node metastasis were included in the RFS analysis; a TTV of 10 ml or more independently predicted poorer RFS (HR 1·90, 1·12 to 3·57; P = 0·017). The 5-year OS rate for a TTV of 100 ml or more was 41 per cent, compared with 67 per cent for a TTV below 100 ml (P = 0·006). Corresponding RFS rates with TTV of 10 ml or more, or less than 10 ml, were 14 and 58 per cent respectively (P = 0·009). A TTV of at least 100 ml conferred a higher rate of unresectable initial recurrences (12 of 15, 80 per cent) after initial hepatic resection. CONCLUSION: TTV was associated with RFS and OS after initial hepatic resection for CRLM; TTV of 100 ml or above was associated with a higher rate of unresectable recurrence.

  Apr. 2020, BJS open[Epub ahead of print], English, International magazine

  [Refereed]

  Link to Kobe Univ. Repository (Kernel)


• 肝癌の局所治療とその戦略 肝外転移を有する高度進行肝細胞癌に対する肝切除術の意義

  小松 昇平, 木戸 正浩, 福本 巧

  (一社)日本肝臓学会, Apr. 2020, 肝臓, 61(Suppl.1) (Suppl.1), A161 - A161, Japanese


• Impact of Albumin-Bilirubin Score on Short- and Long-Term Survival After Living-Donor Liver Transplantation: A Retrospective Study.

  Kentaro Tai, Kaori Kuramitsu, Masahiro Kido, Motofumi Tanaka, Shohei Komatsu, Masahide Awazu, Hidetoshi Gon, Shinichi So, Daisuke Tsugawa, Hideyo Mukubo, Sachio Terai, Hiroaki Yanagimoto, Hirochika Toyama, Tetsuo Ajiki, Takumi Fukumoto

  BACKGROUND: The albumin-bilirubin (ALBI) grade, stratified from the ALBI score, may have prognostic value in patients with hepatocellular carcinoma. We aim to evaluate the prognostic abilities of the ALBI score/grade among living-donor liver transplantation patients. METHODS: We retrospectively collected data of 81 patients who underwent living-donor liver transplant at Kobe University Hospital between June 2000 and October 2018. The efficacy of the ALBI score/grade as a prognostic factor was assessed and compared with that of the well-established Model for End-Stage Liver Disease (MELD) score. MAIN FINDINGS: Multivariate analysis indicated that recipient age (P = .003), donor age (P = .003), ALBI score ≥ -1.28 (P = .002), and ALBI grade III (P = .004) were independently associated with post-transplant survival. A high MELD score was not associated with post-transplant survival in univariate or multivariate analyses. Although there was no significant difference in the overall survival rate relative to recipient and donor age, ALBI score/grade was significantly associated with the 1- and 5-year survival rates (P = .023, P = .005). ALBI scores specifically detected fatal complications of post-transplant graft dysfunction (P = .031) and infection (P = .020). CONCLUSION: ALBI score/grade predicted patient survival more precisely than the MELD score did, suggesting that it is a more useful prognostic factor compared to the MELD score in living-donor liver transplantation cases.

  Apr. 2020, Transplantation proceedings, 52(3) (3), 910 - 919, English, International magazine

  [Refereed]

  Scientific journal


• Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Extrahepatic Metastases.

  Shohei Komatsu, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Daisuke Tsugawa, Masahide Awazu, Hidetoshi Gon, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

  BACKGROUND: This study evaluated the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases who can undergo hepatectomy. METHODS: A total of 32 patients who underwent hepatectomy for HCC with extrahepatic metastases, including lymph node and/or distant metastases were recruited for this study. RESULTS: Fourteen patients had lymph node metastasis only, 16 had distant metastasis only, and 2 had both metastasis types during preoperative diagnosis. The 3-year overall survival (OS) rate of all patients was 17.9%, and the median survival time (MST) was 11.8 months. Univariate analysis revealed that intrahepatic maximal tumor size, intrahepatic tumor number, and intrahepatic tumor control after hepatectomy were significant factors influencing OS (p < 0.05). Multivariate analysis revealed that independent risk factors for OS were intrahepatic maximal tumor size and intrahepatic tumor number (p < 0.05). The MST and 3-year OS rate of patients with maximal tumor size <100 mm and intrahepatic tumor number ≤2 were 39.0 months and 51.9%, respectively. CONCLUSIONS: Hepatectomy is not recommended for HCC patients with extrahepatic metastasis with ≥3 intrahepatic tumors, even when all intrahepatic tumors can be eliminated via hepatectomy. Aggressive surgery may be justified for HCC patients with ≤2 intrahepatic tumors and maximal tumor size <100 mm, irrespective of vascular invasion.

  2020, Digestive surgery, 37(5) (5), 411 - 419, English, International magazine

  [Refereed]

  Scientific journal


• 【"超"高難度手術!他臓器合併切除術を極める】肝胆膵の拡大手術 門脈腫瘍栓合併肝細胞癌に対する外科治療 門脈腫瘍栓の進展度,形態および進展速度を考慮した治療戦略

  権 英寿, 木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 粟津 正英, 宗 慎一, 福本 巧

  (株)医学書院, Jan. 2020, 臨床外科, 75(1) (1), 56 - 61, Japanese

  Scientific journal


• [Analysis of Surgical Resection for Elderly Patients with Biliary Tract Cancer].

  Daisuke Tsugawa, Kimihiko Ueno, Masayuki Akita, Yu Hashimoto, Masahide Awazu, Hideyo Mukubo, Shohei Komatsu, Kaori Kuramitsu, Sachio Terai, Motofumi Tanaka, Hirochika Toyama, Masahiro Kido, Tetsuo Ajiki, Takumi Fukumoto

  Although surgical resection is the first-line treatment for biliary tract cancer(BTC), elderly patients often have underlying diseases and decreased cardiopulmonary function that place them at a high risk of undergoing surgery. We examined the safety and efficacy of surgical resection in elderly BTC patients. Among the BTC cases that underwent surgical resection at Kobe University Hospital from 2009 to 2015, the safety and prognosis ofthose aged 75 years or older(Group 1)were compared to those younger than 75 years(Group 2)at the time ofsurgery. Fifty-two patients with perihilar cholangiocarcinoma( Bp), 29 patients with intrahepatic cholangiocarcinoma(ICC), and 40 patients with ampulla ofVater cancer(AV) were included. There was no significant difference between the 2 groups with respect to complications of Grade Ⅲor above, while surgery-related death was more common in Bp and ICC ofGroup 1. The median survival ofGroup 1 following hepatectomy for Bp and ICC(22 months)was significantly shorter than that of Group 2(40 months)(p=0.023). There was no significant difference in overall survival of Group 1 and Group 2 patients with AV(p=0.094). Surgical resection for BP and ICC for elderly patients has a higher risk of hepatectomy; therefore, precise assessment of oncologic and patient risk factors should be performed. As we can expect to achieve similar prognoses between non-elderly and elderly patients with AV, aggressive treatments should be considered for elderly patients with AV.

  Dec. 2019, Gan to kagaku ryoho. Cancer & chemotherapy, 46(13) (13), 2279 - 2281, Japanese, Domestic magazine

  Scientific journal


• 高齢胆道癌患者に対する手術成績の検討

  津川 大介, 上野 公彦, 秋田 真之, 橋本 悠, 粟津 正英, 椋棒 英世, 小松 昇平, 蔵満 薫, 寺井 祥雄, 田中 基文, 外山 博近, 木戸 正浩, 味木 徹夫, 福本 巧

  (株)癌と化学療法社, Dec. 2019, 癌と化学療法, 46(13) (13), 2279 - 2281, Japanese


• Space-Making Particle Therapy with Surgical Spacer Placement in Patients with Sacral Chordoma.

  Daisuke Tsugawa, Shohei Komatsu, Yusuke Demizu, Nor Shazrina Sulaiman, Masaki Suga, Masahiro Kido, Hirochika Toyama, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  BACKGROUND: Sacral chordomas are rare malignant bone tumors and are often very large for complete resection. Particle therapy for these tumors, which are adjacent to the gastrointestinal tract, is restricted because the tolerance dose of the intestine is low. This study aimed to demonstrate the technical aspects and treatment results of space-making particle therapy with surgical spacer placement for sacral chordoma. We aimed to investigate the dosimetric change in the particle therapy before and after spacer placement and the safety, efficacy, and long-term outcomes of space-making particle therapy. STUDY DESIGN: Twenty-one patients with sacral chordomas who were excluded from typical particle therapy were enrolled between 2007 and 2015. Gore-Tex sheets (WL Gore & Assoc) were folded and placed between the sacral and rectum. Particle therapy with 70.4 Gy (relative biologic effectiveness) was then performed. RESULTS: The mean volume that allows 95% of the treatment plan dose of the gross tumor volume and clinical tumor volume after spacer placement was improved to 97.7% and 96.4% from preoperative values of 91.0% and 89.5%, respectively. The recurrence rate within the gross tumor volume was only 4.8%. The 4-year local progression-free survival rate was 68.4%. The 5-year overall survival rate was 100% and the adverse events were acceptable. CONCLUSIONS: Considering improvements in the dose-volume histogram after spacer placement, low recurrence rates within the gross tumor volume, good survival rates, and low incidences of side effects, treatment of sacral chordoma with space-making particle therapy shows promise.

  Nov. 2019, Journal of the American College of Surgeons, 230(2) (2), 207 - 215, English, International magazine

  [Refereed]

  Scientific journal


• 進行肝細胞癌に対する減量肝切除術の有用性の検討

  保原 祐樹, 小松 昇平, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 西沢 祐輔, 中川 大佑, 大宮 悟志, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  (株)医薬情報研究所, Nov. 2019, 新薬と臨牀, 68(11) (11), 1429 - 1429, Japanese

  [Refereed]


• Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single-Center Experience of 102 Patients.

  Shohei Komatsu, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Daisuke Tsugawa, Masahide Awazu, Hidetoshi Gon, Hirochika Toyama, Kimihiko Ueno, Takumi Fukumoto

  BACKGROUND: This study aimed to evaluate the clinical relevance of hepatectomy for Barcelona Clinic Liver Cancer (BCLC) stages B and C advanced hepatocellular carcinoma (HCC). METHODS: A total of 314 patients (149 and 165 BCLC stages B and C, respectively) who underwent hepatectomy were included. Complete hepatectomy (without residual tumors after hepatectomy) and reductive hepatectomy (apparent residual tumors after hepatectomy) were performed for 212 and 102 patients, respectively. Short-term operative and postoperative outcomes, as well as long-term outcomes, were evaluated. RESULTS: The median survival times of patients with stage B disease undergoing complete hepatectomy and reductive hepatectomy were 48.9 and 20.1 months, respectively (p = 0.0075), whereas those of patients with stage C disease were 19.5 and 17.6 months, respectively (p = 0.0140). The 3-year overall survival rates of patients with stage B disease undergoing reductive hepatectomy with and without subsequent local treatments after surgery were 47.5% and 0%, respectively, whereas those of patients with stage C diseases were 18.6% and 0%, respectively. CONCLUSIONS: Survival benefits are obvious for both BCLC stages B and C HCC when complete hepatectomy can be performed safely. Reductive hepatectomy is also acceptable for BCLC stages B and C when subsequent local treatment for remnant liver tumors can be performed safely after reductive hepatectomy. Without subsequent local treatment, reductive hepatectomy has little clinical relevance. Thus, a cautious approach to patient selection is required for this aggressive strategy.

  Oct. 2019, World journal of surgery, 43(10) (10), 2571 - 2578, English, International magazine

  [Refereed]

  Scientific journal


• 放射線治療 QOLを考慮した局所治療 小児がんに対する吸収性スペーサー留置を併用した粒子線治療

  佐々木 良平, 出水 祐介, 岩田 宏満, 亀井 美智, 文野 誠久, 赤坂 浩亮, 王 天縁, 妹尾 悟史, 犬伏 祥子, 宮脇 大輔, 吉田 賢史, 小松 昇平, 福本 巧

  (一社)日本小児血液・がん学会, Sep. 2019, 日本小児血液・がん学会雑誌, 56(2) (2), 148 - 152, Japanese

  [Refereed]


• Real-time navigation during hepatectomy using fusion indocyanine green-fluorescence imaging: protocol for a prospective cohort study.

  Hidetoshi Gon, Shohei Komatsu, Sae Murakami, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Daisuke Tsugawa, Masahide Awazu, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: In-vivo fluorescence imaging techniques using indocyanine green (ICG) to identify liver tumours and hepatic segment boundaries have been recently developed. The purpose of this study is to evaluate the efficacy of fusion ICG-fluorescence imaging for navigation during hepatectomy. METHODS AND ANALYSIS: This will be an exploratory single-arm clinical trial; patients with liver tumours will undergo hepatectomy using the ICG-fluorescence imaging system. In total, 110 patients with liver tumours scheduled for elective hepatectomy will be included in this study. Preoperatively, ICG will be intravenously injected at a dose of 0.5 mg/kg body weight within 2 days. To detect liver tumours intraoperatively, the hepatic surface will be initially observed using the ICG-fluorescence imaging system. After identifying and clamping the portal pedicle corresponding to the hepatic segments, including the liver tumours to be resected, additional ICG will be injected intravenously at a dose of 0.5 mg/kg body weight to identify the boundaries of the hepatic segments. The primary outcome measure will be the success or failure of the ICG-fluorescence imaging system in identifying hepatic segments. The secondary outcomes will be the success or failure in identifying liver tumours, liver function indicators, operative time, blood loss, rate of postoperative complications and recurrence-free survival. The findings obtained through this study are expected to help to establish the utility of ICG-fluorescence imaging systems, and therefore contribute to prognostic outcome improvements in patients undergoing hepatectomy for various causes. ETHICS AND DISSEMINATION: The protocol has been approved by the Kobe University Clinical Research Ethical Committee. The findings of this study will be disseminated widely through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: UMIN000031054 and jRCT1051180070.

  Aug. 2019, BMJ open, 9(8) (8), e030233, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-centre, open-label, single-arm, historically controlled study.

  Kimihiko Ueno, Tetsuo Ajiki, Daisuke Tsugawa, Masayuki Akita, Yu Hashimoto, Masahide Awazu, Hideyo Mukubo, Shohei Komatsu, Kaori Kuramitsu, Sachio Terai, Motofumi Tanaka, Hirichika Toyama, Masahiro Kido, Takumi Fukumoto

  INTRODUCTION: Multimodal treatment prolongs the survival of patients with biliary tract cancer (BTC). However, the chemotherapy choices for this disease are few, and completing each chemotherapy session is important. Adjuvant chemotherapy has been attempted for BTC, but has only had a 75% completion rate. Body weight loss and cholangitis are reasons for the interruption of chemotherapy. Previous reports suggested that nutritional intervention with omega-3 fatty acids maintained body weight and improved the completion rate for chemotherapy. Moreover, omega-3 fatty acids have an anti-inflammatory effect. Therefore, we theorised that omega-3 fatty acids would improve the completion rate of adjuvant chemotherapy in patients with BTC. The aim of this study is thus to evaluate the effectiveness of omega-3 fatty acids for patients planning adjuvant chemotherapy for BTC. METHOD AND ANALYSIS: This study is a single-centre, open-label, single-arm, historically controlled study with a planned enrolment of 55 participants. Protocol treatment consists of four courses of S-1 adjuvant chemotherapy and an oral omega-3 fatty acid pharmaceutic adjuvant (LOTRIGA 2 g (Takeda Pharmaceutical Co.)), which includes 2 g of omega-3 fatty acids from day 1 until day 168 of the treatment period. The primary endpoint is the completion rate of four total courses of S-1. Secondary endpoints are postoperative cholangitis, time to recurrence or distant metastasis, changes in nutritional index, changes in the lymphocyte blast transformation test induced by phytohaemagglutinin, and concanavalin A and diamine oxidase serum activity during adjuvant chemotherapy. All adverse events will be evaluated. ETHICS AND DISSEMINATION: This protocol was approved by the Institutional Review Board of Kobe University Hospital. The findings from this study will be presented at national and international conferences and published in peer-reviewed journals. TRIAL REGISTRATION NUMBER: UMIN000031247.

  Aug. 2019, BMJ open, 9(8) (8), e029915, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Validation of combination treatment with surgical spacer placement and subsequent particle radiotherapy for unresectable hepatocellular carcinoma.

  Shohei Komatsu, Kazuki Terashima, Yoshiro Matsuo, Daiki Takahashi, Masaki Suga, Naoko Nishimura, Dongha Lee, Kentaro Tai, Masahiro Kido, Hirochika Toyama, Yusuke Demizu, Sunao Tokumaru, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  Aug. 2019, Journal of surgical oncology, 120(2) (2), 214 - 222, English, International magazine

  [Refereed]

  Scientific journal


• 【肝炎・肝癌】肝細胞癌に対する外科治療の最前線

  粟津 正英, 浦出 剛史, 権 英寿, 小松 昇平, 蔵満 薫, 田中 基文, 木戸 正浩, 福本 巧

  (株)北隆館, Jul. 2019, BIO Clinica, 34(7) (7), 691 - 696, Japanese

  [Refereed]


• Efficacy of the bile leak test using contrast-enhanced intraoperative ultrasonic cholangiography in liver resection: a study protocol for a non-randomised, prospective, off-label, single-arm trial.

  Motofumi Tanaka, Masahiro Kido, Kaori Kuramitsu, Shohei Komatsu, Masahide Awazu, Hidetoshi Gon, Daisuke Tsugawa, Hideyo Mukubo, Hirochika Toyama, Takumi Fukumoto

  INTRODUCTION: Bile leak is still a major complication after liver resection to be improved. To intraoperatively detect this adverse complication, leak test is commonly performed after hepatic resection. However, by the conventional leak test, it is often difficult to know whether the test reagent reaches to intrahepatic bile duct near cut surface of liver with adequate volume and pressure to identify the existence of bile leak. Thus, in order to perform leak test more accurately, this study aims to evaluate the efficacy and safety of the leak test using contrast-enhanced intraoperative ultrasonic cholangiography (CE-IOUSC), which was reported by our group as a procedure for detection of bile duct. METHODS AND ANALYSIS: The current study is a non-randomised, prospective, off-label, single-arm clinical trial for patients who undergo liver resection. A total of 100 patients will be enrolled. After completion of liver resection, the leak test is performed with CE-IOUSC using Sonazoid as a contrast agent to visualise dye injection into the intrahepatic bile duct. The primary endpoint is the success of the leak test, defined as clear visualisation of intrahepatic bile duct around cut surface by ultrasonography that indicates enough volume of dye injection. Secondary endpoints are postoperative bile leak and all adverse events related to CE-IOUSC. The findings obtained through this study will establish this procedure to assist surgeons for adequately performing the leak test, precisely detecting intraoperative biliary leak strictly and reducing postoperative bile leak. ETHICS AND DISSEMINATION: The protocol is approved by Institutional Review Boards of Kobe University Hospital (No.290069). Our findings will be widely disseminated through conference presentations and peer-reviewed publications. TRIAL REGISTRATION NUMBER: UMIN000031236 and jRCTs051180027.

  Jun. 2019, BMJ open, 9(6) (6), e029330, English, International magazine

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 【肝胆膵外科手術におけるトラブルシューティング】肝臓 開腹肝切除術における下大静脈出血に対する対処法

  権 英寿, 木戸 正浩, 田中 基史, 蔵満 薫, 小松 昇平, 福本 巧

  金原出版(株), Jun. 2019, 手術, 73(7) (7), 959 - 969, Japanese

  [Refereed]


• First-In-Human Phase 1 Study of a Nonwoven Fabric Bioabsorbable Spacer for Particle Therapy: Space-Making Particle Therapy (SMPT).

  Sasaki R, Demizu Y, Yamashita T, Komatsu S, Akasaka H, Miyawaki D, Yoshida K, Wang T, Okimoto T, Fukumoto T

  May 2019, Adv Radiat Oncol., 4(4) (4), 729 - 737, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Conversion Surgeryを施行し得た高度進行胆嚢癌の1例

  橋本 悠, 上野 公彦, 秋田 真之, 津川 大介, 粟津 正英, 椋棒 英世, 小松 昇平, 寺井 祥雄, 田中 基文, 木戸 正浩, 外山 博近, 味木 徹夫, 福本 巧

  (株)癌と化学療法社, Apr. 2019, 癌と化学療法, 46(4) (4), 775 - 777, Japanese

  [Refereed]


• 超高齢者肝細胞癌患者に対する肝切除術の検討

  津川 大介, 木戸 正浩, 田中 基文, 木下 秘我, 小松 昇平, 粟津 正英, 権 英寿, 山下 博成, 白川 幸代, 椋棒 英世, 寺井 祥雄, 上野 公彦, 外山 博近, 味木 徹夫, 福本 巧

  (株)癌と化学療法社, Feb. 2019, 癌と化学療法, 46(2) (2), 315 - 317, Japanese

  [Refereed]


• 再肝切除に対する腹腔鏡手術適応の有効性について

  権英寿, 木戸正浩, 田中基文, 粟津正英, 浦出剛史, 田井謙太郎, 保原祐樹, 西沢祐輔, 吉岡佑太, 津川大介, 椋棒英世, 外山博近, 上野公彦, 味木徹夫, 福本巧

  (株)医薬情報研究所, Dec. 2018, 新薬と臨牀, 67(12) (12), 1531 - 1531, Japanese

  [Refereed]

  Research society


• Novel Extracorporeal Hemoperfusion System for Hepatic Arterial Infusion of Cisplatin.

  Shinichi So, Shohei Komatsu, Atsushi Takebe, Masahiro Kido, Motofumi Tanaka, Hirochika Toyama, Kimihiko Ueno, Takumi Fukumoto

  BACKGROUND/AIM: Hepatic venous isolation and extracorporeal charcoal hemoperfusion (HVI-CHP) can reduce systemic exposure to hepatic arterial infusion (HAI) chemotherapy. The pre-existing HVI-CHP system has limited effectiveness against high-dose cisplatin; therefore, we designed a new system and evaluated its efficacy in a canine model. MATERIALS AND METHODS: Cisplatin was administered via HAI under HVI-CHP. HVI-CHP was performed using one charcoal column in group I and two charcoal columns in group II; it was not performed in group III. The plasma cisplatin levels in the systemic circulation and at the column inlet and outlet, and the column extraction rate of were analyzed. RESULTS: The column extraction rates of free and total cisplatin in group II were significantly higher than those in group I. The systemic concentration of free cisplatin was significantly lower in group II than in groups I and III after HAI. No significant differences were observed in cisplatin concentrations in the liver tissue among all groups. CONCLUSION: A novel HVI-CHP system for HAI of cisplatin was successfully developed.

  Nov. 2018, Anticancer research, 38(11) (11), 6445 - 6452, English, International magazine

  [Refereed]

  Scientific journal


• Growth velocity of the portal vein tumor thrombus accelerated by its progression, alpha-fetoprotein level, and liver fibrosis stage in patients with hepatocellular carcinoma.

  Hidetoshi Gon, Masahiro Kido, Motofumi Tanaka, Hisoka Kinoshita, Shohei Komatsu, Daisuke Tsugawa, Masahide Awazu, Hirochika Toyama, Ippei Matsumoto, Tomoo Itoh, Takumi Fukumoto

  BACKGROUND: Progression of portal vein tumor thrombus directly affects the prognosis and treatment for patients with hepatocellular carcinoma; there are no data on the growth velocity of portal vein tumor thrombus. We analyzed the growth velocity of portal vein tumor thrombus and its risk factors to propose the best timing of surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus. METHODS: We retrospectively collected data on 57 hepatocellular carcinoma patients with portal vein tumor thrombus who underwent computed tomography twice preoperatively and hepatectomy between 2005 and 2015. To calculate the growth velocity of portal vein tumor thrombus, migration lengths of portal vein tumor thrombus were divided by the number of days. To identify risk factors for rapid growth of portal vein tumor thrombus, patients were classified according to the velocity: rapid (≥ 1.0 mm/day, n = 23) and slow (< 1.0 mm/day, n = 34). RESULTS: Median survival times of patients with portal vein tumor thrombus that invaded the ipsilateral second portal branch, ipsilateral first portal branch, and portal trunk were 42.9, 11.7, and 12.3 months, respectively. The average growth velocity of portal vein tumor thrombus was 0.9 ± 1.0 mm/day. Median estimated times required from ipsilateral second portal branch to ipsilateral first portal branch and ipsilateral first portal branch to portal trunk were 8.2 and 11.5 days, respectively. Liver fibrosis, alpha-fetoprotein, and extent of portal vein tumor thrombus were independent risk factors for rapid progression of portal vein tumor thrombus. Proteins induced by vitamin K absence or antagonist II, extent of portal vein tumor thrombus, and liver fibrosis, not rapid growth of portal vein tumor thrombus, were independent prognostic factors. CONCLUSION: An understanding of the rapid progression of portal vein tumor thrombus and its risk factors can be helpful in deciding an appropriate timing of surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus.

  Nov. 2018, Surgery, 164(5) (5), 1014 - 1022, English, International magazine

  [Refereed]

  Scientific journal


• 3D vision and maintenance of stable pneumoperitoneum: a new step in the development of laparoscopic right hepatectomy.

  Takayuki Kawai, Claire Goumard, Florence Jeune, Shohei Komatsu, Olivier Soubrane, Olivier Scatton

  BACKGROUND: Although laparoscopic liver resection is widely performed, many technical difficulties remain, such as accurate isolation/division of hepatic vessels in laparoscopic right hepatectomy (LRH). Innovative surgical devices, such as three-dimensional (3D) laparoscopy and optimized carbon dioxide (CO2) insufflation system, may help to overcome technical difficulties in LRH. The purpose of this study was to analyze the efficacy of 3D vision associated with active pneumoperitoneum maintenance in LRH. METHODS: In our prospectively maintained database from 2006, 75 consecutive LRH from May 2011 to June 2017 were included in this study. All LRH were performed with 2D vision and standard CO2 insufflator (2D-LRH group, 45 cases) or 3D vision with optimized CO2 insufflator (3D-LRH group, 30 cases). Preoperative clinical characteristics, surgical data including operation time of separate steps within the procedure, and postoperative complications were compared between the two groups. RESULTS: Clinical and pathological factors were comparable between two groups. Total operative time was significantly shorter in 3D-LRH group than in 2D-LRH (360 vs 390 min, P = 0.029). Right hepatic pedicle dissection time was significantly shorter in 3D-LRH group (101 vs 123 min, P = 0.003). Liver parenchyma transection time was also shorter in 3D-LRH group (138 vs 151 min, P = 0.089), although not significant. There was no significant difference in liver mobilization time, intraoperative bleeding/transfusion, and postoperative complications. CONCLUSIONS: 3D vision with maintenance of pneumoperitoneum facilitates hepatic vascular isolation/division, and may contribute to the development of LRH.

  Aug. 2018, Surgical endoscopy, 32(8) (8), 3706 - 3712, English, International magazine

  [Refereed]

  Scientific journal


• 日本の脳死移植の課題と対策

  福本巧, 木戸正浩, 田中基文, 蔵満薫, 粟津正英, 権英寿

  (株)へるす出版, Jul. 2018, 中毒研究, 31(2) (2), 206 - 206, Japanese

  [Refereed]

  Research society


• 当院の肝移植後末期腎不全の現状

  後藤公彦, 吉川美喜子, 福本巧, 西慎一

  (一社)日本透析医学会, May 2018, 日本透析医学会雑誌, 51(Suppl.1) (Suppl.1), 605 - 605, Japanese

  Research society


• Particle radiotherapy, a novel external radiation therapy, versus liver resection for hepatocellular carcinoma accompanied with inferior vena cava tumor thrombus: A matched-pair analysis.

  Shohei Komatsu, Masahiro Kido, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Yusuke Demizu, Kazuki Terashima, Tomoaki Okimoto, Ryohei Sasaki, Takumi Fukumoto

  Dec. 2017, Surgery, 162(6) (6), 1241 - 1249, English, International magazine

  [Refereed]

  Scientific journal


• C型慢性肝炎に対するDAA治療 肝細胞癌根治切除例の検討

  田井 謙太郎, 田中 基文, 木戸 正浩, 木下 秘我, 小松 昇平, 津川 大介, 粟津 正英, 権 英寿, 中馬 正志, 荒井 啓輔, 保原 祐樹, 椋棒 英世, 寺井 祥雄, 外山 博近, 上野 公彦, 楠 信也, 福本 巧

  (株)医薬情報研究所, Nov. 2017, 新薬と臨牀, 66(11) (11), 1438 - 1438, Japanese

  [Refereed]


• 脳死肝移植におけるサイズミスマッチグラフトに対する静脈吻合の工夫

  木戸 正浩, 田中 基文, 木下 秘我, 小松 昇平, 津川 大介, 荒井 啓輔, 田井 謙太郎, 保原 祐樹, 福本 巧

  (一社)日本移植学会, Nov. 2017, 移植, 52(4-5) (4-5), 459 - 459, Japanese

  [Refereed]


• 腹膜播種を伴う肝細胞癌に対する集学的治療

  山内菜津子, KIDO MASAHIRO, KOMATSU SHOUHEI, TANAKA MOTOFUMI, KINOSHITA HISOKA, TSUGAWA DAISUKE, AWAZU MASAHIDE, UENO KIMIHIKO, TOYAMA HIROCHIKA, TERAI SACHIO, MUKUBOU HIDEYO, AJIKI TETSUO, FUKUMOTO TAKUMI

  (株)癌と化学療法社, Nov. 2017, 癌と化学療法, 44(12) (12), 1717 - 1719, Japanese

  Scientific journal


• Outcomes of Consistent Conservative Management for Acute Cholecystitis Followed by Delayed Cholecystectomy.

  Shohei Komatsu, Shinobu Tsuchida, Tomoyuki Wakahara, Nozomi Ueno, Akihiro Toyokawa, Akihiko Watanabe, Atsushi Sugahara, Hidekazu Mukai

  OBJECTIVE: This study's objective was to assess outcomes of a totally conservative strategy for acute cholecystitis (AC) followed by delayed elective cholecystectomy. PATIENTS AND METHODS: Consecutive patients who underwent cholecystectomy for AC were divided into the Emergent and Elective cholecystectomy groups. Patients in the elective cholecystectomy group were divided into early, medium, and late groups according to time from symptoms onset. RESULTS: The success rate for conservative management reached 97.2%. Increased blood loss and a higher conversion rate were significantly associated with the emergent group. Patients in the late group had significantly lower operative time and tended to have lower blood loss and less frequent conversion to open surgery than those in the early and medium groups. CONCLUSIONS: Most AC cases could be managed conservatively, and elective cholecystectomy was performed safely regardless of the time. Elective cholecystectomy carried out in late phase was likely to be associated with decreased surgical difficulty.

  Oct. 2017, Surgical laparoscopy, endoscopy & percutaneous techniques, 27(5) (5), 404 - 408, English, International magazine

  Scientific journal


• New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch.

  Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Hisoka Kinoshita, Kaori Kuramitsu, Shohei Komatsu, Daisuke Tsugawa, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Yonson Ku

  Sep. 2017, Surgery today, 47(9) (9), 1094 - 1103, English, Domestic magazine

  [Refereed]

  Scientific journal


• Development Process and Technical Aspects of Laparoscopic Hepatectomy: Learning Curve Based on 15 Years of Experience

  Shohei Komatsu, Olivier Scatton, Claire Goumard, Ailton Sepulveda, Raffaele Brustia, Fabiano Perdigao, Olivier Soubrane

  May 2017, JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 224(5) (5), 841 - 850, English, International magazine

  [Refereed]

  Scientific journal


• Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE-PVE: a comparative study

  Claire Goumard, Shohei Komatsu, Raffaele Brustia, Lastitia Fartoux, Olivier Soubrane, Olivier Scatton

  May 2017, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 31(5) (5), 2340 - 2349, English

  [Refereed]

  Scientific journal


• Clinical impact of laparoscopic hepatectomy: technical and oncological viewpoints

  Shohei Komatsu, Raffaele Brustia, Claire Goumard, Ailton Sepulveda, Fabiano Perdigao, Olivier Soubrane, Olivier Scatton

  Mar. 2017, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 31(3) (3), 1442 - 1450, English

  [Refereed]

  Scientific journal


• Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis.

  Keisuke Arai, Takumi Fukumoto, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Daisuke Tsugawa, Sachio Terai, Taku Matsumoto, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Yonson Ku

  Mar. 2017, Surgery today, 47(3) (3), 385 - 392, English, Domestic magazine

  [Refereed]

  Scientific journal


• 【進行肝細胞癌に対する治療戦略(集学的治療を含めて)】総論および最新の内科的治療 進行肝細胞癌に対する経皮的肝灌流化学療法(PIHP)

  田中 基文, 福本 巧, 木戸 正浩, 木下 秘我, 蔵満 薫, 小松 昇平, 津川 大介, 具 英成

  (株)南江堂, Feb. 2017, 外科, 79(2) (2), 124 - 129, Japanese

  [Refereed]


• Outcome of Gastric Cancer Surgery in Patients with Chronic Kidney Disease.

  Tomoyuki Wakahara, Nozomi Ueno, Shohei Komatsu, Hiroshi Ashitani, Shinobu Tsuchida, Akihiro Toyokawa

  BACKGROUND: The influence of chronic kidney disease (CKD) on the outcome of gastric cancer surgery has rarely been reported. METHODS: Retrospectively collected clinicopathological data on patients who underwent elective gastrectomy between January 2007 and December 2014 were analyzed (n = 500). The patients were divided into 2 groups based on the preoperative estimated glomerular filtration rate (eGFR): a non-CKD group (eGFR ≥60 ml/min/1.73 m2, n = 392) and a CKD group (eGFR <60 ml/min/1.73 m2, n = 108). Short- and long-term results of the surgery were compared. RESULTS: There was no significant difference between the 2 groups in terms of the overall morbidity rate (p = 0.215), and in any kind of postoperative complication, including infectious and cardiovascular complications. Additionally, there was no significant difference in the morbidity rate irrespective of the type of gastrectomy and the extent of lymph node dissection. The 3-year relapse-free survival rates in the non-CKD and CKD groups were 92.1 and 92.0%, respectively, in stage I disease (p = 0.640), 81.4 and 73.7%, respectively, in stage II disease (p = 0.825), and 35.9 and 31.9%, respectively, in stage III disease (p = 0.784). CONCLUSION: CKD did not affect the short- and long-term outcomes in patients after gastric cancer surgery.

  2017, Digestive surgery, 34(3) (3), 241 - 246, English, International magazine

  Scientific journal


• Current role of percutaneous transhepatic gallbladder aspiration: from palliative to curative management for acute cholecystitis.

  Shohei Komatsu, Shinobu Tsuchida, Tadashi Tsukamoto, Tomoyuki Wakahara, Hiroshi Ashitani, Nozomi Ueno, Akihiro Toyokawa, Akihiko Watanabe, Atsushi Sugahara, Hidekazu Mukai

  BACKGROUND: The present study assessed conservative management of acute cholecystitis (AC) with a focus on percutaneous transhepatic gallbladder aspiration (PTGBA). METHODS: Consecutive 275 patients with AC who underwent PTGBA were reviewed. Patients aged ≥80 years and/or with American Society of Anesthesiologists score III to IV and/or performance status 3 to 4 were defined as high risk. Patients were classified according to duration from symptom onset to first PTGBA: within 3 days (early PTGBA) or over 3 days (late PTGBA). They were also classified according to duration from first PTGBA to surgery: within 30 days (early surgery) or over 30 days (late surgery). RESULTS: A total of 263 patients (95.6%) showed recovery after PTGBA. There were no significant differences in operating time, blood loss, operating procedure, conversion rate to open surgery, postoperative complications, or postoperative hospital stay between the early and late PTGBA groups or between the early and late surgery groups. No significant complications associated with PTGBA or surgery were observed, including in those at high risk. CONCLUSIONS: Percutaneous transhepatic gallbladder aspiration can be a useful alternative for most patients with AC, including those at high risk. Elective cholecystectomy can be performed safely regardless of the timing of PTGBA or surgery.

  Nov. 2016, Journal of hepato-biliary-pancreatic sciences, 23(11) (11), 708 - 714, English, Domestic magazine

  Scientific journal


• Impact for prognosis after non-anatomical resection for hepatocellular carcinoma historically proven micro portal vein tumor thrombus

  Shohei Komatsu, Takumi Fukumoto, Masahiro Kido, Motofumi Tanaka, Hisoka Kinoshita, Tadahiro Goto, Sadaki Asari, Hirochika Toyama, Tetsuo Ajiki, Yonson Ku

  Nov. 2016, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31, 410 - 410, English


• 【肝癌治療を極める】切除適応拡大をどう考えるか

  小松 昇平, 福本 巧, 津川 大介, 木下 秘我, 蔵満 薫, 田中 基文, 木戸 正浩, 具 英成

  医学図書出版(株), Oct. 2016, 肝臓クリニカルアップデート, 2(2) (2), 135 - 141, Japanese

  [Refereed]


• Improving graft survival by understanding the mechanism of segment 4 complications after split liver transplantation.

  Shohei Komatsu, Fernando Pompeu Piza Vicentine, Sanaâ El Mouhadi, Raffaele Brustia, Fabiano Perdigao, Ailton Sepulveda, Olivier Soubrane, Olivier Scatton

  BACKGROUND: This study was designed to assess the actual mechanism of segment 4 (S4)-related complications after split liver transplantation (SLT) and their impact on graft and overall survival with reference to those of left lateral sectionectomy for pediatric living donor liver transplantation (LLSLD). METHODS: Clinical data from 53 SLT recipients and 62 LLSLD patients were assessed to determine the mechanism of S4-related complications. The postoperative parameters of SLT and their impact on graft and overall survival were also evaluated. RESULTS: Although two biliary leakages were noted (3.2%), no necrosis of S4 developed after LLSLD. S4-related complications were seen in 15 (28.3%) patients after SLT. Radiological volumetry of S4 and the ischemic area after SLT showed no significant difference between those with and without S4-related complications. There were no significant differences between the patients with and without S4-related complications regarding both overall and graft survival rates. Significant better overall and graft survival rates were observed in patients treated during the later period. CONCLUSIONS: S4-related complications after SLT are totally independent of the S4 volume, and biliary leakage is inherently an actual mechanism. Adequate intervention with early identification leads to better graft and overall survival, which validates SLT as a treatment option.

  Sep. 2016, Clinical transplantation, 30(9) (9), 1165 - 72, English, International magazine

  Scientific journal


• Laparoscopic versus open major hepatectomy for hepatocellular carcinoma: a matched pair analysis

  Shohei Komatsu, Raffaele Brustia, Claire Goumard, Fabiano Perdigao, Olivier Soubrane, Olivier Scatton

  May 2016, SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 30(5) (5), 1965 - 1974, English

  [Refereed]

  Scientific journal


• From the left to the right: 13-year experience in laparoscopic living donor liver transplantation.

  Raffaele Brustia, Shohei Komatsu, Claire Goumard, Denis Bernard, Olivier Soubrane, Olivier Scatton

  Living Donors are the best theoretical candidates to benefit from the advantages of laparoscopy, but development was slow because of concerns about graft integrity and donor safety. Herein our 13-year experience in laparoscopic Living Donor Liver Transplantation (LDLT) is presented. Laparoscopic Left Lateral Section (LLLS) was performed in children receiver, while Laparoscopic Left Hepatectomy (LLH)-including or not the middle hepatic vein-and Laparoscopic Right Hepatectomy (LRH) in adults. Two senior surgeons were always involved for each procedure. All donors were first-degree relatives. From 2001 to 2014, 71 procedures were performed: 63 LLLS (88.7%, 6 LLH (8.4%), and 2 LRH (2.8%). Surgical procedures required a mean of 271.1 ± 65.9, 318 ± 40.2, and 480 ± 0 min for LLLS, LLH, and LRH, respectively with a learning curve toward LLLH over the years (r = 0.09). Seven procedures (9.8%) required conversion. The mean hospital stay was 5.5 ± 3.4, 5.3 ± 0.6, and 8 ± 0 days for LLLS, LLH, and LRH, respectively. Complications occurred in 11 patients (17.3%) undergoing LLLS: 8 (12.7%) grade I and 3 (4.7%) grade II, according to the Modified Clavien-Dindo classification. Laparoscopic liver resection for LDLT requires an equivalent and parallel expertise in open LDLT and LLR. If LLLS for LDLT is now in an exploration phase in highly specialized centers, LLH and LRH for LDLT in adults lack evidence and cannot be recommended for wide introduction. For laparoscopic LDLT beginners, LLLS offers optimal conditions.

  Jun. 2015, Updates in surgery, 67(2) (2), 193 - 200, English, International magazine

  Scientific journal


• Recurrent hepatocellular carcinoma: A Western strategy that emphasizes the impact of pathologic profile of the first resection

  Roberto L. Meniconi, Shohei Komatsu, Fabiano Perdigao, Pierre-Yves Boelle, Olivier Soubrane, Olivier Scatton

  Mar. 2015, SURGERY, 157(3) (3), 454 - 462, English

  [Refereed]

  Scientific journal


• Role of percutaneous transhepatic gallbladder aspiration in the early management of acute cholecystitis.

  Shohei Komatsu, Tadashi Tsukamoto, Takeshi Iwasaki, Akihiro Toyokawa, Yasuhisa Hasegawa, Shinobu Tsuchida, Tsuyoshi Takahashi, Atsushi Takebe, Tomoyuki Wakahara, Akihiko Watanabe, Atsushi Sugahara, Hidekazu Mukai

  OBJECTIVE: Early cholecystectomy is currently the gold standard treatment for acute cholecystitis (AC). However, the acceptability and safety of this strategy remain in dispute. The aim of this study was to clarify the role of percutaneous transhepatic gallbladder aspiration (PTGBA) in the early management of AC in a single center. METHODS: A total of 147 consecutive patients who were treated with PTGBA for AC from 2008 to 2012 were included in the study. The therapeutic outcomes and adverse events were evaluated. RESULTS: A single PTGBA was adequate for 96 (65.3%) patients with AC. Of the remaining 51 patients, 43 (29.3%) showed an improvement after repeated PTGBA and/or percutaneous transhepatic gallbladder drainage (PTGBD), while semi-emergency cholecystectomy was needed in eight patients. Although five patients experienced adverse events (intra-abdominal hemorrhage in two, bile leakage in two and gallbladder hemorrhage in one), no patient died of treatment-related complications. Subsequently, 87 (59.2%) patients underwent cholecystectomy after PTGBA (a single PTGBA in 48 and repeated PTGBA and/or PTGBD in 39 patients). No significant differences were observed in the conversion rate from laparoscopic surgery to open cholecystectomy, operative time or intraoperative hemorrhage volume between the two groups. CONCLUSIONS: The present study demonstrated the safety and acceptability of treatment with PTGBA for AC at our center. This elective treatment strategy may be a useful alternative option in the treatment of AC.

  Dec. 2014, Journal of digestive diseases, 15(12) (12), 669 - 75, English, International magazine

  Scientific journal


• Hemobilia associated with a giant thrombosed aneurysm of the hepatic artery requiring hepatectomy.

  Shohei Komatsu, Takeshi Iwasaki, Naritomo Nishioka, Akihiro Toyokawa, Kazuhiro Teramura

  Hemobilia is an unusual and potentially catastrophic cause of gastrointestinal bleeding. Although hepatic artery aneurysm is a cause of hemobilia, nontraumatic cases are infrequently reported. Herein, we describe the case of a giant hepatic artery aneurysm requiring hepatectomy because of repeated hemobilia in a patient with Marfan syndrome. A 53-year-old man presented to our hospital with sudden epigastric pain and jaundice. Abdominal computed tomography showed a giant hepatic arterial aneurysm in the porta hepatis, and emergency endoscopic retrograde cholangiography revealed hemobilia. Assuming that the aneurysm caused the hemobilia, we performed an abdominal angiogram for treatment. The study revealed a thrombosed aneurysm along with tortuous abnormal vessels in the periphery of the left hepatic artery, which appeared to surround the aneurysm. Therefore, we embolized the left hepatic artery, and immediate hemostasis was achieved. Rebleeding occurred 3 times thereafter, and each time, transarterial embolization was performed, resulting in prompt but only temporary hemostasis. Then, emergency left hemihepatectomy and resection of the aneurysm were performed. Pathologic examination of the resected specimen revealed that the aneurysm was completely thrombosed and organized; however, abnormal arterioles proliferated between the aneurysmal wall and the bile duct. The unique feature of this case was that the abnormal arterioles induced by the organized hepatic artery aneurysm, not the aneurysm itself, caused the hemobilia.

  Nov. 2014, Annals of vascular surgery, 28(8) (8), 1934.e13-7, English, International magazine

  Scientific journal


• Two-stage treatment with hepatectomy and carbon-ion radiotherapy for multiple hepatic epithelioid hemangioendotheliomas

  Shohei Komatsu, Takeshi Iwasaki, Yusuke Demizu, Kazuki Terashima, Osamu Fujii, Atsushi Takebe, Akihiro Toyokawa, Kazuhiro Teramura, Takumi Fukumoto, Yonson Ku, Nobukazu Fuwa

  Jul. 2014, WORLD JOURNAL OF GASTROENTEROLOGY, 20(26) (26), 8729 - 8735, English

  [Refereed]

  Scientific journal


• The Volumes of Segment 4 and Necrosis Are Not Risk factors for Graft Complications and Graft Survival in Extended Right Split Liver Transplantation.

  Shohei Komatsu, Fernando Pompeu Piza Vicentine, Sanaa El Mouhadi, Fabiano Perdigao, Ailton Sepulveda, Olivier Soubrane, Olivier Scatton

  Jun. 2014, LIVER TRANSPLANTATION, 20, S295 - S295, English


• 進行肝細胞癌に対する粒子線治療後にPIHPを施行した症例の検討

  田中 基文, 福本 巧, 木戸 正浩, 武部 敦志, 蔵満 薫, 木下 秘我, 小松 昇平, 福島 健司, 浦出 剛史, 宗 慎一, 新関 亮, 松本 逸平, 味木 徹夫, 寺嶋 千貴, 藤井 收, 出水 祐介, 不破 信和, 具 英成

  (株)癌と化学療法社, Nov. 2013, 癌と化学療法, 40(12) (12), 1681 - 1683, Japanese


• 集学的治療における術前経皮的肝灌流化学療法と肝切除の位置付け

  吉田 俊彦, 木戸 正浩, 福本 巧, 小松 昇平, 高橋 応典, 武部 敦志, 田中 基文, 蔵満 薫, 木下 秘我, 味木 徹夫, 松本 逸平, 新関 亮, 岡崎 太郎, 浅利 貞毅, 具 英成

  (株)癌と化学療法社, Nov. 2013, 癌と化学療法, 40(12) (12), 1822 - 1824, Japanese


• Back flow thrombectomy and PIHP for the treatment of multiple bilobular HCC with Vp4 PVTT

  Takumi Fukumoto, Kaori Kuramitsu, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Hisoka Kinoshita, Shohei Komatsu, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 785A - 785A, English


• Dual Treatment; A Novel Strategy for Highly-Advanced Hepatocellular carcinoma

  Shinichi So, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Motofumi Tanaka, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 230A - 230A, English


• Usefulness of 99mTc-GSA scintigraphy on preoperative evaluation of liver function for hepatectomy

  Motofumi Tanaka, Takumi Fukumoto, Masahiro Kido, Atsushi Takebe, Kaori Kuramitsu, Hisoka Kinoshita, Shohei Komatsu, Kenji Fukushima, Takeshi Urade, Shinichi So, Yonson Ku

  Oct. 2013, HEPATOLOGY, 58, 781A - 781A, English


• Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

  Shohei Komatsu, Takumi Fukumoto, Yusuke Demizu, Daisuke Miyawaki, Kazuki Terashima, Ryohei Sasaki, Yuichi Hori, Yoshio Hishikawa, Yonson Ku, Masao Murakami

  Nov. 2011, Cancer, 117(21) (21), 4890 - 904, English, International magazine

  [Refereed]

  Scientific journal


• The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus.

  Shohei Komatsu, Takumi Fukumoto, Yusuke Demizu, Daisuke Miyawaki, Kazuki Terashima, Yasue Niwa, Masayuki Mima, Osamu Fujii, Ryohei Sasaki, Isamu Yamada, Yuichi Hori, Yoshio Hishikawa, Mitsuyuki Abe, Yonson Ku, Masao Murakami

  Jul. 2011, Journal of gastroenterology, 46(7) (7), 913 - 20, English, Domestic magazine

  [Refereed]

  Scientific journal


• Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinoma

  S. Komatsu, M. Murakami, T. Fukumoto, Y. Hori, Y. Hishikawa, Y. Ku

  Apr. 2011, BRITISH JOURNAL OF SURGERY, 98(4) (4), 558 - 564, English

  [Refereed]

  Scientific journal


• Morphometric analysis of conformational changes in hepatic venous system after right lobe living donor liver transplantation

  Masanori Takahashi, Takumi Fukumoto, Masahiro Kido, Shinobu Tsuchida, Atsushi Takebe, Kaori Kuramitsu, Shohei Komatsu, Isamu Yamada, Yuichi Hori, Yonson Ku

  Apr. 2011, HEPATOLOGY RESEARCH, 41(4) (4), 318 - 327, English

  [Refereed]

  Scientific journal


• Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma

  Shohei Komatsu, Yuichi Hori, Takumi Fukumoto, Masao Murakami, Yoshio Hishikawa, Yonson Ku

  Apr. 2010, WORLD JOURNAL OF GASTROENTEROLOGY, 16(14) (14), 1800 - 1803, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• HOW I DO IT Particle Beam Radiotherapy With a Surgical Spacer Placement for Advanced Abdominal Leiomyosarcoma Results in a Significant Clinical Benefit

  Takumi Fukumoto, Shohei Komatsu, Yuichi Hori, Masao Murakami, Yoshio Hishikawa, Yonson Ku

  Jan. 2010, JOURNAL OF SURGICAL ONCOLOGY, 101(1) (1), 97 - 99, English

  [Refereed]

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• HCCに対する粒子線治療施行後Bilomaを形成した1例

  小松 昇平, 村上 昌雄, 宮脇 大輔, 小田 康江, 西村 英輝, 佐々木 良平, 香川 一史, 菱川 良夫, 福本 巧, 具 英成

  (公社)日本医学放射線学会, Apr. 2009, Japanese Journal of Radiology, 27(Suppl.) (Suppl.), 48 - 48, Japanese


• A novel two-stage treatment combining surgical spacer placement and proton beam radiotherapy for unresectable colonic liver metastases: Report of a case

  Shohei Komatsu, Takumi Fukumoto, Yuichi Hori, Masao Murakami, Yoshio Hishikawa, Yonson Ku

  Japanese Society of Gastroenterological Surgery, 2009, Japanese Journal of Gastroenterological Surgery, 42(12) (12), 1831 - 1836, Japanese

  [Refereed]

  Scientific journal


• 巨大肝癌に対して2回の陽子線治療で制御できた1例

  宮脇 大輔, 村上 昌雄, 小松 昇平, 一宮 結加子, 小田 康江, 西村 英輝, 佐々木 良平, 香川 一史, 菱川 良夫, 杉村 和朗

  (公社)日本医学放射線学会, Apr. 2008, Radiation Medicine, 26(Suppl.I) (Suppl.I), 52 - 52, Japanese


• Proton therapy and carbon ion therapy for patients with hepatocellular carcinoma: The hyogo ion beam medical center experience

  S. Komatsu, M. Murakami, T. Fukumoto, M. Tominaga, T. Iwasaki, D. Miyawaki, H. Nishimura, R. Sasaki, Y. Ku, Y. Hishikawa

  2007, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69(3) (3), S266 - S266, English


• inflow及びoutflowの最適化により生体肝移植後良好に経過した肝右葉過小グラフトの一例

  楠 信也, 富永 正寛, 岩崎 武, 福本 巧, 杉本 武巳, 木戸 正浩, 尾形 哲, 武部 敦志, 田中 基文, 木下 秘我, 蔵満 薫, 小松 昇平, 具 英成

  (一社)日本移植学会, Oct. 2006, 移植, 41(5) (5), 484 - 484, Japanese

  [Refereed]

• -

  -

  -, Sep. 2026, Japanese, 特別講演, Domestic conference

  Invited oral presentation


• -

  -

  -, Sep. 2026, Japanese, 講演①, Domestic conference

  Oral presentation


• -

  -

  -, Aug. 2026, Japanese, 特別講演Ⅱ, Domestic conference

  Invited oral presentation


• -

  -

  -, Aug. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Aug. 2026, Japanese, 演題3, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 特別講演, Domestic conference

  Invited oral presentation


• -

  -

  -, Jul. 2026, Japanese, ワークショップ3, Domestic conference

  Public symposium


• -

  -

  Immuno-HCC Seminar ～irAE Management and Pharmacotherapy～, Jul. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, ワークショップ8, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, 一般口演14, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般口演24, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, シンポジウム6, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, ワークショップ2, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, パネルディスカッション3, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, 研修医01, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題109, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題132, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題017, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題193, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題236, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題084, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題012, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 一般演題084, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 要望演題9【肝胆膵】, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, シンポジウム7【肝胆膵】, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, シンポジウム7【肝胆膵】, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2026, Japanese, 横断的企画1【総論】, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 座長（一般演題272）, Domestic conference

  Others


• -

  -

  -, Jul. 2026, Japanese, 特別講演, Domestic conference

  Invited oral presentation


• -

  -

  -, Jul. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2026, Japanese, ミニレクチャー, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, 一般演題5, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, 要望演題1, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, パネルディスカッション4, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2026, Japanese, 座長（一般演題6）, Domestic conference

  Others


• -

  -

  -, Jun. 2026, Japanese, パネリスト（パネルディスカッション）, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2026, Japanese, ミニオーラル39, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, ミニオーラル47, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, ミニオーラル29, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, ミニオーラル45, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, ミニオーラル19, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, 口演15, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, 口演20, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, 口演18, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2026, Japanese, ワークショップ1, Domestic conference

  Public symposium


• Assessment of surgical difficulty in multiple laparoscopic liver resection using the aggregate value of scores based on the IWATE criteria

  Takimoto D, Gon H, Kido M, Komatsu S, Fukushima K, Urade T, Yoshida T, Arai K, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  -, Jun. 2026, English, E-Poster, International conference

  Poster presentation


• -

  -

  -, Jun. 2026, Japanese, 司会（一般演題1）, Domestic conference

  Others


• -

  -

  -, Jun. 2026, Japanese, パネルディスカッション2, Domestic conference

  Public symposium


• Comparison of Open and Laparoscopic Partial Resection for Caudate Lobe Tumors: Surgical Outcomes According to Tumor Location

  Takimoto D, Urade T, Kido M, Komatsu S, Fukushima K, Yoshida T, Arai K, Asari S, Nanno Y, Yanagimoto H, Fukumoto T

  -, May 2026, English, E-Poster 43, Domestic conference

  Poster presentation


• A case of laparoscopic distal pancreatectomy for branch-duct intraductal papillary mucinous neoplasm with a preoperatively diagnosed portal annular pancreas

  Hosoe A, Nanno Y, Ishida J, Mizumoto T, Ueda Y, Lee D, Komatsu S, Yanagimoto H, Asari S, Kido M, Fukumoto T

  -, May 2026, English, Resident & Student Session 2, Domestic conference

  Oral presentation


• Infectious Complications After Hepatectomy in Patients With Prior Biliary-Enteric Anastomosis

  Sano H, Urade T, Takebe A, Tanaka M, Komatsu S, Fukushima K, Yoshida T, Arai K, Kido M, Matsumoto I, Fukumoto T

  -, May 2026, English, Requested Oral 10, Domestic conference

  Oral presentation


• -

  -

  -, May 2026, Japanese, ランチョンセミナー8, Domestic conference

  Public discourse


• -

  -

  -, May 2026, Japanese, モーニングセミナー1, Domestic conference

  Public discourse


• Enhancing Recruitment and Retention of Young Surgeons: The Kobe University Model of Career Support and Training Programs

  Komatsu S, Fukushima K, Mizumoto T, Yoshida T, Ishida J, Nanno Y, Urade T, Yanagimoto H, Kido M, Fukumoto T

  -, May 2026, English, Special Program 5, Domestic conference

  Invited oral presentation


• A Retrospective Study on the Prognosis of All Disappearing Colorectal Liver Metastases

  Shimura Y, Yoshida T, Komatsu S, Kido M, Fukushima K, Urade T, Arai K, Asari S, Yanagimoto H, Fukumoto T

  -, May 2026, English, Mini-Symposium 1, Domestic conference

  Public symposium


• Toward Five-Year Survival: Multimodal Strategies and Surgical Selection After Recurrence Of Resected Pancreatic Cancer

  Ishida J, Nanno Y, Mizumoto T, Lee D, Urade T, Fukushima K, Komatsu S, Yanagimoto H, Asari S, Kido M, Fukumoto T

  -, May 2026, English, Mini-Symposium 9, Domestic conference

  Public symposium


• Robot-assisted liver resection with da Vinci and hinotori: a single-center comparative study

  Urade T, Komatsu S, Fukushima K, So S, Yoshida T, Arai K, Iguchi K, Nanno Y, Yanagimoto H, Kido M, Fukumoto T

  -, May 2026, English, Video Symposium 1, Domestic conference

  Public symposium


• Progress in our robot-assisted pancreaticoduodenectomy approach focusing on optimal surgical field exposure

  Nanno Y, Ishida J, Mizumoto T, Lee D, Urade T, Fukushima K, Komatsu S, Yanagimoto H, Asari S, Kido M, Fukumoto T

  -, May 2026, English, Video Symposium 2, Domestic conference

  Public symposium


• Significance of Conversion Therapy Following Atezolizumab Plus Bevacizumab for Unresectable Advanced Hepatocellular Carcinoma

  Fukushima K, Komatsu S, Kido M, Urade T, Yoshida T, Arai K, Ishida J, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  -, May 2026, English, Workshop 9, Domestic conference

  Public symposium


• Moderator（Mini-Workshop 5）

  Komatsu S

  -, May 2026, English, Moderator（Mini-Workshop 5）, Domestic conference

  Others


• -

  -

  -, Apr. 2026, Japanese, 研修医の発表セッション（35）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, 医学生の発表セッション（33）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（101）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（24）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（19）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（101）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（19）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, デジタルポスター（97）, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2026, Japanese, サージカルフォーラム（24）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, サージカルフォーラム（9）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, サージカルフォーラム（47）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, サージカルフォーラム（25）, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, 126回企画6, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, 126回企画2, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, イブニングセミナー6, Domestic conference

  Public discourse


• -

  -

  -, Apr. 2026, Japanese, ランチョンセミナー9, Domestic conference

  Public discourse


• -

  -

  -, Apr. 2026, Japanese, ワークショップ7, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2026, Japanese, ワークショップ14, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2026, Japanese, パネルディスカッション 10, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2026, Japanese, パネルディスカッション 22, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2026, Japanese, パネルディスカッション30, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2026, Japanese, 特別講演, Domestic conference

  Invited oral presentation


• A Propensity Score-Matched Comparison of Particle Therapy and Transarterial Chemoembolization for Hepatocellular Carcinoma

  Yamanaka T, Ueshima E, Terashima K, Sofue K, Komatsu S, Omori M, Inoue Y, Umeno A, Kozuki R, Gentsu T, Sasaki K, Takahashi D, Matsuo Y, Tokumaru S, Matsuo T, Tada T, Yamaguchi M, Okimoto T, Murakami T

  APASL Oncology 2026 Tokyo, Apr. 2026, English, Poster, International conference

  Poster presentation


• Strategic Integration of Locoregional Interventions to Optimize Survival Outcomes following First-line ICI Combinations in Advanced Hepatocellular Carcinoma

  Omori M, Komatsu S, Tada T, ishihara N, Matsuura T, Ueshima E, Gon H, Fukushima K, Urade T, Yoshida T, Arai K, Iguchi K, Hamanaka M, Sano H, Terashima K, Okimoto T, Nanno Y, Yanagimoto H, Kido M, Fukumoto T

  APASL Oncology 2026 Tokyo, Apr. 2026, English, Young Investigator Award Session 1, International conference

  Oral presentation


• -

  -

  -, Mar. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2026, Japanese, 特別講演, Domestic conference

  Invited oral presentation


• -

  -

  -, Mar. 2026, Japanese, 基調講演, Domestic conference

  Keynote oral presentation


• -

  -

  -, Mar. 2026, Japanese, 講演, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, 演題Ⅴ, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, 演題Ⅱ, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, 座長（演題Ⅲ）, Domestic conference

  Others


• -

  -

  -, Feb. 2026, Japanese, 一般演題③, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, アワードセッション③, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, アワードセッション③, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, アワードセッション③, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, 一般演題<セッション1>, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2026, Japanese, 一般演題<セッション1>, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2026, Japanese, アフタヌーンセミナー3, Domestic conference

  Public discourse


• -

  -

  -, Jan. 2026, Japanese, ワークショップ2, Domestic conference

  Public symposium


• -

  -

  -, Aug. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Others


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Others


• A Case of Successful Conversion Hepatectomy Following Durvalumab plus Tremelimumab Therapy under Nasogastric Feeding for Advanced Vp4 Hepatocellular Carcinoma

  Sano H, Fukushima K, Komatsu S, Kido M, Urade T, So S, Yoshida T, Tai K, Arai K, Iguchi K, Nanno Y, Asari S, Yanagimoto H, Kodama T, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Impact of tumor size on liver regeneration after hepatectomy

  Takimoto D, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Fujinaka R, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

  Omori M, Komatsu S, Tada T, ishihara N, Matsuura T, Ueshima E, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Evaluation of Nutritional Risk Assessment Methods for Hepatectomy in Hepatocellular Carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Fukushima K, Yoshida T, Tai K, Arai K, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Outcomes and Indications of Curative Conversion Therapy After Immunotherapy

  Tai K, Komatsu S, Tada T, Matsuura T, Ueshima E, Omori M, Ishihara N, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Impact of Initial Hepatectomy With Hilar Manipulation on Short-Term Outcomes of Repeat Hepatectomy for Recurrent Liver Cancer

  Arai K, Gon H, Komatsu S, Fukushima K, Kido M, Urade T, So S, Yoshida T, Tai K, Akita M, Yanagimoto H, Mizumoto T, Ishida J, Nanno Y, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Treatment strategy for Colorectal liver metastases based on liver resection and the benefit of preoperative chemotherapy

  Yoshida T, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, So S, Tai K, Arai K, Iguchi K, Mizumoto T, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Laparoscopic right posterior sectionectomy using the anterior approach for huge hepatocellular carcinoma

  Urade T, Kido M, Komatsu S, Fukushima K, So S, Yoshida T, Tai K, Arai K, Iguchi K, Mizumoto T, Ishida J, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Impact of Post-Hepatectomy Liver Failure on Long-Term Liver Function and Prognosis in Patients with Hepatocellular Carcinoma

  Fukushima K, Komatsu S, Kido M, Urade T, So S, Yoshida T, Tai K, Arai K, Iguchi K, Mizumoto T, Ishida J, Nanno Y, Asari S, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Poster presentation


• Prognostic and predictive value of lymphocyte-to-monocyte transition in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab

  Omori M, Komatsu S, Tada T, ishihara N, Matsuura T, Ueshima E, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Fukumoto T

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Oral presentation


• Utilizing the conversion concept based on disease status following systemic chemotherapy for hepatocellular carcinoma

  Komatsu S

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Oral presentation


• Multidisciplinary Treatment for Hepatocellular Carcinoma: Combination Therapy with TACE and TKI

  Komatsu S

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Public symposium


• Current status and Future perspectives of multidisciplinary treatment for advanced HCC in Kobe University

  Fukumoto T, Komatsu S

  The 15th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE2025), Jul. 2025, Japanese, International conference

  Public discourse


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Comparison of short-term outcomes between open and laparoscopic surgery for multiple liver resections

  Takimoto D, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  ILLS2025, Jun. 2025, Japanese, International conference

  Poster presentation


• Impact of malnutrition on short- and long-term outcomes in laparoscopic liver resection for hepatocellular carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Fukushima K, So S, Yoshida T, Tai K, Arai K, Fukumoto T

  ILLS2025, Jun. 2025, Japanese, International conference

  Oral presentation


• Re-staining method with indocyanine green fluorescence imaging for laparoscopic liver resection

  Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  ILLS2025, Jun. 2025, Japanese, International conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• Volume- and quality-controlled certification system promotes centralization of complex hepato-pancreatic-biliary surgery

  Saiura A, Mise Y, Hirakawa S, Tachimori H, Kakeji Y, Kitagawa Y, Komatsu S, Nanashima A, Nakamura M, Endo I

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Nutritional Status Assessed by GLIM and PNI as Predictors of Textbook Outcome in Liver Resection for Hepatocellular Carcinoma

  Oji K, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Acase of T1b ampullary adenocarcinoma with para-aortic lymph node metastasis

  Takahashi T, Yanagimoto H, Tsugawa D, Akita M, Urade T, Fukushima K, Gon H, Komatsu S, Toyama H, Kido M, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Effects of simultaneous portal and hepatic vein ligation for the induction of liver regeneration: Arat model of liver venous deprivation

  Fujinaka R, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Anomalous origin of the posterior superior pancreaticoduodenal artery (PSPDA): critical vascular variations in the field of hepato-pancreato-biliary surgery

  Okazoe Y, Yanagimoto H, Tsugawa D, Akita M, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Association between S-1 postoperative adjuvant chemotherapy and early postoperative recurrence in biliary tract cancer

  Yoshida M, Yanagimoto H, Tsugawa D, Akita M, Fukushima K, Gon H, Komatsu S, Asari S, Kido M, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Utility of oncological resectability criteria for recurrent hepatocellular carcinoma after hepatectomy

  Ishihara N, Komatsu S, Omori M, Tai K, Kido M, Gon H, Fukushima K, Urade T, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Outcomes of Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Major Hepatectomy or sectionectomy

  Tai K, Komatsu S, Kido M, Gon H, Fukushima K, Urade T, Yoshida T, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Aretrospective study on the accuracy of preoperative diagnosis of pancreatic carcinoma in situ

  Mizumoto T, Toyama H, Nanno Y, Ishida J, Urade T, Fukushima K, Komatsu S, Yanagimoto H, Asari S, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Technical tips and postoperative management for prevention of postoperative pancreatic fistula after minimally invasive distal pancreatectomy

  Ishida J, Toyama H, Nanno Y, Misumoto T, Lee D, Gon H, Tsugawa D, Komatsu S, Yanagimoto H, Kido M, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Identifying the Best Nutritional Prognostic Marker for Survival in Pancreatic Ductal Adenocarcinoma Patients

  Nanno Y, Toyama H, Ishida J, Mizumoto T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Yanagimoto H, Kido M, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Re-staining method with indocyanine green fluorescence imaging for laparoscopic anatomical liver resection

  Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• Comparison of the utility of liver reserve and fibrosis indicators in predicting posthepatectomy liver failure after right hepatectomy for hepatocellular carcinoma

  Fukushima K, Komatsu S, Kido M, Gon H, Urade T, Yoshida T, Tai K, Arai K, Yanagimoto H, Toyama H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Public discourse


• Prognosis of hepatectomy versus systemic chemotherapy based on oncological resectability criteria for borderline resectable hepatocellular carcinoma

  Komatsu S, Tanaka M, Takebe A, Ishihara N, Kido M, Gon H, Fukushima K, Urade T, Nanno Y, Yanagimoto H, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Public symposium


• A case of laparoscopic distal pancreatectomy with misdissection of the portal vein and reconstruction with artificial vascular graft

  Toyama H, Nanno Y, Ishida J, Mizumoto T, Asari S, Yanagimoto H, Komatsu S, Gon H, Tsugawa D, Kido M, Fukumoto T

  -, Jun. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Others


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2025, Japanese, Domestic conference

  Others


• -

  -

  -, May 2025, Japanese, Domestic conference

  Public discourse


• -

  -

  -, May 2025, Japanese, Domestic conference

  Others


• -

  -

  -, May 2025, Japanese, Domestic conference

  Others


• -

  -

  -, May 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Others


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Others


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jan. 2025, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2024, Japanese, Domestic conference

  Others


• Postoperative complications assessed by the comprehensive complication index (CCI) are associated with early recurrence after curative resection for biliary tract cancer

  Okazoe Y, Yanagimoto H, Akita M, Tsugawa D, Arai K, Yoshida T, So S, Ishida J, Nanno Y, Urade T, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Fukumoto T

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• Clinical Significance of Laparoscopic 0-mm Margin Liver Resection for Vascular in Patients with Hepatocellular Carcinoma

  Shimura Y, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, Yoshida T, Arai K, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Oct. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  ILLS2024, Oct. 2024, Japanese, International conference

  Public symposium


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Others


• Future perspectives of systemic chemotherapy and surgery in the treatment of hepatocellular carcinoma

  -

  Asian Pacific Association for the Study of the Liver APASL Oncology 2024 Chiba, Sep. 2024, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Sep. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Aug. 2024, English, International conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, English, International conference

  Poster presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public discourse


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, English, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, English, Domestic conference

  Poster presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jun. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, May 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Mar. 2024, Japanese, International conference

  Poster presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Poster presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, International conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Mar. 2024, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2024, Japanese, Domestic conference

  Others


• -

  -

  -, Feb. 2024, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Others


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Dec. 2023, Japanese, Domestic conference

  Public symposium


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Public symposium


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Others


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Public symposium


• --

  --

  --, Nov. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• The feasibility of laparoscopic liver resection with 0-mm surgical margin for hepatocellular carcinoma

  Shimura Y, Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Tsugawa D, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Nov. 2023, Japanese, Domestic conference

  Public discourse


• Current status of liver transplantation for HCC after the transition of indication for transplantation

  Kuramitsu K, Komatsu S, Fukumoto T

  --, Nov. 2023, Japanese, Domestic conference

  Public symposium


• --

  --

  --, Nov. 2023, Japanese, International conference

  Poster presentation


• ーー

  --

  --, Oct. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Oct. 2023, Japanese, Domestic conference

  Oral presentation


• Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study

  Ami K, Terashima K, Ishida J, Matsuo Y, Suga M, Fukuoka H, Okawa T, Takahashi D, Park S, Matsuo Y, Nanno Y, Komatsu S, Asari S, Yanagimoto H, Kido M, Tokumaru S, Okimoto T, Toyama H, Fukumoto T

  7th Kansai-Yeungnam HBP Surgeons Meeting, Oct. 2023, Japanese, International conference

  Poster presentation


• Risk Factors for Recurrence of Cholangitis After Pancreaticoduodenectomy and Comparison of Stents in Hepaticojejunostomy

  Fukuoka H, Toyama H, Ishida J, Asari S, Goto T, Nanno Y, Okawa T, Urade T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Yanagimoto H, Kido M, Fukumoto T

  7th Kansai-Yeungnam HBP Surgeons Meeting, Oct. 2023, Japanese, International conference

  Poster presentation


• ーー

  --

  --, Oct. 2023, Japanese, Domestic conference

  Keynote oral presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Others


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Poster presentation


• A comparative study of laparo-scopic liver resection for the segment 8 dorsal and ventral area

  Oji K, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Akita M, Ishida J, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  4th World Congress of International Laparoscopic liver Society（ILLS）, Sep. 2023, Japanese, International conference

  Oral presentation


• Short-term impact of laparoscopic liver resection with 0-mm surgical margin for HCC

  Shimura Y, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Tsugawa D, Yanagimoto H, Toyama H, Fukumoto T

  4th World Congress of International Laparoscopic liver Society（ILLS）, Sep. 2023, Japanese, International conference

  Invited oral presentation


• Acceptability of Laparoscopic Liver Resection of Segment I: A Retrospective Study

  Fujinaka R, Urade T, Kido M, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Tsugawa D, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  4th World Congress of International Laparoscopic liver Society（ILLS）, Sep. 2023, Japanese, International conference

  Oral presentation


• Laparoscopic segmentectomy2 versus left lateral sectionecto-my for liver tumors in segment2

  Urade T, Kido M, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Omiya S, Shimura Y, Yanagimoto H, Toyama H, Fukumoto T

  4th World Congress of International Laparoscopic liver Society（ILLS）, Sep. 2023, Japanese, International conference

  Oral presentation


• Impact of malnutrition diagnosed by the GLIM criteria on postoperative complications after pancreaticoduodenectomy for biliary tract cancer

  Okazoe Y, Yanagimoto H, Tsugawa D, Akita M, Okawa T, Omiya S, Arai K, Yoshida T, So S, Ishida J, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Asari S, Toyama H, Kido M, Ajiki T, Fukumoto T

  45th ESPEN Congress, Sep. 2023, Japanese, International conference

  Poster presentation


• Impact of malnutrition diagnosed by the GLIM criteria on outcome of elderly patients with hepatocellular carcinoma after liver resection

  Omiya S, Urade T, Komatsu S, Kido M, So S, Gon H, Fukushima K, Yoshida T, Arai K, Okazoe Y, Akita M, Ishida J, Nanno Y, Tsugawa D, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  45th ESPEN Congress, Sep. 2023, Japanese, International conference

  Poster presentation


• ーー

  --

  --, Sep. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Aug. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jul. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  Oji K, Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Akita M, Ishida J, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  Ishihara N, Komatsu S, Sofue K, Yano Y, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Yamamoto A, Ueshima E, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ueda Y, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  Akita M, Yanagimoto H, Tsugawa D, Nanno Y, Urade T, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Kido M, Toyama H, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  Tsugawa D, Yanagimoto H, Akita M, Arai K, Yoshida T, Ishida J, Nanno Y, Urade T, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Asari S, Toyama H, Kido M, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  Arai K, Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Yoshida T, Akita M, Ishida J, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  Okazoe Y, Yanagimoto H, Tsugawa D, Akita M, Omiya S, Arai K, Yoshida T, So S, Ishida J, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Asari S, Toyama H, Kido M, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  Shimura Y, Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Yoshida T, Arai K, Tsugawa D, Goto T, Yanagimoto H, Toyama H, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  Ishida J, Toyama H, Asari S, Goto T, Nanno Y, Fukuoka H, Ami K, Akita M, Arai K, Yoshida T, So S, Urade T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  Nanno Y, Toyama H, Matsumoto I, Uemura J, Asari S, Goto T, Lee D, Murakami T, Komatsu S, Yanagimoto H, Kido M, Ajiki T, Okano K, Takeyama Y, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Yoshida T, Arai K, Omiya S, Fujinaka R, Akita M, Ishida J, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  Toyama H, Goto T, Nanno Y, Ishida J, Asari S, Yanagimoto H, Komatsu S, Tsugawa D, Gon H, Fukushima K, Urade T, Fukuoka H, Ami K, Kido M, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, Tsugawa D, Goto T, Yanagimoto H, Toyama H, Fukumoto T

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  Kido M, Komatsu S, Gon H, Fukushima K, Urade T, Tsugawa D, Yanagimoto H, Toyama H, Fukumoto T

  The 31st International Congress of the European Association for Endoscopic Surgery (EAES), Jun. 2023, Japanese, International conference

  Oral presentation


• ーー

  Komatsu S

  Trans Tasman Radiation Oncology Group Annual Scientific Meeting 2023（TROG), Jun. 2023, Japanese, International conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jun. 2023, Japanese, International conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Jun. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, May 2023, Japanese, Domestic conference

  Invited oral presentation


• ーー

  --

  --, May 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, May 2023, Japanese, Domestic conference

  Others


• The factors of predicting over-time weight increase after liver transplantation

  Shimura Y, Kuramitsu K, Kido M, Komatsu S, Gon H, Fukushima K, Urade T, So S, Yoshida T, Arai K, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Fukumoto T

  ILTS2023, May 2023, Japanese, International conference

  Poster presentation


• Indication of liver transplantation in the treatment of newly categorized acute-on-chronic liver failure in Japan

  Kuramitsu K, Komatsu S, Kido M, Tsugawa D, Gon H, Fukushima K, Goto T, Yanagimoto H, So S, Arai K, Yoshida T, Ajiki T, Toyama H, Fukumoto T

  ILTS2023, May 2023, Japanese, International conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Poster presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Invited oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Invited oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Others


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Apr. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Mar. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Mar. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Mar. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Mar. 2023, Japanese, Domestic conference

  Public symposium


• ーー

  --

  --, Feb. 2023, Japanese, Domestic conference

  Others


• ーー

  --

  --, Feb. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jan. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jan. 2023, Japanese, Domestic conference

  Oral presentation


• ーー

  --

  --, Jan. 2023, Japanese, Domestic conference

  Others


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Oral presentation


• Laparoscopic anatomical resection of segment 2 by Glissonean approach

  -

  -, Dec. 2022, Japanese, International conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Dec. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2022, Japanese, International conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Others


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  -, Nov. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Oct. 2022, Japanese, Domestic conference

  Others


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Public discourse


• -

  -

  -, Sep. 2022, Japanese, Domestic conference

  Oral presentation


• Hepatic Resection versus Particle Therapy for Single Hepatocellular Carcinoma as An Initial Treatment: A Multicenter Propensity Score Matched Analysis

  Omiya S, Komatsu S, Terashima K, Park SC, Matsuo Y, Sulaiman NS, So S, Nanno Y, Urade T, Fukushima K, Gon H, Tsugawa D, Kuramitsu K, Goto T, Yanagimoto H, Kido M, Toyama H, Tokumaru S, Okimoto T, Fukumoto T

  -, Sep. 2022, English, International conference

  Poster presentation


• -

  -

  -, Aug. 2022, Japanese, Domestic conference

  Others


• -

  -

  -, Aug. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  Goto T, Toyama H, Mizumoto T, Nanno Y, Asari S, Komatsu S, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  Komatsu S, Yano Y, Kido M, Kuramitsu K, Gon H, Fukushima K, Goto T, Yanagimoto H, Toyama H, Fukumoto T

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  Nanno Y, Toyama H, Mizumoto T, Nanno Y, Asari S, Komatsu S, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• Survival outcome of chemotherapy-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer

  Ami K, Terashima K, Ogura Y, Takahata D, Park S, Matsuo Y, Mizumoto T, Shazrina SN, Nanno Y, Komatsu S, Kuramitsu K, Goto T, Asari S, Yanagimoto H, Kido M, Tokumaru S, Okimoto T, Ajiki T, Toyama H, Fukumoto T

  -, Jul. 2022, English, Domestic conference

  Oral presentation


• Diagnosis and treatment strategy of patients with early-stage(Stage 0/IA) pancreatic cancer

  Asari S, Toyama H, Goto T, Nanno Y, Mizumoto T, Tsugawa D, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jul. 2022, English, Domestic conference

  Oral presentation


• Our standardized technique of laparoscopic distal pancreatectomy for pancreatic cancer

  Goto T, Toyama H, Asari S, Nanno Y, Mizumoto T, Tsugawa D, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jul. 2022, English, Domestic conference

  Public symposium


• -

  ー

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jul. 2022, Japanese, Domestic conference

  Public symposium


• -

  ー

  -, Jul. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Invited oral presentation


• -

  小松 昇平, 秋田 真之, 吉田 俊彦, 宗 慎一, 南野 佳英, 浦出 剛史, 福島 健司, 権 英寿, 津川 大介, 蔵満 薫, 後藤 直大, 柳本 泰明, 木戸 正浩, 外山 博近, 福本 巧

  -, Jun. 2022, Japanese, Domestic conference

  Public symposium


• Impact of Delayed Gastric Emptying After Pancreatoduodenectomy on Postoperative Nutritional Status

  Mizumoto T, Toyama H, Asari S, Goto T, Nanno Y, So S, Urade T, Fukushima K, Gon H, Tsugawa D, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Spontaneous rupture of splenic hilar lymph node metastasis from hepatocellular carcinoma: a rare case report

  Fujinaka R, Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Laparoscopic anatomic liver resection of segment 2 based on the anatomical variation of the hepatic veins

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Yanagimto H, Asari S, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Low levels of C-reactive protein on postoperative day 1 are an early predictor for posthepatectomy liver failure in hepatocellular carcinoma patients undergoing right hepatectomy

  Fukushima K, Kido M, Kuramitsu K, Komatsu S, Gon H, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Current role of atezolizumab plus bevacizumab therapy in the sequential treatment of unresectable hepatocellular carcinoma

  Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Utility of plasma serum D-dimer for diagnosis of venous thromboembolism after hepatectomy

  Yanagimoto H, Miyake T, Tsugawa D, Urade T, Nanno Y, Fukushima K, Gon H, Komatsu S, Kuramitsu K, Goto T, Asari S, Kido M, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Efficacy analyses of neoadjuvant treatment for patients with “resectable” pancreatic ductal adenocarcinoma

  Asari S, Toyama H, Goto T, Nanno Y, Mizumoto T, Komatsu S, Kuramitsu K, Yanagimoto H, Kido M, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• Laparoscopic Spleen Preserving Distal Pancreatectomy with Splenic Vessels Preservation

  Toyama H, Goto T, Nanno Y, Mizumoto T, Ogura Y, Fukuoka H, Ami K, Asari S, Kuramitsu K, Komatsu S, Tsugawa D, Yanagimoto H, Ajiki T, Kido M, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Poster presentation


• The usefulness of total tumor volume as a prognostic factor in patients with colorectal cancer liver metastases

  Shimura Y, Komatsu S, Kido M, Kuramitsu K, Gon H, Fukushima K, Urade T, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Public symposium


• Multidisciplinary approach for advanced hepatocellular carcinoma

  Kido M, Komatsu S, Kuramitsu K, Gon H, Fukushima K, Urade T, Ajiki T, Yanagimoto H, Goto T, Tsugawa D, Toyama H, Fukumoto T

  -, Jun. 2022, English, Domestic conference

  Public symposium


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Others


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Poster presentation


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, Jun. 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, May 2022, Japanese, Domestic conference

  Invited oral presentation


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Oral presentation


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Public discourse


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  ー

  -, May 2022, Japanese, Domestic conference

  Public symposium


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Nominated symposium


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Poster presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Apr. 2022, Japanese, Domestic conference

  Invited oral presentation


• Intraoperative Assessment of the Demarcation Line and Intersegmental/Sectional Planes in Liver Surgery

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Tsugawa D, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  15th World Congress of the International Hepato-Pancreati-Biliary Association (IHPBA), Mar. 2022, English, International conference

  Poster presentation


• -

  -

  -, Mar. 2022, Japanese, Domestic conference

  Nominated symposium


• Laparoscopic anatomic liver resection if segment 2 by glissonean approach

  Urade T, Kido M, Kuramitsu K, Komatsu S, Gon H, Fukushima K, So S, Mizumoto T, Nanno Y, Goto T, Asari S, Yanagimoto H, Toyama H, Ajiki T, Fukumoto T

  SAGES 2022 Annual Meeting, Mar. 2022, English, International conference

  Poster presentation


• -

  -

  -, Feb. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2022, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  -, Feb. 2022, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Feb. 2022, Japanese, Domestic conference

  Oral presentation


• ー

  Komatsu S, Kido M, Fukumoto T

  ー, Dec. 2021, English, Domestic conference

  Poster presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Public symposium


• ー

  ー

  ー, Dec. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Nov. 2021, Japanese, Domestic conference

  Others


• ー

  ー

  ー, Nov. 2021, Japanese, Domestic conference

  Oral presentation


• ー

  ー

  ー, Nov. 2021, Japanese, Domestic conference

  Public symposium


• ー

  ー

  ー, Nov. 2021, Japanese, Domestic conference

  Public symposium


• ー

  ー

  ー, Nov. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第19回消化器外科学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第25回日本肝臓学会大会（JDDW2021）, Nov. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第59回日本癌治療学会学術集会, Oct. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第57回日本移植学会総会, Sep. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第57回日本移植学会総会, Sep. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第44回日本膵・胆管合流異常研究会, Sep. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  LENVATINIB Meet The Surgery Expert, Sep. 2021, Japanese, Domestic conference

  Keynote oral presentation


• -

  -

  第57回日本肝癌研究会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第57回日本肝癌研究会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第57回日本肝癌研究会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第57回日本肝癌研究会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第57回日本肝癌研究会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第1回パパドクターフォーラム, Jul. 2021, Japanese, Domestic conference

  Public discourse


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第76回日本消化器外科学会総会, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  肝細胞癌 EXPERT WEB SEMINAR, Jul. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第2回スペーサー治療研究会 スペーサー手術手技検討会, Jun. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第39回日本肝移植学会学術集会, Jun. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第39回日本肝移植学会学術集会, Jun. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第47回日本急性肝不全研究会, Jun. 2021, Japanese, Domestic conference

  Oral presentation


• Prognosis after total pancreatectomy and total remnant pancreatectomy for pancreatic cancer

  Ishida J、Toyama H、Terai S、Yamashita H、Shirakawa S、Asakura Y、Shimizu T、Ogura Y、Fukuoka H、So S、Urade T、Gon H、Tsugawa D、Komatsu S、Kuramitsu K、Asari S、Yanagimoto H、Kido M、Ajiki T、Fukumoto T

  第33回日本肝胆膵外科学会学術集会, Jun. 2021, English, Domestic conference

  Invited oral presentation


• Present status of outpatient clinic for transplant patients

  Kuramitsu K、Kido M、Komatsu S、Urade T、So S、Ishida J、Shirakawa S、Yamashita H、Tsugawa D、Terai S、Asari S、Yanagimoto H、Toyama H、Ajiki T、Fukumoto T

  第33回日本肝胆膵外科学会学術集会, Jun. 2021, English, Domestic conference

  Public symposium


• Impact of hepatectomy for advanced hepatocellular carcinoma with major portal vein tumor thrombus

  Komatsu S、Kido M、Kuramitsu K、Gon H、Urade T、So S、Ishida J、Shirakawa S、Yamashita H、Tsugawa D、Terai S、Asari S、Yanagimoto H、Toyama H、Ajiki T、Fukumoto T

  第33回日本肝胆膵外科学会学術集会, Jun. 2021, English, Domestic conference

  Public symposium


• Long term survival following resection for ampullary carcinoma

  Yanagimoto H、Ajiki T、Matsumoto T、Akita M、Ueno K、Tsugawa D、Kuramitsu K、Komatsu S、Shirakawa S、Yamashita H、Gon H、Urade T、So S、Ishida J、Asari S、Toyama H、Kido M、Fukumoto T

  第33回日本肝胆膵外科学会学術集会, Jun. 2021, English, Domestic conference

  Public symposium


• -

  -

  外科医から見た肝細胞癌治療セミナー, Jun. 2021, Japanese, Domestic conference

  Public discourse


• -

  -

  第43回日本癌局所療法研究会, May 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第43回日本癌局所療法研究会, May 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第43回日本癌局所療法研究会, May 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第43回日本癌局所療法研究会, May 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第43回日本癌局所療法研究会, May 2021, Japanese, Domestic conference

  Oral presentation


• How to control long term complications after liver transplantation

  Omiya S、Kuramitsu K、Gon H、So S、Awazu M、Tsugawa D、Komatsu S、Tanaka M、Kido M、Fukumoto T

  The 2022 Virtual International Congress of ILTS, ELITA annd LICAGE, May 2021, English, International conference

  Poster presentation


• The impact of albumin-bilirubin score on short- and long-term survival after living-donor liver transplantation: a retrospective study

  So S、Kuramitsu K、Gon H、Awazu M、Tsugawa D、Komatsu S、Tanaka M、Kido M、Fukumoto T

  The 2021 Virtual International Congress of ILTS, ELITA annd LICAGE, May 2021, English, International conference

  Poster presentation


• Indication of liver transplantation in the treatment of newly categorized acute-on-chronic liver failure in Japan

  Kuramitsu K、Yano Y 、Tanaka M、Komatsu S、Tsugawa D、Awazu M、Gon H、So S、Kido M、Fukumoto T

  The 2021 Virtual International Congress of ILTS, ELITA annd LICAGE, May 2021, English, International conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第121回日本外科学会定期学術集会, Apr. 2021, Japanese, Domestic conference

  Poster presentation


• -

  -

  第204回近畿外科学会, Mar. 2021, Japanese, Domestic conference

  Oral presentation


• -

  -

  第5回神戸肝胆膵外科ビデオクリニック, Mar. 2021, Japanese, Domestic conference

  Oral presentation


• Laparoscopic liver resection for the paracaval tumor

  Kido M、Tanaka M、Komatsu S、So S、Ajiki T、Yanagimto H、Terai S、Shirakawa S、Toyama H、Fukumoto T、、、、、、、、、、、、、、、

  第33回日本内視鏡外科学会, Mar. 2021, English, Domestic conference

  Public symposium


• Oncological outcomes of laparoscopic distal pancreatectomy for pancreatic cancer

  Toyama H、Ishida J、Terai S、Mukubou H、Shirakawa S、Asakura Yu、Shimizu T、Ajiki T、Kido M、Yanagimoto H、Tanaka M、Komatsu S、Tsugawa D、Gon H、Fukumoto T、、、、、、、、、、

  第33回日本内視鏡外科学会, Mar. 2021, English, Domestic conference

  Public symposium


• -

  -

  日本消化器病学会近畿支部第114回例会, Feb. 2021, Japanese, Domestic conference

  Public symposium


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Public symposium


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Public symposium


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Public symposium


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Poster presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Invited oral presentation


• -

  -

  第32回日本肝胆膵外科学会, Feb. 2021, English, Domestic conference

  Invited oral presentation


• -

  -

  Lilly HCC Interactive Seminar, Feb. 2021, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  LENVATINIB Meet The Surgery Expert, Jan. 2021, Japanese, Domestic conference

  Keynote oral presentation


• -

  -

  第17回 関西肝臓外科医育成の会, Jan. 2021, Japanese, Domestic conference

  Others


• -

  -

  第17回 関西肝臓外科医育成の会, Jan. 2021, Japanese, Domestic conference

  Public discourse


• -

  -

  第17回 関西肝臓外科医育成の会, Jan. 2021, Japanese, Domestic conference

  Others


• -

  -

  第38回日本肝移植学会学術集会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  日本外科代謝栄養学会第57回学術集会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝癌研究会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝癌研究会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝癌研究会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝癌研究会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝癌研究会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第75回日本消化器外科学会総会, Dec. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  Lilly HCC Virtual Symposium Seminar, Dec. 2020, Japanese, Domestic conference

  Public discourse


• -

  -

  第43回日本膵・胆管合流異常研究会, Nov. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第18回日本消化器外科学会大会（JDDW2020）, Nov. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第18回日本消化器外科学会大会（JDDW2020）, Nov. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第18回日本消化器外科学会大会（JDDW2020）, Nov. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本移植学会総会, Nov. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第56回日本移植学会総会, Nov. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第56回日本移植学会総会, Nov. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第56回日本移植学会総会, Nov. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第82回日本臨床外科学会総会, Oct. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第82回日本臨床外科学会総会, Oct. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第82回日本臨床外科学会総会, Oct. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第82回日本臨床外科学会総会, Oct. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本腹部救急医学会総会, Oct. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第56回日本腹部救急医学会総会, Oct. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第56回日本腹部救急医学会総会, Oct. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  -

  第56回日本胆道学会学術集会, Oct. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第56回日本胆道学会学術集会, Oct. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第56回日本肝臓学会総会, Aug. 2020, Japanese, Domestic conference

  Public symposium


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Poster presentation


• -

  -

  第120回日本外科学会定期学術集会, Aug. 2020, Japanese, Domestic conference

  Oral presentation


• -

  -

  -, Jul. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  朝倉 悠, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 清水 貴, 李 東河, 小倉 佑太, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Feb. 2020, Japanese, Domestic conference

  Poster presentation


• -

  西沢 祐輔, 田中 基文, 木戸 正浩, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 保原 祐樹, 中川 大佑, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Feb. 2020, Japanese, Domestic conference

  Poster presentation


• -

  小松 昇平, 矢野 嘉彦, 祖父江 慶太郎, 福本 巧

  -, Feb. 2020, Japanese, Domestic conference

  Public symposium


• -

  小松 昇平

  -, Feb. 2020, Japanese, Domestic conference

  Invited oral presentation


• -

  宗 慎一, 木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Feb. 2020, Japanese, Domestic conference

  Oral presentation


• -

  小松 昇平

  -, Feb. 2020, Japanese, Domestic conference

  Others


• -

  小松 昇平

  -, Feb. 2020, Japanese, Domestic conference

  Oral presentation


• -

  Shirakawa S, Toyama H, Komatsu S, Ishida J, Kido M, Fukumoto T

  -, Jan. 2020, English, United States, International conference

  Poster presentation


• -

  大宮 悟志, 蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  石田 潤, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 山下 博成, 朝倉 悠, 粟津 正英, 津川 大介, 小松 昇平, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Public symposium


• -

  権 英寿, 権 英寿, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  椋棒 英世, 寺井 祥雄, 外山 博近, 石田 潤, 山下 博成, 白川 幸代, 粟津 正英, 津川 大介, 小松 昇平, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 味木 徹夫, 柳本 泰明, 津川 大介, 寺井 祥雄, 椋棒 英世, 外山 博近, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 朝倉 悠, 粟津 正英, 津川 大介, 小松 昇平, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  椋棒 英世, 外山 博近, 寺井 祥雄, 津川 大介, 小松 昇平, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Public symposium


• -

  粟津 正英, 木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 権 英寿, 宗 慎一, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Dec. 2019, Japanese, Domestic conference

  Oral presentation


• -

  橋本 悠, 秋田 真之, 津川 大介, 粟津 正英, 椋棒 英世, 小松 昇平, 寺井 祥雄, 蔵満 薫, 田中 基文, 木戸 正浩, 外山 博近, 上野 公彦, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Poster presentation


• -

  津川 大介, 上野 公彦, 秋田 真之, 橋本 悠, 権 英寿, 白川 幸代, 山下 博成, 粟津 正英, 椋棒 英世, 小松 昇平, 寺井 祥雄, 蔵満 薫, 田中 基文, 外山 博近, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Poster presentation


• -

  小松 昇平, 木戸 正浩, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  大宮 悟志, 小松 昇平, 祖父江 慶太郎, 上嶋 英介, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 権 英寿, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 杉本 幸司, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Poster presentation


• -

  保原 祐樹, 小松 昇平, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 権 英寿, 宗 慎一, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Invited oral presentation


• -

  橋本 悠, 味木 徹夫, 上田 泰弘, 粟津 正英, 津川 大介, 椋棒 英世, 小松 昇平, 寺井 祥雄, 蔵満 薫, 田中 基文, 柳本 泰明, 外山 博近, 木戸 正浩, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Oral presentation


• -

  朝倉 悠, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Oral presentation


• -

  清水 貴, 清水 貴, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Poster presentation


• -

  小倉 佑太, 石田 潤, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Poster presentation


• -

  白川 幸代, 外山 博近, 石田 潤, 寺井 祥雄, 椋棒 英世, 山下 博成, 李 東河, 清水 貴, 朝倉 悠, 蔵満 薫, 小松 昇平, 津川 大介, 田中 基文, 木戸 正浩, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  権 英寿, 吉田 俊彦, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 宗 慎一, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  小松 昇平, 木戸 正浩, 寺嶋 千貴, 出水 祐介, 津川 大介, 椋棒 英世, 蔵満 薫, 寺井 祥雄, 田中 基文, 柳本 泰明, 外山 博近, 味木 徹夫, 沖本 智昭, 佐々木 良平, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  田中 基文, 木戸 正浩, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  柳本 泰明, 津川 大介, 味木 徹夫, 上野 公彦, 秋田 真之, 橋本 悠, 上田 泰弘, 寺井 祥雄, 蔵満 薫, 小松 昇平, 椋棒 英世, 田中 基文, 外山 博近, 木戸 正浩, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Invited oral presentation


• -

  木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 椋棒 英世, 寺井 祥雄, 津川 大介, 柳本 泰明, 蔵満 薫, 味木 徹夫, 外山 博近, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 李 東河, 味木 徹夫, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 福本 巧

  -, Nov. 2019, Japanese, Domestic conference

  Public symposium


• -

  大宮 悟志, 蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 津川 大介, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Poster presentation


• -

  津川 大介, 田中 基文, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 白川 幸代, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Poster presentation


• -

  蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 津川 大介, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 保原 祐樹, 西沢 祐輔, 吉岡 佑太, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Public symposium


• -

  渡邊 陽香, 粟津 正英, 木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 権 英寿, 中馬 正志, 宗 慎一, 石田 潤, 白川 幸代, 上田 泰弘, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 小松 正人, 児玉 良典, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Oral presentation


• -

  小倉 佑太, 石田 潤, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 李 東河, 朝倉 悠, 清水 貴, 権 英寿, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Oral presentation


• -

  清水 貴, 外山 博近, 寺井 祥雄, 椋棒 英世, 白川 幸代, 石田 潤, 李 東河, 朝倉 悠, 小倉 佑太, 田村 太一, 権 英寿, 粟津 正英, 津川 大介, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Oral presentation


• -

  中川 大佑, 田中 基文, 木戸 正浩, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 田井 謙太郎, 保原 祐樹, 西沢 祐輔, 大宮 悟志, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Oral presentation


• -

  西沢 祐輔, 小松 昇平, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 権 英寿, 宗 慎一, 津川 大介, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Oct. 2019, Japanese, Domestic conference

  Oral presentation


• -

  安達 祐里, 津川 大介, 柳本 泰明, 上田 泰弘, 橋本 悠, 粟津 正英, 椋棒 英世, 小松 昇平, 寺井 祥雄, 蔵満 薫, 田中 基文, 外山 博近, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Sep. 2019, Japanese, Domestic conference

  Oral presentation


• -

  Tai K, Kuramitsu K, Kido M, Tanaka M, Komatsu S, Awazu M, Gon H, Nishizawa Y, Yasuhara Y, Tsugawa D, Mukubou H, Toyama H, Ajiki T, Fukumoto T

  19th Congress of the European Society for Organ Transplantation (ESOT 2019), Sep. 2019, Japanese, Denmark, International conference

  Poster presentation


• -

  李 東河, 外山 博近, 小倉 佑太, 田村 太一, 清水 貴, 朝倉 悠, 石田 潤, 山下 博成, 白川 幸代, 椋棒 英世, 寺井 祥雄, 小松 昇平, 蔵満 薫, 田中 基文, 柳本 泰明, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Sep. 2019, Japanese, Domestic conference

  Public symposium


• -

  粟津 正英, 木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 権 英寿, 宗 慎一, 田井 謙太郎, 保原 祐樹, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 福本 巧

  -, Sep. 2019, Japanese, Domestic conference

  Public symposium


• -

  保原 祐樹, 小松 昇平, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 西沢 祐輔, 中川 大佑, 大宮 悟志, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Oral presentation


• -

  大宮 悟志, 蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 保原 祐樹, 西沢 祐輔, 吉岡 佑太, 曽山 弘敏, 中川 大祐, 白川 幸代, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  田井 謙太郎, 蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 保原 祐樹, 西沢 祐輔, 吉岡 佑太, 中川 大祐, 曽山 弘敏, 大宮 悟志, 白川 幸代, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  小松 昇平, 蔵満 薫, 木戸 正浩, 田中 基文, 粟津 正英, 権 英寿, 津川 大介, 椋棒 英世, 寺井 祥雄, 柳本 泰明, 外山 博近, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  蔵満 薫, 権 英寿, 宗 慎一, 粟津 正英, 津川 大介, 小松 昇平, 田中 基文, 香川 友紀, 山本 洋子, 菊本 さやか, 佐伯 綾子, 原 麻由美, 木戸 正浩, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 粟津 正英, 権 英寿, 宗 慎一, 田井 謙太郎, 保原 祐樹, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  西沢 祐輔, 田中 基文, 木戸 正浩, 蔵満 薫, 小松 昇平, 粟津 正英, 外山 博近, 上野 公彦, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Poster presentation


• -

  李 東河, 小松 昇平, 外山 博近, 寺嶋 千貴, 松尾 圭朗, 田中 基文, 上野 公彦, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Poster presentation


• -

  保原 祐樹, 小松 昇平, 木戸 正浩, 田中 基文, 蔵満 薫, 粟津 正英, 外山 博近, 上野 公彦, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Poster presentation


• -

  粟津 正英, 木戸 正浩, 権 英寿, 小松 昇平, 蔵満 薫, 田中 基文, 津川 大介, 上野 公彦, 外山 博近, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Invited oral presentation


• -

  津川 大介, 上野 公彦, 小松 昇平, 蔵満 薫, 寺井 祥雄, 田中 基文, 外山 博近, 木戸 正浩, 味木 徹夫, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Poster presentation


• -

  小松 昇平, 木戸 正浩, 田中 基文, 外山 博近, 上野 公彦, 味木 徹夫, 出水 祐介, 沖本 智昭, 佐々木 良平, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Poster presentation


• -

  蔵満 薫, 木戸 正浩, 田中 基文, 小松 昇平, 津川 大介, 粟津 正英, 権 英寿, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Invited oral presentation


• -

  田中 基文, 木戸 正浩, 蔵満 薫, 小松 昇平, 外山 博近, 上野 公彦, 味木 徹夫, 寺嶋 宏明, 富永 正寛, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  木戸 正浩, 田中 基文, 蔵満 薫, 小松 昇平, 粟津 正英, 津川 大介, 椋棒 英世, 味木 徹夫, 外山 博近, 福本 巧

  -, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  -

  第55回日本肝癌研究会, Jul. 2019, Japanese, Domestic conference

  Oral presentation


• -

  -

  第55回日本肝癌研究会, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  -

  第55回日本肝癌研究会, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  -

  第55回日本肝癌研究会, Jul. 2019, Japanese, Domestic conference

  Public symposium


• -

  -

  第41回日本癌局所療法研究会, Jun. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第41回日本癌局所療法研究会, Jun. 2019, Japanese, Domestic conference

  Public symposium


• Impact of conversion surgery for advanced gallbladder cancer

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Public symposium


• A case of hypereosinophilic syndrome developing eosinophilic cholecystitis and postoperative eosinophilic cholangitis

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Poster presentation


• Surgical spacer placement and proton radiotherapy for unresectable locally advanced pancreatic cancer nearby gastrointestinal tract

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Poster presentation


• Short-term outcomes of clamp crush method with HARMONIC HD 1000i for laparoscopic liver resection for hepatocellular carcinoma

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Poster presentation


• Analysis of hepatectomy for elderly patients with bile tract cancer

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Poster presentation


• Pancreatic body cancer with type1 autoimmune pancreatitis. A case report

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Poster presentation


• Clinical features of Lenvatinib for unresectable hepatocellular carcinoma Clinical features of Lenvatinib for unresectable hepatocellular carcinoma

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Public symposium


• Contrast-enhanced Intraoperative ultrasonic cholangiography for real time biliary navigation in hepatobiliary surgery

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Public symposium


• The management of biliary complications in laparoscopic liver resection

  -

  第31回日本肝胆膵外科学会・学術集会, Jun. 2019, English, Domestic conference

  Public symposium


• -

  -

  第55回日本肝臓学会総会, May 2019, Japanese, Domestic conference

  Public symposium


• Short-term outcomes of clamp crush method with HARMONIC HD 1000i for laparoscopic liver resection for hepatocellular carcinoma

  -

  ILLS2019 The 2nd World Congress of the International Laparoscopic Liver Society, May 2019, English, Japan, International conference

  Poster presentation


• Efficacy and feasibility of laparoscopic surgery for repeat hepatectomy

  -

  ILLS2019 The 2nd World Congress of the International Laparoscopic Liver Society, May 2019, English, Japan, International conference

  Poster presentation


• -

  -

  第105回日本消化器病学会総会, May 2019, Japanese, Domestic conference

  Public symposium


• -

  -

  第105回日本消化器病学会総会, May 2019, Japanese, Domestic conference

  Poster presentation


• -

  小松 昇平

  -, Apr. 2019, Japanese, Domestic conference

  Public discourse


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Oral presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Oral presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Oral presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• -

  -

  第119回日本外科学会定期学術集会, Apr. 2019, Japanese, Domestic conference

  Poster presentation


• 肝切除における当科独自の工夫：ソナゾイドを用いた術中胆道造影下超音波の有用性

  荒井 啓輔, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 保原 祐樹, 田井 謙太郎, Terai Sachio, Tanaka Motofumi, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第46回近畿肝臓外科研究会, Feb. 2018, Japanese, 近畿肝臓外科研究会, 大阪, Domestic conference

  Oral presentation


• 座長（一般演題）

  小松 昇平

  第14回関西肝臓外科医育成の会, Jan. 2018, Japanese, 関西肝臓外科医育成の会, 大阪, Domestic conference

  Others


• 腹腔鏡下肝前区域切除における課題

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第11回肝臓内視鏡外科研究会, Dec. 2017, Japanese, 東京医科歯科大学, 京都, Domestic conference

  Public symposium


• 当院における肝移植後de novo 悪性腫瘍の検討

  権 英寿, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 荒井 啓輔, 田井 謙太郎, 保原 祐樹, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第34回近畿肝移植検討会プログラム, Dec. 2017, Japanese, 大阪大学大学院, 吹田, Domestic conference

  Oral presentation


• 胆嚢・総胆管4

  Ueno Kimihiko, Ajiki Tetsuo, 篠﨑 健太, Terai Sachio, Tanaka Motofumi, Toyama Hirochika, Kido Masahiro, Fukumoto Takumi

  第30回日本内視鏡外科学会総会, Dec. 2017, Japanese, 京都大学, 京都, Domestic conference

  Poster presentation


• 術中の胆管損傷に対するトラブル対処法を考える

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, 権 英寿, Fukumoto Takumi

  第11回肝臓内視鏡外科研究会, Dec. 2017, Japanese, 東京医科歯科大学, 京都, Domestic conference

  Public symposium


• 手術用3D内視鏡システムを用いた腹腔鏡下尾側膵切除術

  後藤 直大, Toyama Hirochika, Terai Sachio, 白川 幸代, 山下 博成, 南野 佳英, Kinoshita Hisoka, Tanaka Motofumi, Ueno Kimihiko, Kido Masahiro, Ajiki Tetsuo, Fukumoto Takumi, 具 英成

  第30回日本内視鏡外科学会総会, Dec. 2017, Japanese, 京都大学, 京都, Domestic conference

  Oral presentation


• 再肝切除への腹腔鏡手術適応の妥当性について

  権 英寿, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第11回肝臓内視鏡外科研究会, Dec. 2017, Japanese, 東京医科歯科大学, 京都, Domestic conference

  Public symposium


• 肝臓7

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Ajiki Tetsuo, Toyama Hirochika, Ueno Kimihiko, Terai Sachio, Fukumoto Takumi

  第30回日本内視鏡外科学会総会, Dec. 2017, Japanese, 京都大学, 京都, Domestic conference

  Poster presentation


• 肝臓10

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 荒井 啓輔, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第30回日本内視鏡外科学会総会, Dec. 2017, Japanese, 京都大学, 京都, Domestic conference

  Poster presentation


• 膵癌に対するD2郭清を伴う腹腔鏡下膵体尾部切除（LAP-DPD2）の導入と当科の標準手技

  Toyama Hirochika, Terai Sachio, 白川 幸代, 山下 博成, 南野 佳英, Ajiki Tetsuo, 上田 悠貴, Kido Masahiro, Tanaka Motofumi, 篠崎 健太, 水本 拓也, 李 東河, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Public symposium


• 当施設における腹腔鏡下肝切除の定型化

  権 英寿, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Public symposium


• 当施設における肝前/後区域切除術での検討

  田井 謙太郎, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 荒井 啓輔, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Public symposium


• 当科における若手外科医の獲得と育成の取り組み

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Oral presentation


• 胆管侵襲を伴う進行肝細胞癌に対する治療戦略

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Oral presentation


• 生体肝移植後胆管合併症の対策と予防

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 白川 幸代, 山下 博成, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Oral presentation


• 高度進行肝細胞癌における減量肝切除術の意義

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Public symposium


• 肝切除時の下大静脈損傷に対する出血制御

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Toyama Hirochika, Ueno Kimihiko, Terai Sachio, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Public symposium


• 10cm以上の大型肝細胞癌に対する肝切除の意義

  岡本 柊志, Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第79回日本臨床外科学会総会, Nov. 2017, Japanese, 日本大学, 東京, Domestic conference

  Oral presentation


• 膵管に沿った曲面任意多段面再構成画像（Curved MPR）の有用性

  南野 佳英, Toyama Hirochika, 浅利 貞毅, Terai Sachio, 白川 幸代, 水本 拓也, 上田 悠貴, 篠崎 健太, Kinoshita Hisoka, 松本 拓, Tanaka Motofumi, Kido Masahiro, Ajiki Tetsuo, Fukumoto Takumi

  第15回日本消化器外科学会（JDDW2017）, Oct. 2017, Japanese, 岐阜大学大学院, 福岡, Domestic conference

  Poster presentation


• 当科における難治性腹水に対するDever型腹腔静脈シャントの成績

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, Terai Sachio, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第21回日本肝臓学会大会（JDDW2017）, Oct. 2017, Japanese, 信州大学, 福岡, Domestic conference

  Poster presentation


• 切除困難幹細胞癌における粒子線治療の可能性

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, 寺嶋 千貴, 出水 祐介, 沖本 智昭, Fukumoto Takumi

  第15回日本消化器外科学会（JDDW2017）, Oct. 2017, Japanese, 岐阜大学大学院, 福岡, Domestic conference

  Poster presentation


• 術中Shear Wave Elastgraphyによる肝硬度測定と肝線維化診断

  荒井 啓輔, Tanaka Motofumi, Kido Masahiro, Kinoshita Hisoka, 吉田 俊彦, Terai Sachio, 松本 拓, 浅利 貞毅, Toyama Hirochika, Kusunoki Nobuya, Ajiki Tetsuo, Fukumoto Takumi

  第59回日本消化器病学会（JDDW2017）, Oct. 2017, Japanese, 杏林大学, 福岡, Domestic conference

  Poster presentation


• 腫瘍マーカーおよび炎症による胆道癌患者の層別化

  篠﨑 健太, Ajiki Tetsuo, Ueno Kimihiko, 松本 拓, 秋田 真之, Terai Sachio, Kinoshita Hisoka, Tanaka Motofumi, 浅利 貞毅, Toyama Hirochika, Kido Masahiro, Fukumoto Takumi

  第15回日本消化器外科学会（JDDW2017）, Oct. 2017, Japanese, 岐阜大学大学院, 福岡, Domestic conference

  Poster presentation


• 嚢胞性肝腫瘍と鑑別が困難であった単純性肝嚢胞の1切除例

  都 鍾智, Kinoshita Hisoka, Terai Sachio, Tanaka Motofumi, Kido Masahiro, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, 寺嶋 千貴, 出水 祐介, 沖本 智昭, Fukumoto Takumi

  第200回近畿外科学会, Sep. 2017, Japanese, 京都府立医科大学, 京都, Domestic conference

  Oral presentation


• 当施設による臓器提供推進への取り組み

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 荒井 啓輔, Toyama Hirochika, Terai Sachio, Fukumoto Takumi

  第53回日本移植学会総会, Sep. 2017, Japanese, 旭川医科大学 外科学講座 消化器病態外科学分野, 旭川, Domestic conference

  Oral presentation


• 当科における切除可能膵癌に対する術前治療の経験

  飯盛 信哉, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 南野 佳英, 篠崎 健太, 山下 博成, 白川 幸代, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第200回近畿外科学会, Sep. 2017, Japanese, 京都府立医科大学, 横浜, Domestic conference

  Oral presentation


• 当院の脳死肝移植チームにおける現状から見えてきたもの

  荒井 啓輔, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Kusunoki Nobuya, Ajiki Tetsuo, Fukumoto Takumi

  第53回日本移植学会総会, Sep. 2017, Japanese, 旭川医科大学 外科学講座 消化器病態外科学分野, 旭川, Domestic conference

  Oral presentation


• 当院における膵移植後社会復帰の現状と問題点

  南野 佳英, Kido Masahiro, Toyama Hirochika, 水本 拓也, 上田 悠貴, 白川 幸代, 山下 博成, Terai Sachio, Kinoshita Hisoka, Tanaka Motofumi, Kido Masahiro, Fukumoto Takumi

  第53回日本移植学会総会, Sep. 2017, Japanese, 旭川医科大学 外科学講座 消化器病態外科学分野, 旭川, Domestic conference

  Oral presentation


• 当院におけるアルコール性肝硬変に対する肝移植患者の社会復帰の現状

  南野 佳英, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 権 英寿, 荒井 啓輔, Terai Sachio, Toyama Hirochika, Ueno Kimihiko, Ajiki Tetsuo, Fukumoto Takumi

  第53回日本移植学会総会, Sep. 2017, Japanese, 旭川医科大学 外科学講座 消化器病態外科学分野, 旭川, Domestic conference

  Oral presentation


• 胆管・十二指腸メタリックステント挿入の3年後に治療切除しえた進行十二指腸癌の1例

  松本 拓, Ajiki Tetsuo, Ueno Kimihiko, 篠崎 健太, 秋田 真之, Kinoshita Hisoka, Terai Sachio, Tanaka Motofumi, Kido Masahiro, Toyama Hirochika, Fukumoto Takumi

  第53回日本胆道学会学術集会, Sep. 2017, Japanese, 山形大学医学部第一外科, 山形, Domestic conference

  Poster presentation


• 腎容積の変化にも着目した、肝移植後の慢性腎臓病(CKD)に関する検討

  後藤 公彦, Yoshikawa Mikiko, Fukumoto Takumi, Nishi Shinichi

  第53回 日本移植学会総会, Sep. 2017, Japanese, 日本移植学会, Asahikawa, 旭川, Domestic conference

  Poster presentation


• 肝移植後腎機能障害に対し腎生検を施行した2例の検討

  清水 真央, Yoshikawa Mikiko, Hara Shigeo, Fukumoto Takumi, Nishi Shinichi

  第53回 日本移植学会総会, Sep. 2017, Japanese, 日本移植学会, Asahikawa, 旭川, Domestic conference

  [Invited]

  Invited oral presentation


• 「重症急性膵炎後の胆管癌患者に膵頭十二指腸切除を施行し、術後膵液瘻と被包化壊死（WON）の感染により横行結腸瘻を認めた一例」

  朝倉 悠, 山下 博成, Toyama Hirochika, Terai Sachio, 白川 幸代, 南野 佳英, 水本 拓也, 上田 悠貴, 李 東河, Kinoshita Hisoka, Tanaka Motofumi, Ueno Kimihiko, Kido Masahiro, Kusunoki Nobuya, Ajiki Tetsuo, Fukumoto Takumi

  第20回近畿外科病態研究会, Sep. 2017, Japanese, 大阪国際がんセンター, 大阪, Domestic conference

  Oral presentation


• ドナーを増やすために移植医ができること

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, Toyama Hirochika, Terai Sachio, 権 英寿, 山下 博成, 荒井 啓輔, Fukumoto Takumi

  第53回日本移植学会総会, Sep. 2017, Japanese, 旭川医科大学 外科学講座 消化器病態外科学分野, 旭川, Domestic conference

  Oral presentation


• 腹部悪性腫瘍に対する粒子線治療適応拡大を可能とする新規素材吸収性スペーサーの開発と臨床応用

  Kido Masahiro, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, 具 英成, 出水 祐介, 沖本 智昭, Sasaki Ryohei

  第72回日本消化器外科学会総会, Jul. 2017, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Public symposium


• 当科における腹腔鏡下肝切除の実際と工夫

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, 松本 拓, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第72回日本消化器外科学会総会, Jul. 2017, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Oral presentation


• 超高齢者肝癌患者に対する肝切除術

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, Terai Sachio, 松本 拓, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第53回日本肝癌研究会, Jul. 2017, Japanese, 東京大学, 東京, Domestic conference

  Oral presentation


• 自然退縮をきたした肝細胞癌の5例

  堀川 学, Tanaka Motofumi, Kido Masahiro, Kinoshita Hisoka, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi, 具 英成

  第72回日本消化器外科学会総会, Jul. 2017, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Oral presentation


• 肝静脈腫瘍栓を有する肝細胞癌に対する外科的切除の成績

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, Terai Sachio, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第53回日本肝癌研究会, Jul. 2017, Japanese, 東京大学, 東京, Domestic conference

  Oral presentation


• 肝細胞癌のoncologic emergencyに対する治療戦略：Vp4,Vv3

  Tanaka Motofumi, Kido Masahiro, Kinoshita Hisoka, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi, 具 英成

  第72回日本消化器外科学会総会, Jul. 2017, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Public symposium


• Tis/T1 膵癌の診断と治療戦略

  浅利 貞毅, Toyama Hirochika, Terai Sachio, 白川 幸代, Ajiki Tetsuo, 松本 拓, 篠崎 健太, Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, Fukumoto Takumi, 具 英成

  第48回日本膵臓学会大会, Jul. 2017, Japanese, 関西医科大学 内科学第三講座（消化器肝臓内科）, 金沢, Domestic conference

  Public symposium


• StageB,C肝細胞癌に対する集学的治療

  Kido Masahiro, Fukumoto Takumi, Kinoshita Hisoka, Ajiki Tetsuo, Toyama Hirochika, 浅利 貞毅, 具 英成

  第72回日本消化器外科学会総会, Jul. 2017, Japanese, 金沢大学 消化器・腫瘍・再生外科学, 金沢, Domestic conference

  Public symposium


• BCLC intermediate stage 肝癌に対する切除適応の検討

  Tanaka Motofumi, Kido Masahiro, Kinoshita Hisoka, 吉田 俊彦, 荒井 啓輔, Fukumoto Takumi

  第53回日本肝癌研究会, Jul. 2017, Japanese, 東京大学, 東京, Domestic conference

  Public symposium


• 傍大動脈リンパ節を含む多発リンパ節転移を伴った膵VIP 産生腫瘍の切除例

  上田 悠貴, Toyama Hirochika, 水本 拓也, 南野 佳英, 白川 幸代, Kinoshita Hisoka, Terai Sachio, 松本 拓, Tanaka Motofumi, 浅利 貞毅, Kido Masahiro, Kusunoki Nobuya, Ajiki Tetsuo, Fukumoto Takumi

  第39回日本がん局所療法研究会, Jun. 2017, Japanese, 京都府立医科大学, 京都, Domestic conference

  Oral presentation


• 脳死肝移植手術におけるサイズミスマッチグラフトに対する静脈吻合の工夫

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 荒井 啓輔, 田井 謙太郎, 保原 祐樹, Fukumoto Takumi

  第35回日本肝移植研究会, Jun. 2017, Japanese, 大阪大学大学院, 大阪, Domestic conference

  Oral presentation


• 脳死肝移植後の虚血性胆管障害の治療経過中に肛門部胆管癌を発症した一例

  Tanaka Motofumi, Kido Masahiro, Kinoshita Hisoka, 吉田 俊彦, 荒井 啓輔, Fukumoto Takumi

  第35回日本肝移植研究会, Jun. 2017, Japanese, 大阪大学大学院, 大阪, Domestic conference

  Oral presentation


• 当科における肝移植後のde novo悪性腫瘍の検討

  Kinoshita Hisoka, Kido Masahiro, Tanaka Motofumi, Terai Sachio, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第35回日本肝移植研究会, Jun. 2017, Japanese, 大阪大学大学院, 大阪, Domestic conference

  Oral presentation


• 胆管上皮内腫瘍（BilIN-3）の切除後に発生した遠位胆管癌の1 切除例

  松本 拓, Ajiki Tetsuo, 篠崎 健太, 秋田 新之, Terai Sachio, Kinoshita Hisoka, Tanaka Motofumi, 浅利 貞毅, Toyama Hirochika, Kido Masahiro, Fukumoto Takumi

  第39回日本がん局所療法研究会, Jun. 2017, Japanese, 京都府立医科大学, 京都, Domestic conference

  Oral presentation


• 肝移植後胆管合併症の頻度とIVR-内視鏡的アプローチによる治療成績の検討

  Kido Masahiro, Tanaka Motofumi, Kinoshita Hisoka, 松本 拓, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, Fukumoto Takumi

  第35回日本肝移植研究会, Jun. 2017, Japanese, 大阪大学大学院, 大阪, Domestic conference

  Oral presentation


• 膵癌術前精査におけるEOB-MRIと審査腹腔鏡の意義

  白川 幸代, Toyama Hirochika, 浅利 貞毅, 後藤 直大, Terai Sachio, 南野 佳英, 上田 悠貴, 水本 拓也, Ajiki Tetsuo, Kido Masahiro, Tanaka Motofumi, 松本 拓, 蔵満 薫, Kinoshita Hisoka, Fukumoto Takumi, 具 英成

  第117回日本外科学会定期学術集会, Apr. 2017, Japanese, 日本外科学会, 横浜, Domestic conference

  Poster presentation


• 腹腔鏡下脾動静脈温存脾温存膵体尾部切除術の成績と課題

  後藤 直大, Toyama Hirochika, 浅利 貞毅, Terai Sachio, 白川 幸代, 上田 悠貴, 水本 拓也, 南野 佳英, Kinoshita Hisoka, 蔵満 薫, 松本 拓, Tanaka Motofumi, Kido Masahiro, 松本 逸平, Ajiki Tetsuo, Fukumoto Takumi, 具 英成

  第117回日本外科学会定期学術集会, Apr. 2017, Japanese, 日本外科学会, 横浜, Domestic conference

  Poster presentation


• 肝切除における術中超音波を用いた胆道ナビゲーションサージャリーの現状と将来展望

  浦出 剛史, Fukumoto Takumi, Kido Masahiro, Tanaka Motofumi, 蔵満 薫, Kinoshita Hisoka, 吉田 俊彦, 荒井 啓輔, Toyama Hirochika, Ajiki Tetsuo, 黒田 大介, 具 英成

  第117回日本外科学会定期学術集会, Apr. 2017, Japanese, 日本外科学会, 横浜, Domestic conference

  Public symposium


• 下大静脈腫瘍栓合併肝細胞癌に対する粒子線と肝切除のMatched pair analysisによる治療成績の比較検討

  Fukumoto Takumi, Kido Masahiro, Tanaka Motofumi, 蔵満 薫, Kinoshita Hisoka, 後藤 直大, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, 寺嶋 千貴, 出水 祐介, 沖本 智昭, 具 英成

  第117回日本外科学会定期学術集会, Apr. 2017, Japanese, 日本外科学会, 横浜, Domestic conference

  Oral presentation


• C型慢性肝炎に対するDAA治療：肝細胞癌根治切除例の検討

  荒井 啓輔, Tanaka Motofumi, Fukumoto Takumi, Kido Masahiro, Kinoshita Hisoka, 蔵満 薫, 吉田 俊彦, Terai Sachio, 松本 拓, 後藤 直大, 浅利 貞毅, Toyama Hirochika, Kusunoki Nobuya, Ajiki Tetsuo, 具 英成

  第103回日本消化器病学会総会, Apr. 2017, Japanese, 日本消化器病学会, 東京, Domestic conference

  Poster presentation


• 仙骨脊索腫に対する体内空間可変粒子線治療の長期成績

  津川大介, Fukumoto Takumi, 小松 昇平, 相部則博, 出水祐介, Sasaki Ryohei, 沖本智昭

  第21回兵庫粒子線治療研究会, Mar. 2017, Japanese, 兵庫県立粒子線医療センター, 神戸, Domestic conference

  Public discourse


• 黄色肉芽腫性胆嚢炎に合併した胆嚢十二指腸瘻の1例

  堀川 学, Ajiki Tetsuo, 篠崎 健太, 秋田 真之, Kinoshita Hisoka, Terai Sachio, Tanaka Motofumi, 浅利 貞毅, Toyama Hirochika, Kido Masahiro, Fukumoto Takumi, 具 英成

  第53回日本腹部救急医学会, Mar. 2017, Japanese, 那須赤十字病院, 横浜, Domestic conference

  Oral presentation


• 著明なAP shuntを伴う両葉多発進行肝細胞癌に対する術前経皮的肝灌流化学療法

  荒井 啓輔, Fukumoto Takumi, Kido Masahiro, Tanaka Motofumi, 蔵満 薫, Kinoshita Hisoka, 松本 拓, Terai Sachio, 後藤 直大, 浅利 貞毅, Toyama Hirochika, Ajiki Tetsuo, 具 英成

  第23回肝血流動体・機能イメージ研究会, Feb. 2017, Japanese, 近畿大学, 大阪, Domestic conference

  Oral presentation